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IPEX   immunodysregulation polyendocrinopathy enteropathy X-  
                                                linked syndrome 
IRF-4   interferon regulatory factor 4 
IS   immune synapse 
ITAM   immunoreceptor tyrosine-based activatory motif 
Itk   inducible T-cell kinase 
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iT reg   induced T regulatory cell 
Jak   Janus activated kinase 
Jnk   c-Jun terminal kinase 
kDa   kilo Daltons 
KEGG   Kyoto Encyclopaedia of Genes and Genomes 
KLF2   Kruppel-like factor 2 
KLRG1   Killer cell Lectin-like receptor G1 
KO   knock out 
Kyn   kynurenine 
LAT   Linker for activation of T-cells 
LAMP   lysosomal membrane proteins 
Lck   lymphocyte-specific protein tyrosine kinase 
LCMV   Lymphocytic choriomeningitis virus 
LM   Listeria monocytogenes 
LDH   lactate dehydrogenase 
LFA-1    leukocyte function antigen-1 
LN    Lymph nodes 
LP    lamina propria 
LPS    Lipopolysaccharide 
LXR    Liver X receptor 
Maf    musculoaponeurotic fibrosarcoma oncogene homolog 
MAPK    Mitogen Activated Protein Kinase 
MAPKK   MAPK-kinase 
MCF    Michigan Cancer Foundation (cells) 
MEK    mitogen activated ERK kinase 
MHC    major histocompatibility complex 
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mLST8   mammalian LST8/G-protein  β-subunit like protein 
mRNA    messenger RNA 
MTB    Mycobacterium tuberculosis 
mTOR    mammalian target of rapamycin 
mTORc1   mTOR complex 1 
myc    Myelocytomatosis oncogene 
NCR    Natural cytoxicity receptor 
NFAT    nuclear factor of activated T cells 
NF-κB    nuclear factor κ-light-chain-enhancer of activated B cells 
NK    natural killer  
NOD    Non-obese diabetic (mice) 
ODD    oxygen dependent degradation 
p-    phospho 
PAH    Polycyclic aromatic hydrocarbons 
PAS    Per ARNT Sim family of proteins 
PBS    phosphate buffered saline 
PBS-T    phosphate buffered saline plus 0.5% Tween 20 
PCR    polymerase chain reaction 
PD-1    Programmed death 1 
PdBU/I   Phorbol-12,13-dibutyrate 
PDK1    3-phosphoinositide-dependent protein kinase-1 
PE    phycoerythrin 
PFA    paraformaldehyde 
PFK    phosphofructokinase 
PGC-1    Peroxisome proliferator-activated receptor-γ coactivator 
PH    pleckstrin homology 
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PHD    prolyl hydroxylase 
PI(3,4)P2   Phosphatidylinositol (3,4)-biphosphate 
PI(3,4,5)P3   Phosphatidylinositol (3,4,5)-triphosphate 
PI3K    Phosphoinositide 3-kinase 
PKB    Protein kinase B 
PKC    Protein kinase C 
PKM2    Pyruvate kinase isozymes M1/M2 
PLC-γ1   Phospholipase C gamma 1 
PPP    Pentose phosphate pathway 
PPARγ    Peroxisome proliferator-activated receptor gamma 
PRAS40   Proline rich PKB substrate of 40kDa 
Protor    Protein observed with rictor 
PRR    pattern recognition receptors 
PSGL-1   P-selectin glycoprotein ligand-1 
PTEN    Phosphatase and tensin homologue deleted on                              
                                                chromosome 10 
q-RT PCR   Quantitative real time PCR 
RA    Rheumatoid arthritis 
RAG    Recombinase activating gene 
Raptor    Regulatory associated protein of mTOR 
Rheb    Ras homologue enriched in brain 
Rho    Ras homologue gene family 
Rictor    Rapamycin-insensitive companion of mTOR 
RNA    Ribonucleic acid 
Rorγt    Retinoic acid receptor-related orphan receptor gamma T 
ROS    Reactive oxygen species 
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RPMI    Roswell Park Memorial Institute media 
RSK    ribosomal S6 kinase 
S6K1    p70 ribosomal S6 kinase 1  
SAPK    Stress-activated protein kinases 
S/Ser    Serine 
S1P1    Sphingosine-1-phosphate receptor 
SCID    Severe combined immunodeficiency 
SEM    standard error of mean 
SH2    Src homology domain 2 
SHIP    SH2 domain containing inositol phosphate 
SIGIRR   Single Ig IL-1-related receptor 
siRNA    small inhibitory RNA 
SLP-76   SH2 domain containing Lymphocyte protein of 76kDa 
SIRT    stress-responsive genetic regulator sirtuin 
SMAC    Supramolecular activation cluster 
SmCI    Structural maintenance of chromosome 1 
SP    Single positive 
Src    Proto-oncogene tyrosine protein kinase Src 
SREBP1   sterol regulatory element binding protein 
SSC    side scatter 
ST    Salmonella typhimurium 
Stat    Signal transducer and activator of transcription 
Syk    Spleen tyrosine kinase 
T/Thr    threonine 
T-bet    T-box expressed in T cells  
TCA    tricarboxylic acid cycle 
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TCDD    2,3,7,8-Tetrachlorodibenzo-p-dioxin 
TEM    Effector memory cell 
TCR     T-cell receptor 
Tfh    T follicular cells 
TGF-β    tumor growth factor β 
Th    T helper cell 
TNF    Tumour necrosis factor 
Tr    T regulatory cell 
TRAF6   tumour necrosis factor receptor-associated factor 6 
T reg    regulatory T cell 
TSC    Tuberous sclerosis complex 
Vav 1    Vav 1 oncogene  
V(D)J    Variable (diversity) joining 
VEGF    vascular endothelial cell growth factor 
VHL    von Hippel Lindau  
WT    Wild type 
Y/Tyr    Tyrosine 
YFP    Yellow fluorescent protein 
UGT1A6   UDP glucoronosyltransferase 1 family polypeptide A6 
ZAP-70   Zeta-associated protein of 70kD 
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Abstract 
The Aryl Hydrocarbon Receptor (AhR) and the Aryl Hydrocarbon Nuclear Translocator 
(ARNT) play a role in mediating transcriptional responses to environmental pollutants, 
including the highly toxic compound 2,3,7,8-tetrachlorodibenzo -p-dioxin (TCDD) but 
also endogenous physiological ligands. More recent studies have also indicated that the 
AhR plays a role in the immune system notably in effector Th17 cells where it seems to 
be critical for the production of the IL-22 cytokine. It is known that AhR ligands such 
as dioxins can suppress CD8 T cell mediated antiviral immune responses but it is not 
known whether this reflects a direct role of the AhR in CD8 T cells.  
Accordingly, one objective of the present study was to explore AhR and ARNT 
expression in CD8 T cells. The initial strategy was to probe AhR and ARNT expression 
by western blot analysis. A second approach was to develop a mouse model that would 
fate mark single lymphocytes that have activated AhR signaling pathways. A third 
strategy was to examine the impact of deletion of AhR and ARNT on CD8 T-cell 
function.  
The data show that AhR and ARNT expression in CD8 T cells is limited to immune 
activated effector cells and these transcription factors are not expressed in naïve CD8 T 
cells. There are only low levels of AhR complexes in conventional CD8 positive 
cytotoxic T cells. To investigate AhR function at the single cell level we developed a 
mouse model to fate mark cells that have activated AhR signaling. In this model a 
mouse expressing Cre recombinase ‘knocked in’ to the CYP1A locus (CYP1A1Cre+/-) 
was backcrossed to the R26REYFP reporter mouse. In R26REYFP mice, a gene encoding 
EYFP is knocked into the ubiquitously expressed Rosa26 locus preceded by a loxP 
flanked stop sequence. CYP1A1 expression is controlled by AhR/ARNT complexes and 
the concept of our model was that cells that express AhR and ARNT complexes and are 
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triggered with AhR ligands will express Cre recombinase and delete the loxP flanked 
stop sequence in the R26REYFP reporter locus and hence begin to express YFP.  
In vitro experiments demonstrated the validity of this AhR reporter model. The in vitro 
data reveal that expression of functional AhR/ARNT complexes occurs during Th17 
and Tc17 cell differentiation but only a very low frequency of cytotoxic T cells 
activates the AhR. In vivo data found no evidence for AhR activation during T cell 
development in the thymus but show strong evidence for activation of AhR/ARNT 
signaling in innate lymphocytes in the gut.  
 
The ARNT transcription factor is highly expressed in cytotoxic T cells. These cells do 
not express functional AhR complexes, yet we considered that ARNT might play a role 
in CD8 T cell biology because of its ability to dimerise with the transcription factor Hif-
1α. Our studies of T cells lacking ARNT expression revealed that in CD4 T cells the 
ARNT transcription factor regulates IL-17 and IL-22 production. In CD8 T cells we 
discovered that Hif-1α/ARNT signaling controls glycolysis in immune activated cells 
by sustaining expression of glucose transporters and multiple rate limiting glycolytic 
enzymes. ARNT was not required for CD8 T cell proliferation but was required for 
immune activated CD8 T cells to normally differentiate to express perforin and 
granzymes and to acquire the migratory program of effector T cells. Importantly, we 
discovered that Hif-1α/ARNT signaling is regulated by mTOR (mammalian target of 
rapamycin) thus revealing a fundamental mechanism linking nutrient sensing and 
transcriptional control of CD8 T-cell differentiation. 
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Chapter 1 Introduction 
1.1 Principles of innate and adaptive immune systems 
In order to protect an individual from disease the different components of the immune 
system must perform four main functions: 1. An infection must be detected by the white 
blood cells, which are part of the innate immune system and by lymphocytes, which 
belong to the adaptive immune system. 2. Subsequently, various cells of the immune 
system using different effector functions such as killing capabilities and antibody 
production try to reduce and possibly eradicate the source of infection. 3. These 
functions have to be tightly regulated otherwise an unrestrained immune response might 
result in allergies and autoimmune diseases thus damaging the body 4. Finally, the 
fourth function is the ability of the adaptive immune system to generate an 
immunological memory, which mounts a much stronger and faster response upon a 
secondary encounter with the same pathogen.  
 
The cells of both the innate and the adaptive immune system originate from the 
pluripotent hematopoietic stem cells in the bone marrow (BM). Stems cells in the BM 
produce two types of progenitors: common lymphoid progenitor and common myeloid 
progenitor. Common lymphoid progenitors give rise to natural killer cells (NK), T and 
B lymphocytes, whereas the myeloid progenitors give rise to granulocytes, dendritic 
cells, macrophages and mast cells (Figure 1.1). Although both T and B cells originate in 
the BM, only B lymphocytes mature there while T cells migrate to the thymus where 
they differentiate into mature CD4+ or CD8+ T cells. Subsequently, B cells from the 
bone marrow and mature T cells from the thymus enter the bloodstream and circulate 
through peripheral lymphoid tissues that include lymph nodes, spleen, mucosal 
lymphoid tissues of the gut and respiratory tract. Circulation of naïve mature 
lymphocytes from the blood to peripheral lymphoid organs and back is constant until 
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they are activated by antigen presented on antigen presenting cells in the draining 
lymphoid tissues. Upon antigen activation, lymphocytes stop migrating and go through 
a process of blasting during which new RNA and proteins are synthesized followed by 
clonal expansion and differentiation into effector cells. Effector cells then migrate to 
sites of infection or stay in the lymphoid organs to activate B cells.  
 
 
 
Figure 1.1 Cells of the Innate and Adaptive Immune System. 
The cells of the immune system originate from pluripotent haemotopoietic stem cells in 
the bone marrow (BM). Stems cells in the BM produce two types of progenitors: 
common lymphoid progenitor and common myeloid progenitor. Common lymphoid 
progenitors give rise to natural killer cells (NK), T and B lymphocytes, whereas the 
myeloid progenitors give rise to granulocytes, dendritic cells, mast cells and monocytes 
that can differentiate into tissue resident macrophages.  
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1.1.1 T cells and T-cell antigen receptors 
T lymphocytes develop in the thymus where they accomplish the task of generating a 
mature and functional T cell receptor (TCR) and either CD4 or CD8, the major 
histocompatibility (MHC) co-receptors. Each mature T cell bears about 30,000 identical 
antigen receptors on its surface. T cell receptors recognize specific antigens that are 
presented to them by a self-MHC molecules. Two classes of TCR were described: αβ-
TCR and γδ-TCR. T cell receptors consist of the αβ or γδ-heterodimer in a complex 
with a homodimer of two ζ chains that are linked by a disulfide bond and four CD3 
chains: CD3δ, CD3γ and two CD3ε chains, which together form the CD3 complex.  
 
Importantly, there is a great diversity in the specificity of the T cell receptors for the 
processed antigens, which is determined by the structure of the antigen-binding site. 
This structural diversity in the specificity is achieved by combinatorial and junctional 
diversity generated during the process of gene rearrangements. The result is a T cell 
receptor in which the highest diversity is in the central part of the receptor-the CDR3 
region which contacts the unique peptide. The T cell receptor is associated with a 
complex of four chains that collectively called CD3 and with a homodimer of ζ chains. 
CD3 and ζ chains are required for the signal transduction events that occur upon antigen 
binding and activation of the TCR. Those signaling events will be discussed later in the 
introduction. 
1.1.2 αβ  and γδ-T cell development in the thymus 
Development of T cells in the thymus includes two main processes: 1. a successful 
rearrangement of αβ or γδ T cell receptors and a subsequent commitment to one of the 
two lineages. 2. Positive and negative selection, driven by interactions of a specific αβ 
T cell receptor with a self-peptide bound to MHC presented on the thymic stromal cells.  
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This step allows the generation of a mature repertoire of either CD4+ or CD8+, which 
are both MHC-restricted and self-tolerant.  
The process of development begins when T cells attracted by the CCL21 and CCL25 
chemokines expressed on the cells of the fetal thymic primordium migrate from the 
bone marrow and colonize the thymus (Bleul and Boehm, 2000). T cells that arrive in 
the thymus go through different differentiation stages for seven days before entering an 
intense proliferative stage. Whereas, about 5x107 new cells are generated each day, only 
around 1-2x106 cells will leave the thymus as mature cells. This is because most (98%) 
of the thymocytes that develop in the thymus will also die in the thymus due to 
apoptosis. The steps of the T cell receptor maturation occur in parallel to expression of 
cell-surface markers CD44 and CD25. When T cells arrive in the thymus they lack most 
of the surface molecules that characterise a mature T cell. In this stage they constitute 
about 60% of the thymus and are termed double negative thymocytes since they lack 
both CD4 and CD8. The double negative stage can be further subdivided into DN1, 
DN2, DN3 and DN4. DN1 cells express Kit, CD44 but are negative for the CD25 
marker (α chain of the IL-2 receptor). In these cells, both the α and the β chains genes 
of the T cell receptors are in the germline configuration. Each loci of the T cell receptor 
consists of a variable (V), diversity (D), Joining (J) and constant (C) gene segments. 
While the TCRα locus contains 70-80 Vα gene segments and 61 Jα segments, the 
TCRβ locus in addition to a cluster of 52 Vβ also contains two diversity (D) segments 
separating two clusters of seven Jβ gene segments. In the DN2 stage cells become 
CD44+CD25+ and begin to rearrange the β chain locus via rearrangements of Dβ to Jβ 
gene segments, followed by Vβ to DJβ rearrangement by somatic recombination. 
Somatic V(D)J recombinations are carried out by the lymphoid-specific components of 
the recombinase: RAG-1 and RAG-2, in addition to DNA-modifying proteins such as 
Ku and DNA ligase IV that are involved in the repair of DNA-double-strand breaks. 
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This rearrangement process generates a functional VDJβ V region-exon that is 
transcribed and splices to join to the constant β segment. This mRNA is transcribed to 
the β chain of the T cell receptor. Simultaneously to β chain rearrangement, δ and γ loci 
of the γδ T cell receptor are also rearranged. The decision that a receptor will become γδ 
or αβ depends on whether functional γ and δ chains are formed before the β chain. If 
this occurs, then specific signals are delivered through the γδ TCR to abrogate the β 
chain rearrangement and commit the cell to the γδ lineage. On the other hand if a 
functional β chain was formed before the γδ receptor, it will assemble with the pre-
TCRα (pTα) chain to form the pre-TCR complex.  
It is notable that the initial thymocyte development during DN1 to DN3 stages is 
promoted by signals that are derived from cortical thymic epithelial cell, which include 
Notch-mediated signals delivered by binding of Delta ligands (Radtke et al., 1999) and 
is supported by signals delivered by interleukin-7 (Peschon et al., 1994; Maki et al., 
1996). Notch signaling is required for commitment to the T-cell lineage and absence of 
Notch from haemotopoietic stem cells results in a failure of T cell development and 
causes an accumulation of immature B cells and dendritic cells in the thymus (Boehmer, 
2009). Later on, in the DN3 stage the pre-TCR complex is expressed on the cell surface 
and pairs with the CD3 molecules that contribute the signaling components of the T cell 
receptor. At this stage (DN4) cells become CD44-/CD25-, they rapidly proliferate, 
begin to express both CD4 and CD8 co-receptors and the β chain rearrangement process 
is terminated. While the proliferative burst continues, RAG-1 and RAG-2 genes are 
repressed and only when the proliferative phase ends, RAG-1 and RAG-2 are transcribed 
again and the rearrangement of the α chain initiates. The first step in α chain 
rearrangement is the deletion of all D, J, C and γ gene segments on that chromosome. 
Subsequently, since there are many different Vα and Jα gene segments, rearrangements 
of α-chain locus can progress through several cycles thus almost always guaranteeing a 
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production of a functional α chain. Repeated α chain rearrangements continue until the 
T cell receptors of the CD3lowCD4+CD8+ double thymocytes are positively selected for 
self-peptide:self-MHC recognition.  
During thymocyte selection, CD4 CD8 double positive thymocytes interact via their 
TCRs and via the CD4 and CD8 co-receptors with either MHC class I or MHC class II 
molecules expressed by the thymic epithelial cells. This interaction leads to two 
outcomes: Firstly, dependent on whether the T cell receptor has been engaged by MHC 
class I or MHC class II molecules, a mature thymocyte will stop the expression of one 
of the co-receptors thus committing to a CD4 or a CD8 single positive mature T cell 
lineage. Secondly, dependent on the strength of the signal delivered by the receptor and 
co-receptor upon binding, thymocytes will be either positively or negatively selected 
(Bevan, 1997). If the signal, which is dictated by the affinity of the TCR for the self-
peptide:MHC complex and the density of the complexes expressed by the thymic cells 
is too strong, it will induce apoptosis of the thymocytes. Elimination of these 
thymocytes prevents their potential damaging activation later on when they are mature 
T cells in the periphery. This process is called negative selection. Weak signals on the 
other hand promote thymocyte survival thus leading to a positive selection. The 
majority of thymocytes expressing TCRs with no measurable self-reactivity have a 
short half-life and die by neglect. Subsequently, the CD4+ and CD8+ single positive 
thymocytes relocate to the medulla area of the thymus where they acquire the 
expression of CD62L ligand and CD69 thus becoming CD62LhighCD69low mature naïve 
T cells. It is important to note that in the medulla a further deletion of self-reactive 
thymocytes that escaped negative selection in the cortex continues. Such additional 
deletion is necessary for the establishment of central tolerance. The transcriptional 
regulator, AIRE expressed by medullary thymic epithelial cells and DCs has a key role 
in T cell tolerance diction in the thymus, mainly by promoting ectopic expression of a 
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large number of tissue-specific proteins that are normally restricted to differentiated 
organs in the periphery and that are presented to developing T cells (Mathis and Benoist, 
2009). Mutations in the autoimmune regulator (AIRE) protein cause a breakdown of 
central tolerance that is associated with decreased expression of self antigens in the 
thymus and AIRE KO mice are affected with multiorgan autoimmunity (Anderson et al., 
2002; Ramsey et al., 2002). Single positive CD4 and CD8 T cells that developed and 
maturated in the thymus eventually acquire the expression of CCR7 and G-protein 
coupled receptor, S1P1 which in response to CCL19 and S1P ligands respectively, 
mediate T cell egression from the thymus to peripheral lymphoid tissues through the 
blood (Ueno et al., 2002; Matloubian et al., 2004). 
 
1.2 T cell antigen receptor 
1.2.1 Immunological synapse 
T-cell activation requires interaction of T-cell antigen receptors with antigens presented 
on the major histocompatibility complex of an antigen-presenting cell (APC). This 
interaction is a dynamic process (Beemiller et al., 2012) and takes place in a specialized 
cell-cell junction termed an immunological synapse which was demonstrated using in 
vitro imaging techniques in which both MHC molecules and adhesion molecules that 
support the cell-contact were fluorescently labeled (Grakoui et al., 1999). The 
hypothesis is that the formation of synapse supports the spatial organization in the zone 
of the APC-T cell contact and is required to sustain the subsequent signaling in T cells 
for many hours (Delon and Germain, 2000). Nevertheless, the formation of the synapse 
is not required for the initiation of the TCR signaling since mutagenesis of some of the 
early intracellular components of the TCR signaling was shown to inhibit synapse 
formation (Lowin-Kropf et al., 1998). In addition, there is evidence that synapse 
formation is only just beginning when TCR biochemical signals have already peaked 
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(Lee et al., 2002). Therefore, the current view is that a synapse is an active process 
induced by ongoing TCR signaling and its regulated structure supports the stabilization 
of signal transduction by the TCR for prolonged periods required for gene activation 
(Iezzi et al., 1998).  
 
1.2.2 Structure of the TCR and signaling events. 
T cell antigen receptor structure and the signaling events downstream to TCR are 
depicted in figure 1.2.  
T cell receptor consists of the αβ heterodimer, which is a homodimer of two ζ chains 
that are linked by a disulfide bond and four CD3 chains: CD3δ, CD3γ and two CD3ε 
chains, together forming the CD3 complex. Each of the CD3 chains and the ζ chains 
contains a signaling motif called immunoreceptor tyrosine-based activation motif 
(ITAM) in its cytoplasmic domain. The ITAM motifs contain consensus sequence 
(D/E)XXYXXL(X)6-8YXXL, in which both tyrosines serve as substrates for the Src 
protein tyrosine kinases, Lck and Fyn (Weiss and Littman, 1994). Whereas Fyn kinase 
associates weakly with the cytoplasmic domains of the ζ and CD3 chains, Lck is 
constitutively associated with the cytoplasmic domain of CD4 and CD8 co receptors. 
Upon TCR ligation and subsequent interaction of MHC class I and class II molecules 
with the CD4 and CD8, Lck is rapidly recruited to the vicinity of the TCR/CD3 
complex and phosphorylates their ITAM motifs (Shaw et al., 1989). Although both 
kinases phosphorylate ITAM motifs, their functions seem to be distinct as judged by 
different phenotypes of the Lck and Fyn KO mice. Lck-deficient mice show a profound 
defect in thymocyte development, which leads to almost complete absence of peripheral 
T cells (Molina et al., 1992), whereas Fyn-deficient mice have a normal peripheral T 
cell compartment (van Oers et al., 1992). Activation of the Src kinases is carried out by 
CD45 tyrosine phosphatase, which by dephosphorylation of an inhibitory tyrosine in the 
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carboxy terminus of the Src kinase, releases it from its inactive conformation (Weil and 
Veillette, 1994). Activation of Src kinases and subsequent ITAM motifs 
phosphorylation results in engagement of SH2 domains of the ZAP-70 ζ-chain 
associated kinase by the phosphorylated tyrosines in the ITAMs (Chan et al., 1991; 
1992) and reviewed by (Weiss, 2010) .  
 Once recruited ZAP-70 is activated by phosphorylation on Tyr-493 by Lck (Chan et al., 
1995). Activated ZAP-70 phosphorylates LAT (the transmembrane adapter protein 
linker for the T cell activation) and SLP-76 (Src homology 2 domain-containing 
leukocyte phosphoprotein). When the function of either LAT or SLP-76 is lost, TCR 
signal transduction is completely ablated (Bubeck Wardenburg et al., 1996). 
Phosphorylation of LAT is followed by engagement and binding of PLC-γ 
(phospholipase C-γ) via its C terminal SH2 domain and recruitment of SLP-76 via the 
mutual adaptor protein GAD, which links LAT and SLP-76 (Liu et al., 1999). PLC-γ is 
a key signaling molecule, which is activated by the cytoplasmic tyrosine kinase Itk and 
catalyzes the breakdown of the membrane lipid PI(4,5)P2 to produce the second 
messenger IP3 and DAG (diacylglycerol) (Carpenter and Ji, 1999). IP3 stimulates Ca2+ 
permeable ion channel receptors on the membranes of the ER, driving release of ER 
Ca2+ stores into the cytoplasm. This results in depletion of ER Ca2+, thus driving a 
sustained influx of Ca2+ into the cell via the Ca2+ channels in the membranes. This 
increase in intracellular Ca2+ levels activates the calcineurin phosphatase and Ca2+-
calmodulin-dependent kinase (CaMK) (Savignac et al., 2007). Calcineurin initiates the 
de-phosphorylation of NFAT transcription factor, allows its translocation to the nucleus 
and consequent activation of genes important for T cell activation including interleukin 
-2 (IL-2) (Hogan et al., 2003).  
The second product of PLC-γ activation, DAG activates protein kinase PKC-θ and the 
protein RasGRP, which is a GTP-exchange factor that activates the small G protein, 
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Ras. Ras activates the serine-threonine kinase Raf-1. Raf-1 is a MAPK kinase-kinase 
(MAPKKK) that phosphorylates and activates MAPK kinases (MAPKKs), which in 
turn phosphorylate and activate the MAPK’s extracellular signal-regulated kinase 1 
(Erk1) and Erk2. Erk activates Elk1, which contributes to the activation of the activator 
protein-1 (AP-1) (Jun/Fos) transcription complex. AP-1 in turn controls a number of 
cellular processes including differentiation, proliferation and apoptosis (reviewed in 
(Genot and Cantrell, 2000). 
DAG signaling is important for both thymocytes and peripheral T-cell functions since 
the loss in DAG kinases leads to defects in T cell development (Olenchock et al., 2006; 
Guo et al., 2008). The major signaling pathway that DAG regulates is the activation of 
PKCs and PKD kinases (Matthews and Cantrell, 2009). PKC belongs to a family of 
Ser/Thr kinases that includes ten isoforms. The function of the isoforms differs 
depending on their localization in a cell and they regulate a wide array of cellular 
responses. Binding of DAG to a conserved C1 domain in PKC leads to PKC activation 
and translocation to the membrane.  
The mammalian PKD (protein kinase D) family includes three closely related serine 
kinases: PKD1, PKD2 and PKD3. PKD2, but not PKD1, is selectively expressed in 
lymphoid cells in adult mice and is important for effector cytokine production after 
TCR (T-cell antigen receptor) engagement in effector T cells (Matthews et al., 2010). 
PKD2 is activated by an active PKC which phosphorylates serine residues 744/748 
within the PKD2 catalytic domain (Wood et al., 2005). PKD2 can also be activated by 
direct DAG binding to its N-terminus (Spitaler et al., 2006).  
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1.2.3 Phosphoinositide 3-kinase (PI3K)-mediated signaling in lymphocytes. 
TCR-driven PI3K mediates the phosphorylation of PI(4,5)P2 to generate 
phosphatidylinositol-3,4,5-triphosphate, PI(3,4,5)P3. 
PI3K mediated signaling is of fundamental importance for lymphocyte activation and is 
a pathway that integrates multiple receptor inputs. For example, in naïve T cells, low 
basal levels of PI(3,4,5)P3 are maintained by the cytokine IL-7; these levels increase 
strikingly in response to triggering of the antigen receptor complex. PIP3 levels are then 
sustained by stimuli from co-stimulatory molecules such as CD28. Cytokines such as 
interleukins 2 and 15 can then further sustain intracellular concentrations of PI(3,4,5)P3 
(Costello et al., 2002; Sinclair et al., 2008). Moreover, it was shown that in response to 
stimulation with Ag presented by APCs, CD28 co-stimulation enhanced PIP3 
production at the T-cell synapse independently of the p110δ activity (Garçon et al., 
2008).  
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Figure 1.2 T-cell antigen receptor (TCR) signaling. 
T-cell receptor consists of the αβ heterodimer, which is a homodimer of two ζ chains 
that are linked by a disulfide bond and four CD3 chains: CD3δ, CD3γ and two CD3ε 
chains, which together form the CD3 complex. Each of the CD3 molecules (CD3-γ, δ, ε 
and ζ) contains an ITAM motif (Immunoreceptor Tyrosine-based Activation Motif). 
The TCR polypeptides themselves have short cytoplasmic tails, and all proximal 
signaling events are mediated through the CD3 molecules. T cell receptor (TCR) 
signaling is initiated when TCR recognizes an MHC class I presented peptide. CD8 also 
binds the MHC. This engagement leads to a series of intracellular signaling events that 
culminate in the generation of a T cell response. The protein tyrosine kinase Lck is first 
activated and subsequently phosphorylates the ITAM motifs of the CD3 co-receptor 
cytoplasmic domains. The phosphorylated ITAMs on CD3ζ serve as binding sites the 
protein kinase, ZAP-70. Activated ZAP-70 then phosphorylates a variety of 
linker/adapter proteins, such as linker for activation of T cells (LAT) and SLP-76. 
Further signaling proteins are then recruited, resulting in calcium release from the ER, 
actin cytoskeleton reorganization, and activation of Ras GTPases. 
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1.3 T-cell subpopulations in the periphery 
Once T cells have completed their development, they migrate from the thymus to 
lymphoid tissues and continually re-circulate through the blood and lymphoid organs. 
These T cells are naïve T cells, until they are stimulated by antigen presented to their T 
cell antigen receptors by antigen presenting cells (APCs) in the context of MHC 
molecules. TCR stimulation in combination with co-stimulatory signals delivered by 
antigen-presenting cells is defined as signal 1 and 2, which jointly prime naïve T cells 
and induce IL-2 production, which promotes their survival and proliferation. Signal 3 
includes the various cytokines produced by antigen presenting cells that induce the 
differentiation of T cells down distinct types of effector cell populations. For instance, 
in case of CD4+ T cells different cytokine combinations program distinct transcription 
factor networks that in turn stabilize the phenotype of differentiating CD4+ T cells by 
driving expression of key lineage transcription factors. Most T cell subsets express αβ 
TCR and there are also T cells, which bear the γδ T cell receptor. αβ T cells can be 
divided into cells expressing either CD4 or CD8 MHC co-receptors. In this section I 
will discuss different T cell subsets and their functions during the immune response 
where the main focus will be effector CD8+ cytotoxic T cells, effector IL-17 producing 
CD4+ T cells and the various lymphocyte subsets present in the gut.  
 
1.3.1 CD8+  effector T cells  
Naïve CD8+ T cells proliferate rapidly and differentiate into effector and memory 
cytotoxic T cells (CTLs) following recognition of a specific antigen presented by MHC 
class I molecules on the surface of cells infected with certain viruses, protozoan and 
bacterial pathogens. The differentiation of effector CTL is bioenergetically demanding. 
In order to meet these demands, activated CD8+ T cells upregulate expression of amino 
acid transporters, the transferrin receptor and glucose transporters at their cell surface 
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(Fox et al., 2005a; Kelly et al., 2007; Cham et al., 2008). Upon TCR stimulation, a 
naïve lymphocyte effectively “reprograms” its metabolism, changing from a cell that 
relies on fatty acid oxidation (and some glycolysis), to one that engages robust aerobic 
glycolysis and glutaminolysis (Vander Heiden et al., 2009; Wang et al., 2011). Mature 
cytotoxic T cells also need to sustain high-level glucose uptake and glycolysis by 
regulating activity of rate-limiting glycolytic enzymes and expression of the Glut1 
glucose transporter (Vander Heiden et al., 2009; Marko et al., 2010). Glycolysis is less 
efficient than oxidative phosphorylation: whereas the latter can produce 36 ATP 
molecules from each glucose molecule, glycolysis generates only 2 ATP molecules for 
every glucose molecule. Still, CTLs rely on aerobic glycolysis for energy production. 
The explanation for this effect termed the “Warburg effect” is that glycolysis has an 
advantage since it promotes the use of glucose as a source of carbon for the synthesis of 
nucleic acids and phospholipids that support protein and lipid synthesis in CTLs 
(Vander Heiden et al., 2009).  
CTLs are programmed to kill tumorigenic cells and cells infected with intracellular 
bacteria and viruses. Various infection mouse models identified the ability of CD8+ 
effector T cells to lyse cells infected with intracellular pathogens such as Salmonella 
typhimurium (ST) and Mycobacterium tuberculosis (MTB) and Chlamydia (White et al., 
1996) as well as Listeria monocytogenes - bacterium that resides in the phagosomes of 
the infected cells but can also access the cytosol compartment (Vijh and Pamer, 1997; 
Harty and Bevan, 1999). Aside from fighting intracellular bacterial infections, CTLs 
also play an important role in defense against viruses. Cytotoxic CD8+ T cells 
recognize fragments of viral proteins displayed on MHC class I molecules of the virus- 
infected cells and subsequently target these cells for killing. Main viral infections 
against which CTLs were found to be effective are LCMV (Lymphocytic 
choriomeningitis virus), cytopathic vaccinia virus, influenza virus (McMichael et al., 
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1983), HBV (hepatitis virus) and HIV (human immunodeficiency virus) (reviewed in 
(Harty et al., 2000).  
Effector CD8+ cytotoxic T cells kill their target cells by inducing them to undergo 
apoptosis via two distinct molecular pathways: 1. The first includes the granule 
exocytosis pathway, which is dependent on perforin and granzymes (Jenkins and 
Griffiths, 2010; Thiery et al., 2011). 2. And the second pathway is based on the 
upregulation of the Fas ligand (CD95L), which induces apoptosis in the target 
lymphocytes (Lowin et al., 1994). The importance of FasL pathway was demonstrated 
by a defective activation-induced cell death (AICD) in gld/gld and lpr/lpr mutants that 
are defective in the genes encoding FasL and Fas, respectively (Russell et al., 1993).  
CD8+ cytotoxic T cells also act by releasing cytokines, including IL-2, Ifn-γ, TNF-α 
and LT-α, which contribute to host defense. The importance of Ifn-γ and TNF-α 
production by CTLs was shown in HBV infection models in which these cytokines 
inhibited HBV gene expression in the liver, thus inhibiting virus replication and 
contributing to its clearance (Gilles et al., 1992; Guidotti et al., 1994).  
 
1.3.1.1 IL-2 and other γc-cytokines 
Upon TCR stimulation naïve T cells up-regulate IL-2 receptor expression and can 
respond to the cytokine IL-2. IL-2 was discovered more than 30 years ago and was 
initially identified as a mitogenic growth factor that can support lymphocyte 
proliferation and survival in-vitro (Morgan et al., 1976; Gillis and Smith, 1977). IL-2 is 
produced by activated CD4+, CD8+, dendritic cells and NKT cells (Granucci et al., 
2001; Yui et al., 2004; Setoguchi et al., 2005). The IL-2 receptor consists of three 
chains IL-2Rα (CD25), IL-2Rβ (CD122) and γc (CD132), which together form the 
high-affinity IL-2R (Kd=10-11 M). When those chains form alternative combinations 
with each other such as IL-2Rα alone or IL-2Rβ and γ chain, IL-2 binds to the receptor 
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with low (Kd=10-8 M) and intermediate (Kd=10-9) affinities, respectively.  
Initial binding of IL-2 to the receptor induces heterodimerization of β and γ chains, 
which then can transduce IL-2 signals and initiate complex biochemical pathways 
(Leonard et al., 1994). Mice deficient in IL-2 or in β or α chains of the IL-2 receptor 
exhibit massive lympho-proliferative syndrome and lethal autoimmunity which lead to 
death at 4-12 weeks of age (Sadlack et al., 1995; Suzuki et al., 1995). Initially this 
phenotype was explained by the absence of activation-induced death (AICD) driven by 
IL-2. Antigen-activated T cells expand in response to IL-2 and become very sensitive to 
apoptosis if re-stimulated through their T cell receptor (Lenardo, 1991). Therefore, it 
was proposed that in absence of IL-2, lymphoproliferation and auto-reactive T cells that 
escape thymic-negative selection and unrestrainedly proliferate in the periphery cause 
autoimmunity. However, there are no direct experimental evidence that link AICD and 
autoimmunity. Only later on did several groups unequivocally demonstrate that this 
phenotype is a result of an impaired T regulatory cells production. A key study has 
established that IL-2 controls autoimmunity through the production of CD4+CD25+ T 
regulatory cells (Malek, 2003). In fact, IL-2Rβ-/- mice had significantly fewer 
CD4+CD25+ thymocytes in contrast to WT mice and their survival and expansion was 
impaired in the periphery, meaning that IL-2 response was required as early as during 
the development of CD4+CD25+ T regs in the thymus (Malek et al., 2002). Moreover, 
adoptive transfer of WT T regulatory cells into IL-2Rβ-/- mice was sufficient to not 
only inhibit but also to prevent autoimmunity (Malek et al., 2002).  
 
In CD8 T cells IL-2 controls the transcriptional programs that determine the 
effector/memory fate of CTLs. In particular, IL-2 is important in promoting and 
maintaining virus specific effector CD8+ T cells during chronic virus (LCMV) 
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infections (Kalia et al., 2010). IL-2 was also found to play an important role in 
sustaining CD8+ T cell proliferation in non-lymphoid tissues (Malek and Castro, 2010).  
In addition, IL-2 controls the differentiation of CD8+ memory T cells that are competent 
to undergo secondary expansion (D'Souza and Lefrançois, 2003; Bachmann et al., 
2007). IL-2 is required for CD8 cytotoxic T cells since it can up-regulate glucose, 
amino acid and iron uptake in a response that increases cellular energy production in 
order to meet the biosynthetic demands of rapid cell division and effector function 
(Cornish, 2006; Maciver et al., 2008). Furthermore, IL-2 directs the transcriptional 
program of CTLs and promotes effector CTL differentiation rather then memory cell 
formation (Kalia et al., 2010; Pipkin et al., 2010). 
 
1.3.1.2 Other γc-cytokines  
The IL-2 receptor γ chain is also a subunit of the IL-4, IL-7, IL-9, IL-15 and IL-21 
receptors, collectively termed γc cytokines (reviewed in (Rochman et al., 2009). The 
structure of receptors for IL-2, IL-15 and IL-7 is described in figure 1.3. Whereas IL-4 
and IL-21 are critical for B-cell function (Ozaki et al., 2002; 2004), IL-2, IL-15 and IL-
7 are essential regulators of T cell functions. γc cytokines play a role in shaping T cell 
responses, which is reflected by the fact that during an immune response, cytokine-
receptor subunits for γc cytokines are differentially expressed in activated T cells 
(Schluns and Lefrançois, 2003). The IL-7 receptor is comprised of IL-7Rα and the γc 
chain. IL-7 is produced by stromal and epithelial cells in the bone marrow and thymus 
and by fibroblasts in the T cell zones of secondary lymphoid tissues (Mazzucchelli and 
Durum, 2007). Naïve and memory T cells express high levels of the IL-7R (Schluns et 
al., 2000; Goldrath et al., 2002), which is downregulated upon T cell receptor activation 
(Alves et al., 2008).  
An essential role of IL-7 was shown in maintenance of a constant pool of naïve T cells 
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in the periphery by promoting the survival and homeostatic proliferation of naïve CD8+ 
T cells. This role of IL-7 was demonstrated by experiments in which naïve T cells were 
transferred into IL-7-/- mice. Since IL-7-dependent signals are critical during the double 
negative stage of T cell development in the thymus (Schmitt and Zúñiga-Pflücker, 
2005; Takahama, 2006), IL-7 null mice have no peripheral T cells, making this a 
potential lymphopenic environment, which usually induces proliferation of adoptively 
transferred naïve T cells. However, in the absence of IL-7 in host mice transferred naive 
T cells do not expand, suggesting that IL-7 is required for the homeostatic proliferation 
of naive T cells (Freeden-Jeffry et al., 1995; Fry and Mackall, 2001; Tan et al., 2001). 
IL-7 has also the ability to regulate T cell survival by activating the PI3K-PKB pathway 
and by inducing expression of anti-apoptotic factors such as Bcl-2 and MCL1, while 
inhibiting pro-apoptotic factors BAX and BAD (Mazzucchelli and Durum, 2007; Surh 
and Sprent, 2008). Recently it was shown that a subset of fibroblastic reticular cells 
(FRC) located in the T cell zones produce mixture of IL-7 and chemokines CCL19 and 
CCL21 (the ligands for CCR7), thus attracting CCR7+ T cells and providing these cells 
with signals for their survival (Link et al., 2007).  
IL-15 is another important homeostatic cytokine that plays an important role in memory 
CD8+ T cells in vivo (Zhang et al., 1998; Li et al., 2001). IL-15 receptor is composed of 
the IL-2Rβ-chain, γc chain and the IL-7Rα chain. Unlike IL-7 that is essential for 
maintenance of both CD4+ and CD8+ naïve T cells, IL-15 mainly supports the 
homeostasis of naïve and memory CD8+ T cells since IL-15-/-mice have decreased 
numbers of CD8+ but not CD4+ T cells, which also proliferate slower in comparison to 
the WT CD8+ T cells (Berard et al., 2003; Sandau et al., 2007). In addition, there are 
evidence for a combinatorial action of IL-15, IL-7 and IL-21 in decreasing the apoptotic 
rate in both naïve and memory CD8+ T cells, thus contributing to their expansion in 
vitro (Zeng et al., 2005).  
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IL-21 was shown to have a role in the development of Th17 in vitro (Korn et al., 2007; 
Wei et al., 2007; Zhou et al., 2007), however its role in vivo is less clear. Although one 
study reported that the development of experimental autoimmune encephalomyelitis 
(EAE) was significantly decreased in IL-21 deficient mice (Nurieva et al., 2007), two 
other studies found no difference in the development of EAE in either IL-21- or IL-21R 
deficient mice (Coquet et al., 2008; Sonderegger et al., 2008).  
In addition, while the expression of both γc and IL-7Rα was shown to be necessary for 
the normal development of γδ T cells (Baccala et al., 2005; French et al., 2005), IL-15 
induced signaling was demonstrated to be crucial for the development of NK cells since 
mice deficient in either IL-15 or IL-15Ra lack NK cells (Kennedy et al., 2000).  
 
 
 
Figure 1.3 Receptors for γc family cytokines.  
Shown are the receptors for interleukin 2 (IL-2), interleukin 15 (IL-15) and interleukin 7 
(IL-7). The receptors share the common cytokine receptor γ chain. There are three 
classes of IL‐2 receptor that bind IL‐2 with low affinity (IL‐2Rα alone), intermediate 
affinity (IL‐2Rβ and γc) and high affinity (IL‐2Rα, IL‐2Rβ and γc); only the high‐
affinity and the intermediate affinity structures of IL‐2 receptor are shown. The receptor 
for each γc family cytokine activates Jak1 and Jak3 (Janus kinases), which in turn 
activate the various signal transducers and activators of transcription (STATs).  
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1.3.1.3 IL-2, IL-15 and IL-7 γc cytokine signaling 
Binding of the IL-2, IL-15 and IL-7 cytokines to their respective receptors induces 
oligomerization of the γc and the appropriate cytokine receptor-specific chains (IL-2Rβ 
or IL-7Rα) followed by activation of the Janus tyrosine kinases Jak1 and Jak3. Jaks are 
cytoplasmic tyrosine kinases and are constitutively associated with the proline rich box1 
and box2 domains located in the cytokine receptors cytoplasmic tail. Whereas Jak1 
associates with IL-2Rβ and IL-7Rα, Jak3 associates with γc but also interacts with IL-
2Rβ subunit. Following activation, Jaks phosphorylate tyrosines in the receptor tail. 
Subsequently, tyrosine residues serve as docking sites for phospho-tyrosine binding 
proteins including Shc, Gab2, SHP-2 adaptor molecules and STAT proteins. These 
proteins mediate 3 main signaling pathways that contribute to cytokine-dependent 
transcriptional programs: RAS-mitogen-activated protein kinase (MAPK) pathway, Jak-
STAT pathway and PI3k/PKB pathway.  
 
STAT5a and STAT5b are the key transcription factors activated by IL-2, IL-15 and IL-
7 cytokines. Following activation of the activating receptor, STATs are recruited and 
bind phosphotyrosines via the src-homology 2 (SH2) domains. Subsequently STATs are 
phosphorylated by Jaks and form dimers through reciprocal phosphotyrosine-SH2 
contacts. Activated STAT dimers then translocate to the nucleus where they activate 
transcription of target genes (Lin and Leonard, 2000). The importance of Stat5 signaling 
is demonstrated by the fact that double Stat5a/b KO mice have a SCID phenotype, 
similar to mice that lack the γc cytokine receptors and thus have decreased numbers of 
mature B and T cells (Yao et al., 2006) 
 
The third signaling pathway induced by IL-2R is the PI3K pathway. 
Phosphatidylinositol 3-kinase (PI3K) is a lipid kinase that catalyzes phosphorylation of 
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phosphatidyl inositol (PI) at the D-3 hydroxyl group, generating the intracellular 
messengers PI(3)P, PI(3,4)P2 and PI(3,4,5)P3. IL-2 binding to the IL-2Rβ induces 
phosphorylation of p85 on tyrosine thus recruiting PI3K to the cell membrane 
(Remillard et al., 1991).  
 PI(3,4,5)P3 binds to proteins that contain the pleckstrin homology (PH) domain thus 
controlling the activity and the subcellular localization of various signal transduction 
molecules. One immediate outcome of increasing cellular PI(3,4,5)P3 is the activation 
of the Ser/Thr kinase protein kinase B (PKB). A rate-limiting step for PKB activation is 
the phosphorylation of threonine 308 (T308) within the PKB catalytic domain (Waugh 
et al., 2009). In terms of signaling, activation of PKB is facilitated by receptor-mediated 
activation of PI3K, which drives the production of phosphatidylinositol 3,4,5-
triphosphate, Ptdins(3,4,5)P3. PKB binding of the Ptdins(3,4,5)P3 through the 
pleckstrin homology (PH) domain induces a conformational change within its kinase 
domain. This conformational change allows PDK1 to phosphorylate PKB on Thr308 
residue (Waugh et al., 2009), which is crucial for PKB kinase activity. PKB is also 
phosphorylated by mTORc2 on Ser473 (Sarbassov et al., 2005).  
In the context of IL-2 signaling, active PKB phosphorylates the transcription factors 
Foxo1 and Foxo3a, resulting in their nuclear exclusion and the termination of Foxo-
mediated gene transcription (Biggs et al., 1999; Calnan and Brunet, 2008). A recent 
work by Andrew Macintyre in our lab demonstrated that IL-2 mediated activation of 
PKB does not control metabolism, survival or proliferation of CTLs but has a crucial 
role in the transcriptional program of effector versus memory fate (Macintyre et al., 
2011). In context of effector molecules, PKB controls expression of cytolytic 
molecules, such as IFN-γ and perforin and adhesion molecules, cytokine and chemokine 
receptors such as CD62L and CCR7 (Waugh et al., 2009; Macintyre et al., 2011). 
It is worth to mention that although IL-2 and IL-15 have the same signaling subunit in 
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their receptors and signal through the same pathways, the physiological outcomes of 
their signaling for CD8+ T cells are diverse. Work published by G. Cornish in our lab 
has shown that whereas both IL-2 and IL-15 were able to drive proliferation thus being 
equivalent mitogens for activated CD8+ T cells, those two cytokines were not equal 
growth factors. Both cytokines induced amino acid uptake and protein synthesis, 
however, IL-2 response was much more potent compared with IL-15 response. The 
reason for this difference was that IL-2 could sustain PI3K/PDK1/PKB signaling 
pathways, thus maintaining high expression levels of amino acid transporters and 
transferrin transporters whereas IL-15 response was more transient (Cornish, 2006; 
Sinclair et al., 2008).  
 
1.3.2 Memory CD8+ T cells   
Upon activation, antigen-specific T cells rapidly expand and differentiate into effector 
cells. Effector CD8+ T cells are short lived and characterized by secretion of Ifn-γ and 
cytotoxic capacity due to perforin and granzymes expression. Following this activation 
and expansion phase, a contraction phase proceeds, in which Ag-specific T cell 
numbers drop due to a massive apoptosis to 5–10% of the number observed at the peak 
of the response (Kaech and Wherry, 2007; Cui and Kaech, 2010; Obar and Lefrançois, 
2010). The remaining population gives rise to long-lived memory T cell. Maintenance 
of the memory pool of CD8+ T cells is supported by homeostatic proliferation that is 
independent of specific Ag or MHC molecules, but depends on IL-7, IL-15 and IL-21 
cytokines (Novy et al., 2011; Sneller et al., 2011) and reviewed in (Rochman et al., 
2009).  
Upon re-encounter with even a low dose of the same pathogenic antigen, memory T 
cells will respond more efficiently and proliferate more rapidly, thus resulting in a faster 
pathogen clearance. This sequence of events presents two possible models for memory 
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generation: the first model is the linear pathway model in which a naïve cell 
differentiates into an effector cell which will subsequently re-differentiate into a 
memory T cell. Several studies support this model (Kaech et al., 2003; Bannard et al., 
2009). According to the second model, a single naïve CD8+ T cell can act as a 
precursor to either an effector or a memory cell (Chang et al., 2007; Stemberger et al., 
2007; Schepers et al., 2008; Bannard et al., 2009). The different models of memory 
formation are reviewed in (Ahmed et al., 2009). 
Furthermore, several reports show that the decision whether a T cell would become 
effector or memory is made early on and dictated by the strength of the T cell receptor 
stimulation (Teixeiro et al., 2009; Smith-Garvin et al., 2010). In addition, the magnitude 
of the contraction phase determines the subsequent size of the generated memory pool.  
 
The expression of several surface markers enables identifying memory T cells. Those 
include IL-7R and KLRG1 and the chemokine receptor CCR7 and adhesion molecule 
CD62L. An important feature of memory T cells is their ability to efficiently home to 
lymph nodes via high endothelial venules. Naïve T cells express high levels of CD62L 
and CCR7 lymph node homing receptors. The expression of these receptors is 
downregulated in effector T cells that favorably home to the peripheral tissues. Memory 
T cells on the other hand re-acquire CD62L and CCR7 that support their homing to 
central lymphoid organs (Wherry et al., 2003; Kaech and Wherry, 2007).  
IL-7R is highly expressed by naïve T cells and is downregulated following TCR 
stimulation. However a subpopulation of cells regains IL-7R expression during immune 
response (Bachmann et al., 2005). These IL-7Rhigh cells will preferentially become 
memory T cells whilst IL-7Rlow cells are terminally differentiated effectors that do not 
progress into the memory pool (Kaech et al., 2003).  
Similarly IL-2Rα (CD25) is rapidly upregulated on effector cells. Among those cells 
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IL-2Rαhigh cells give rise to terminally differentiated effector cells while IL-2Rαlow cells 
are capable of strong recall responses and resemble long-lived memory T cells (Pipkin 
et al., 2010).  
In addition, a number of transcription factors including T-bet and Eomes, Bcl-6 and 
Blimp1 are implicated in the regulation of memory T cells. Joshi et al showed that 
CD8+ T cells expressing high T-bet levels become short lived effector T cells while low 
levels of T-bet are associated with memory precursor effector cells (Joshi et al., 2007). 
Similarly, whereas Blimp1 transcription factor is required for the differentiation of 
effector T cells during LCMV infection, Blimp1 deficient CD8+ T cells fail to 
downregulate IL-7R and adopt a memory precursor phenotype rather than an effector 
phenotype (Kallies et al., 2009).  
Although research has mainly focused on the role of cytokines, antigenic signals and 
transcription factors in shaping T cell memory responses, recent several key studies 
demonstrated an important role of cellular metabolism in regulating differentiation of 
effector CD8+ T cells to memory T cells (Araki et al., 2009; Pearce et al., 2009; Rao et 
al., 2010). The view that is put forward by these works is that ATP production by 
effector T cells mainly relies on glycolysis, which is an anabolic form of metabolism 
since it promotes conversion of glucose into various cellular macromolecules (Jones and 
Thompson, 2009). On the other hand, naïve and memory cells are quiescent cells that 
rely on catabolic processes such as oxidative phosphorylation to support their energy 
generation. Therefore, the idea is that the conversion from anabolic metabolism in 
effectors to catabolic metabolism is essential for memory formation. Primarily, studies 
done in E. Pearce, K. Araki and our group proposed mTOR and AMPK signaling 
pathways as central regulators promoting catabolic metabolism, thus augmenting CD8+ 
T cell memory development (Araki et al., 2009; Pearce et al., 2009) and unpublished 
data D.A Cantrell. The role of mTOR in determining effector versus memory generation 
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and fate decision in CD4 T cells subsets will be discussed in greater detail in mTOR 
section.  
1.3.3 Tc17 cells (IL-17 producing CD8 T cells) 
Whereas much is known about cytotoxic T cells and IL-17 producing CD4 T cells, there 
is a limited number of publications that address the role and function of IL-17 
producing CD8 T cells also known as Tc17 cells. Similarly to CD4 T cells, CD8 T cells 
cultured in vitro in presence of pro-inflammatory cytokines IL-6 and TGF-β 
differentiate into IL-17 secreting CD8+ T cells that express Rorγt (Liu et al., 2007). IL-
2, IL-4, Ifn-γ and IL-12 cytokines that were found to antagonize Th17 differentiation 
had also an inhibitory effect on Tc17 polarization.  
Under Th17 polarizing conditions CD8+ T cells express very low levels of the typical 
molecules expressed in CTLs such as granzyme B, Eomes and Ifn-γ, thus lacking 
cytolytic activity (Huber et al., 2009; Yen et al., 2009). Nonetheless, despite the low 
expression of Eomes in differentiated Tc17 in-vitro, Eomes and T-bet joint expression 
and function in CD8+ T cells in vivo was sufficient to suppress IL-17 type program in 
LCMV infected double T-bet and Eomes KO mice. CD8+ T cells from the double KO 
mice exhibited an impaired Ifn-γ production accompanied by an anomalous IL-17 
production (Intlekofer et al., 2008). Moreover, this excessive IL-17 production by 
CD8+ T cells was a direct cause of the virus-induced wasting syndrome, heavy 
neutrophil infiltration and pathology in the lungs, liver and brain.  
In vivo, IL-17 producing CD8 T cells were found in the intestines and lung tissues, 
suggesting a role of Tc17 in immune homeostasis in mucosal tissues (Kryczek et al., 
2007).  
Importantly CD8+ T cells that produced IL-17 cytokine were detected in the lungs of 
mice infected with influenza A virus (Hamada et al., 2009). In this study, the protective 
role of Tc17 was demonstrated using IL-17 depleting antibodies and adoptive transfer 
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of Tc17 generated in vitro. Mice that were injected with anti-IL17 antibodies following 
a secondary lethal challenge with the virus exhibited an increase in weight loss and 
eventually died. In contrast, mice that were injected with in vitro generated Tc17 cells 
lost less weight and showed better survival rates. Injected Tc17 also expanded and 
correlated with a significant recruitment of neutrophils to the lungs shortly after the 
challenge. These results suggest that in this model IL-17 production by Tc17 provides 
protection by recruiting host neutrophils and probably other immune cells including 
macrophages and B cells.  
 
1.4 CD4+ T cells  
CD4+ T cells express the CD4 co-receptor for MHC class II molecules, therefore 
recognizing only peptides presented in the context of MHC class II. Upon stimulation 
CD4 T cells can differentiate into five main types of T helper cells: Th1, Th2, Th17, iT 
regs and Tfh (T follicular helper cells), characterized by unique cytokine profile they 
produce and thus a specialized function in the immune response. The decision of a CD4 
T cell to differentiate to one of these regulatory/effector subpopulations is determined 
by the set of cytokines present during TCR-mediated activation process. Subsequently 
signaling driven by these cytokines induces expression of master transcription factors 
that determine the fate of a helper CD4+ T cell. In the present thesis there is a large 
focus on Th17 cells and hence a more detailed review of the Th17 cell literature is 
required. The various fates of CD4+ T cells are shown in figure 1.4 below. 
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Figure 1.4 Subsets of CD4 helper T cells  
Figure adapted from the article: “Understanding the development and function of T 
follicular helper cells” by Roza I. Nurieva and Yeonseok Chung, Cellular and 
Molecular immunology, 2010. Nurieva, R. I., & Chung, Y. (2010). Figure above 
summarizes the fates of CD4 T helper cells, their function, cytokines they produce, their 
characteristic master transcription factors and cytokines essential for their fate 
determination.  
 
1.4.1 Th17 Cells 
1.4.1.1 Discovery of Th17 T-cells 
Since Coffman and Mosmann proposed the Th1/Th2 hypothesis in 1986 (Mosmann et 
al., 1986) and until about ten years ago, it was believed that Th1 cells were the only 
pathogenic T cells in autoimmune diseases such as experimental autoimmune 
encephalitis (EAE) and collagen-induced arthritis (CIA). In EAE models myelin-
specific T cells produced large amounts of IFN-γ upon recall response to an immunized 
myelin antigen (Zamvil and Steinman, 1990). Moreover, induction of a competent IL-
12 receptor on developing Th1 cells was shown to potentiate their IFN-γ production 
(Yang et al., 1999). Therefore, the link between Th1 and autoimmunity was based on 
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studies in which disease development was prevented by treatment with neutralizing 
antibodies for p40 subunit of the IL-12 receptor (Leonard et al., 1995). However, 
blocking IFN-γ itself seemed to worsen autoimmune responses (Billiau et al., 1988; 
Ferber et al., 1996). Discovery of a new member of IL-12 family, IL-23 receptor, which 
shared the p40 subunit with IL-12 (Oppmann et al., 2000) and later studies by Cua and 
co-workers showing that EAE development is ablated in IL-23 but not IL-12 deficient 
mice (Becher et al., 2003; Cua et al., 2003; Murphy et al., 2003), resolved this paradox 
and led to identification of Th17 cells as an independent subset of T helper cells (Dong, 
2006; Weaver et al., 2006; Bettelli et al., 2007).  
 
1.4.1.2 Th17 differentiation and transcriptional regulation 
As their name implies, Th17 produce IL-17 family cytokines which include 6 members: 
IL-17A, B,C,D,E and F (Xu and Cao, 2010).  IL-22, IL-17A and IL-17F are the main 
cytokines that are co-expressed by Th17 cells and will be discussed later on in this 
section (Chang and Dong, 2007; Wright et al., 2007). 
It is now widely accepted that TGF-β together with recombinant or DC-derived IL-6 are 
essential for Th17 differentiation from naïve CD4 T cells in vitro (Bettelli et al., 2006; 
Mangan et al., 2006; Veldhoen et al., 2006a; 2006b). Since high IL-17 levels are found 
in the serum and cerebrospinal fluid of multiple sclerosis patients (Kebir et al., 2007), 
Th17 cells biology was mainly investigated using Experimental autoimmune 
encephalomyelitis (EAE) mouse model, which partially serves as a model for the human 
multiple sclerosis disease (Fuller et al., 2004). The importance of TGF-β and IL-6 
cytokines in Th17 differentiation in vivo was demonstrated using mice that have a 
defective TGF-β signalling (CD4dnTGFβRII) in their T cells and mice that lack IL-6, 
respectively. Those mice generated less Th17 cells and were resistant to the 
development of EAE (Eugster et al., 1998; Okuda et al., 1998; Samoilova et al., 1998; 
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Bettelli et al., 2006; Veldhoen et al., 2006b). The mechanism of TGF- β action is not 
completely understood, but recently it was shown that TGF-β operated independently of 
Smad2 and Smad3 to supress Eomesodermin expression, which inhibits Th17 
differentiation by binding to IL-17 and Rorc promoters (Ichiyama et al., 2011).  
Although it is clear that TGF- β is required for Th17 differentiation, the source 
of this cytokine is still under investigation. The fact that mice that have a disrupted 
TGF-β gene specifically in T cells exhibit enhanced Th1 and Th2 responses in addition 
to a defect in Th17 generation during EAE, suggests that T cells and even T regs 
themselves can serve as an autocrine or paracrine source of TGF-β (Li et al., 2006). On 
the other hand, a local blockade of TGF-β at the site of immunization rather than a 
systemic blockade was most efficient at delaying the development of EAE, meaning 
that TGF-β is also produced by APCs (antigen presenting cells) upon T cell-APC 
interaction thus promoting Th17 differentiation (Veldhoen et al., 2006b). Like TGF-β 
IL-6 is β a pleiotropic cytokine with many effects. It is produced by dendritic cells, 
monocytes, macrophages, mast cells, B cells and some activated T cells, but also by 
fibroblasts, endothelial cells and keratinocytes (reviewed in (Van Snick, 1990). IL-6 
alone leads to a strong but transient induction of STAT3, a main signal transducer, 
which directly binds to IL-17A/IL-17F locus and has a crucial role in Th17 
differentiation in vitro and in vivo since IL-6 deficient mice do not generate Th17 
responses (Chen et al., 2006; Laurence et al., 2007; Mathur et al., 2007; Liu et al., 
2008). In addition, IL-6 dependent STAT3 activation was shown to inhibit Foxp3 
expression in vitro (Yao et al., 2007). Therefore, STAT3 specific deletion in T cells 
prevented Th17 generation and promoted T regulatory cell differentiation, thus blocking 
inflammatory responses in a mouse colitis model (Durant et al., 2010). In the same 
work using Chip-Seq analysis it was demonstrated that STAT3 induced the 
transcription of multiple genes involved in Th17 differentiation, cell activation, 
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proliferation and survival (Durant et al., 2010). Moreover, selective deficit in 
development of Th17 cells in patients with hyper-IgE syndrome (HIES or Job 
syndrome) reinforces the importance of STAT3 in Th17 differentiation (Milner et al., 
2008). Job syndrome patients have a genetically determined inability to signal through 
STAT3, due to dominant negative mutations in the SH2 domain or the DNA-binding 
domain of this molecule (Holland et al., 2007; Minegishi et al., 2007; Ma et al., 2008). 
In this context it was shown that TGF-β signaling suppresses the induction of Th17 
inhibitors such as SOCS3, a well-known negative regulator of STAT3 (Qin et al., 
2009). Mechanistically, the combinatorial action of IL-6 and TGF-β in inducing Th17 
lineage is not completely understood. It is known that naïve T cells express IL-6R that 
comprises the IL-6Rα and the signaling subunit gp130. When IL-6 binds to IL-6R, 
gp130 is activated and results in a subsequent STAT3 activation (Taga et al., 1989). 
While gp130 subunit is constantly expressed, TCR stimulation as well as exposure to 
IL-6 cytokine lead to shedding of IL-6Rα and subsequently a decreased responsiveness 
to IL-6. TGF-β in turn plays a role in IL-6Rα expression and thus maintenance of 
responsiveness of T cells to IL-6 (Korn et al., 2009).  
TGF-β and IL-6 were also found to drive the expression of the “master 
regulator” of Th17 differentiation, the transcription factor RORγt. Transduction of naïve 
T cells with a retroviral vector containing RORγt was sufficient to induce the 
development of Th17 cells (Ivanov et al., 2006). Furthermore, Rorγt-/- mice have 
reduced numbers of Th17 cells, and are resistant to autoimmune diseases (Ivanov et al., 
2006). IL-1 receptor is induced in T cells by IL-6 and IL-1 signaling is required in 
dendritic cell-mediated Th17 differentiation. Mice that are deficient in IL-1R were 
reported to be resistant to EAE and defective in Th17 generation in contrast to the WT 
mice (Sutton et al., 2006). In vitro, in the absence of dendritic cells, which serve as a 
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good IL-1 source, IL-1 in combination with IL-6 and TGF-β promotes optimal Th17 
differentiation (STOCKINGER and VELDHOEN, 2007).  
Another important cytokine, IL-21 is induced by IL-6 and acts in a positive feedback 
loop to amplify Th17 responses (Nurieva et al., 2007). Using IL-21R deficient mice it 
was shown that IL-6 promotes a sequential engagement of IL-21 and IL-23R in naïve 
antigen-receptor stimulated CD4 cells. This allows IL-21, which is acting partially 
through STAT3 signaling, and in synergy with IL-23 and TGF-β, to induce Rorγt - 
dependent Th-17 differentiation (Zhou et al., 2007).  
Although IL-23 cytokine function in Th17 biology is not yet fully understood, it is 
established that naïve T cells do not express IL-23 receptor (Zhou et al., 2007). 
Therefore, IL-23 plays a role in expanding already differentiated Th17 cells and 
maintaining IL-17 production (Veldhoen et al., 2006a). Those functions were revealed 
since the presence of IL-23 in cultures of activated Th17 cells resulted in their 
proliferation (Oppmann et al., 2000) and increased IL-17 production (Langrish et al., 
2005). In addition, IL-23 could stimulate a renewed expression of IL-7Rα on the surface 
of recently generated Th17 cells in vivo (McGeachy et al., 2009). This receptor was 
highly expressed in cerebrospinal fluid of multiple sclerosis patients (Gregory et al., 
2007). Subsequently, in an in vivo experiments, administration of IL-7 at the onset of 
EAE exacerbated disease severity in mice following an increase in infiltrating Th17 in 
the lymph nodes (Gregory et al., 2007). On the other hand, treatment with anti IL-7Rα 
monoclonal antibodies after the onset of the disease resulted in a reduction in disease 
severity. Thus, IL-7-IL-7R signalling is required for survival and expansion of 
committed Th17 cells, while dispensable during their differentiation (Liu et al., 2010).  
Apart from Rorγt transcription factor other transcription factors were implicated in 
Th17 differentiation such as the Aryl Hydrocarbon Receptor (AhR), IκBζ, BATF, 
Runx1, PPARγ and IRF4. Some, like the AhR serve as positive regulators promoting 
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Th17 differentiation (Veldhoen et al., 2009) and others like PPARγ repress Th17 
lineage (Klotz et al., 2009).  
Microarray analysis showed a high expression of the Aryl Hydrocarbon Receptor in 
Th17 cells differentiated in vitro in contrast to undetectable levels in Th0, Th1 and Th2 
cells (Veldhoen et al., 2008). AhR is a ligand activated transcription factor. It is well 
established that activation of this receptor using endogenous (Veldhoen et al., 2009; 
Quintana et al., 2010) or exogenous ligands such as the 6-formylindolo[3,2-b] carbazole 
(FICZ) induces the frequency of Th17 cells and their production of IL-17 and IL-22 
cytokines. Furthermore, AhR deficiency results in decreased generation of IL-17 
producing T cells (Kimura et al., 2008; Veldhoen et al., 2008) and complete failure in 
IL-22 production (Veldhoen et al., 2008). The type of the culture medium has an impact 
on the differentiation of Th17 cells in vitro: IMDM but not RPMI supports optimal 
Th17 differentiation. The reason is that IMDM contains higher levels of amino acids 
that can be a source of AhR agonists (Veldhoen et al., 2009). The mechanism of how 
exactly AhR promotes Th17 differentiation is not clear yet. Also it is not known which 
signals maintain AhR expression in these cells in vivo and in vitro. Retroviral 
transduction experiments established that AhR alone is not sufficient to promote IL-22 
production and that in addition it requires RORγt transcription factor to induce IL-22 
production. Moreover, neither the transduction with AhR alone or in combination with 
RORγt was sufficient to activate IL-22 production (Veldhoen et al., 2009). However, it 
is not clear whether those retroviral transduction experiments included also the 
transduction of ARNT (AhR nuclear translocator), which was reported to be required 
for the AhR transcriptional function in the nucleus (Tomita et al., 2000). Therefore, it is 
conceivable that AhR interacts with other binding partners that positively or negatively 
influence Th17 differentiation. One such factor is the Liver X receptor (LXR), which 
serves as a negative regulator of Th17 differentiation. LXR mediates the induction of 
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the Srebp-1 transcription factor, which physically interacts with the AhR thus 
interfering its function and suppressing Th17 differentiation (Cui et al., 2011). Another 
factor, which was reported to be downstream AhR target gene is the Aiolos protein. A 
recent work by Quintana et al. demonstrated that initial signaling via IL-6 and TGF-β 
leads to activation of STAT3 and the expression of AhR, which together upregulate 
expression of the gene encoding Aiolos. In Th17 cells, Aiolos, which belongs to the 
Ikaros family of proteins directly binds to and suppresses IL-2 through epigenetic 
modification (Quintana et al., 2012). According to the model proposed by Quintana et 
al., Aiolos therefore acts as an internal safeguard mechanism for the Th17 
differentiation program by opposing IL-2 expression in Th17 cells. 
Interferon regulatory factor-4 (IRF4) has been recently reported to be critical for 
Th17 cell differentiation (Brüstle et al., 2007). IRF-4 deficient T cells fail to produce 
any IL-17. EAE cannot be induced in IRF-4-/- mice and IRF-4 appears to play a role in 
RORγt expression but not in Foxp3 induction. On the other hand the absence of IRF-4 
binding protein (IBP) that negatively regulates IRF-4 signaling results in Th17 
associated autoimmunity (Chen et al., 2008). Another negative regulator of Th17 
differentiation is PPARγ which was found to repress Rorγt induction (Klotz et al., 
2009).  
AP-1 B cell activating transcription factor (Batf) is yet another transcription factor that 
has a vital importance in Th17 differentiation, however, unlike AhR, IκBζ and Rorγt, 
which are unique to the Th17 cells this transcription factor is also expressed in Th1 and 
Th2 subsets (Schraml et al., 2009). In this work it was shown that Batf forms a 
heterodimer with JunB in Th17 cells, and binds to IL-17, IL-21 and IL-22 promoters as 
well as two intergenic regions between the IL-17A and the IL-17F genes. Using T cells 
lacking Batf, the authors showed that Batf is not required for appropriate Th1 or Th2 
cells generation in vitro. However, the differentiation of Th17 cells was completely 
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impaired. Moreover, these mice also failed to produce IL-17 in both CD4+ and CD8+ T 
cells in vivo.  
Th17 cells have reciprocal relationships with T-regulatory cells expressing the 
forkhead/winged helix (Foxp3) transcription factor. Interestingly, TGF-β can induce 
both Foxp3 and Rorγt, the T-reg and Th17 lineage transcription factors, respectively 
(Ichiyama et al., 2008; Zhou et al., 2008). In fact, Foxp3 was reported to physically 
interact with Rorγt, thus inhibiting IL-17 transcription (Zhou et al., 2008). Therefore, 
early signaling by TGF-β in a CD4+ T cell induces both of these transcription factors 
and in fact, CD4+ T cells that express both Rorγt and Foxp3 can be found in the 
periphery (Lochner et al., 2008). Runx1 in turn can bind to both Rorγ and Foxp3 to 
bring about positive and negative effects on IL-17 transcription, thus determining the 
eventual fate of the cell (Zhang et al., 2008). A recent work by Lazarevic et. al showed 
that T-bet Tyr-304 can form a complex with Runx1. This complex blocked Runx1-
mediated transactivation of the Rorc promoter and therefore inhibited Th17 
differentiation program (2010). In this work the authors demonstrated that a master 
regulator T - bet drives commitment to a Th1 lineage by activating one genetic program 
while in parallel silencing the activity of competing regulators. Which transcription 
factor is serving the same role in determining whether a cell would become T-reg or an 
effector Th17 cell is not yet known. However, there is an increasing number of evidence 
that this role can be performed by the mTOR-driven hypoxia inducible factor (Hif-1α) 
(Battaglia et al., 2005; Delgoffe et al., 2009; Dang et al., 2011). The function of Hif-1α 
in Th17 cells will be discussed in more details in the next section.  
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1.4.1.3 Effector cytokines and effector functions of Th17 cells 
Th17 cells mainly produce IL-17A, IL-17F, IL-22 and TNF-α cytokines. It is 
important to mention that IL-17A and IL-17F are also secreted by other immune cells, 
including γδ, NKT cell, NK cells, neutrophils and eosinophils (Korn et al., 2009). 
Therefore, both adaptive and innate cells produce this cytokine, which allows biological 
functions against pathogens. Therefore, when IL-17 mediated innate response fails to 
eradicate the pathogen adaptive IL-17 producing cells are recruited.   
IL-17A is a disulfide-linked glycoprotein and it shares a 55% homology with IL-17F 
cytokine (Yao et al., 1995). IL-17 family of cytokines includes other members such as 
IL-17B, IL- 17C and IL-17D, but those are produced by non T cell sources. IL-17A and 
IL-17F can either exist as IL-17A homodimers or IL-17A/IL-17F heterodimers (Liang 
et al., 2007). IL-17RA is the cognate receptor for IL-17A and IL-17F, although it binds 
to IL-17A with a higher affinity (Moseley et al., 2003).  
IL-17RA is highly expressed on hematopoietic cells and to a lesser extent on 
osteoblasts, fibroblasts, endothelial and epithelial cells. In addition, IL-17RA can form a 
heterodimer with IL-17RC, which is highly expressed on non-hematopoietic cells and 
binds IL-17F cytokine (Kuestner et al., 2007). Both IL-17A and IL-17F have pro-
inflammatory properties and effect various cell types to induce the expression of 
metalloproteinases, cytokines including TNF, IL-1β, IL-6, GM-CSF, G-CSF, and 
chemokines such as CXCL1, CXCL2, and CXCL5 in mouse fibroblasts and CXCL1, 
CXCL2, CXCL5 and CXCL8 in human epithelial cells (Fossiez et al., 1996; Jovanovic 
et al., 1998; Laan et al., 1999; Witowski et al., 2000; Laan and Lindén, 2002). IL-17 is 
also involved in the proliferation, maturation and chemotaxis of neutrophils (Fossiez et 
al., 1996). Therefore, on one hand, IL-17 can have a beneficial effect when it functions 
in host defense, but on the other hand IL-17 mediates immune responses such as 
recruitment of neutrophils and macrophages, which can result in secondary tissue 
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damage after infection. For instance, whereas the clearance of some pathogens such as 
Candida and Klebsiella depends on neutrophil response (see below), other bacteria such 
as Pseudomonas aeruginosa and fungi Aspergillus fumigatus induce IL-17 response and 
neutrophil trafficking but can be also cleared irrespectively of a strong neutrophil 
infiltration. In those cases IL-17 response is not protective and results in 
immunopathology and tissue damage.  
 
The notion that Th17 are involved in host defense derives from key study using IL-17a-
/-, IL-17f-/- and IL-17a/f-/- mice showing that IL-17A and IL-17F are required for the 
clearance of specific types of pathogens that are not eradicated by Th1 and Th2 subsets 
(Ishigame et al., 2009). In this study IL-17 cytokines were shown to play an important 
role in host defense processes by inducing anti-microbial peptides such as β-defensin1, 
3 and 4, and lipocalin2 thus protecting against S. aureus and C. rodentium. IL-17 is also 
important in the host defense against extracellular bacteria such as Klebsiella 
pneumoniae (Happel et al., 2005) or Bacteroides fragilis (Chung et al., 2003) and 
against fungi such as Candida albicans. In fact, IL17-RA KO mice do not mount 
immune responses against Klebsiella (Ye et al., 2001) and Candida (Huang et al., 2004) 
and experience an increased mortality due to deficiency of neutrophils recruitment to 
the site of infection. Additional evidence for the importance of IL-17 during Candida 
infection come from patients with IL-17F or IL-17 receptor A deficiency (Puel et al., 
2011). Those patients are suffering a chronic mucocutaneous candidiasis disease 
(CMCD), which is characterized by persistent infections of the skin, nails, and oral and 
genital mucosal tissues caused by Candida albicans. In other cases of CMCD, the 
patients generated autoantibodies to IL-17 and IL-22 cytokines, thus experiencing 
autoimmunity and persistent Candidiadis (Kisand et al., 2010) or had a gain-of-function 
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mutations in STAT1, which strongly inhibits the development of IL-17-producing cells 
(Liu et al., 2011).  
Th17 cells and Th-17 associated cytokines are also implicated in a variety of 
autoimmune diseases such as arthritis (Lubberts et al., 2005), multiple sclerosis (Lock et 
al., 2002), psoriasis (Teunissen et al., 1998; Res et al., 2010) and inflammatory bowel 
disease (Fujino et al., 2003). In brief: in arthritis IL-17A and IL-17F contribute to the 
destruction of the cartilage since treatment with IL-17A antibodies decreases joint and 
bone damage (Lubberts et al., 2004). Also in multiple sclerosis or the mouse model 
EAE, IL-23 driven Th17 rather than IL-12 driven Th1 responses appeared to be critical 
for the disease development (Cua et al., 2003). At the same time IL-17A deficiency in 
mice results in a delayed onset and reduced severity of EAE (Komiyama et al., 2006). 
Analysis of human psoriatic skin identified Th17 cells that express IL-23R, IL-17A, IL-
17F and CCL20 as well as the transcription factor Rorγt (Wilson et al., 2007). CCL20 is 
a chemokine that can be secreted by Th17 cells in vivo and in vitro. Signaling through 
the CCR6 expressed by Th17 promotes their chemo-attraction and migration to the 
target tissues (Hirota et al., 2007; Yamazaki et al., 2008). Patients with inflammatory 
bowel disease display high levels of IL-17A mRNA and protein in the intestinal 
mucosa. Furthermore, IL-17A expression is exacerbated in the gut and can be detected 
in the serum of patients with an ongoing Crohn’s disease (Fujino et al., 2003). In 
contrast, in IBD mouse model, mice deficient in IL-17AR are significantly protected 
from the disease compared to WT mice (Zhang et al., 2006).  
IL-22 is another important cytokine that is produced by Th17 cells in response to IL-23 
in vivo and in response to IL-6 in vitro (Chung et al., 2006; Liang et al., 2006). 
Therefore, in vivo abundant IL-22 expression by Th17 cells requires the expression of 
IL-23R (Kreymborg et al., 2007). Although Th17 and memory CD4+ T cells are the 
dominant IL-22 producers, gut NK cells and Th1 cells can also make IL-22 (Kumar et 
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al., 2012). Target cells of IL-22 are exclusively cells from a non-hematopoietic origin. 
IL-22R is mainly expressed by epithelial cells, hepatocytes, keratinocytes and epithelial 
cells of the gut, but not by T cells (Andoh et al., 2005; Zheng et al., 2007; Ouyang et al., 
2008). Il-22 has three major biological roles: First, IL-22 can act as a pro-inflammatory 
cytokine by inducing production of cytokines, chemokines and acute-phase proteins in 
various immune cell types. Second: IL-22 induces production of anti-microbial peptides 
such as β-defensins and finally IL-22 activates the transcription of multiple genes 
involved in wound healing and tissue repair (Boniface et al., 2005; Brand et al., 2006; 
2007). Therefore, like IL-17, IL-22 under certain circumstances is not pro-inflammatory 
but has a protective role in inflammation as shown in the liver (Zenewicz et al., 2008), 
the gut (Sugimoto et al., 2008) and the myocardium (Chang et al., 2006). In other cases, 
IL-22 in combination with IL-17 cytokine has a pathological role in autoimmunity. For 
instance, IL-22 is upregulated in psoriatic skin (Wolk et al., 2009) and in vitro it 
induced psoriatic features in cultured human epidermis (Boniface et al., 2005). In 
addition, its expression similarly to IL-17 was augmented in Crohn’s disease and colitis 
(Andoh et al., 2005; Brand et al., 2006), in rheumatoid arthritis (Ikeuchi et al., 2005) 
and asthma (Whittington et al., 2004).  
 
Are Th17 cells terminally differentiated or do they show any plasticity? The answer is 
that several studies showed the ability of Th17 cells to convert from IL-17 to Ifn-γ 
producers. Purified Th17 were shown to give rise to Th1 cells after exposure to IL-12 
cytokine in a Stat4 and T-bet-dependent manner (Bending et al., 2009; Lee et al., 2009; 
Nurieva et al., 2009). In these studies it was demonstrated that converted Th1-like cells 
produced Ifn-γ and induced colitis upon transfer of Th17 cells into lymphopenic mice 
(Lee et al., 2009) whereas in a diabetes model transferred Th17 cells, completely devoid 
of Ifn-γ expression at the time of transfer, rapidly converted to secrete Ifn-γ in the 
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NOD/SCID recipients thus causing a disease (Bending et al., 2009). Similarly, using an 
adoptive transfer induced ocular inflammation model, it was shown that transfer of 
Th17 into an inflamed eye of the host resulted in Th17 that expressed both IL-17 and 
Ifn-γ or only Ifn-γ cytokine (Shi et al., 2008). Comparative long-range DNase I 
hypersensitivity (HS) and histone modification analyses of the IL-17A, IL-17F and Ifn-
γ loci in naive, Th1, and Th17 cells revealed chromatin instability of key transcription 
factors and cytokine genes of Th17 cells (Mukasa et al., 2010). This work identified the 
existence of permissive epigenetic modifications across the clusters of IL-17A and IL-
17F loci. Those modifications however, could be rapidly reversed upon exposure to IL-
12 cytokine that mediated T-bet dependent Rorc silencing thus converting Th17 to Th1 
cells. In the same work it was also shown that Th17 cells showed bivalency at the T-bet 
and Gata-3 promoters, suggesting that these genes, and the transcriptional programs 
they initiate, are poised for expression. A recent work by Hirota et. al provided a solid 
proof to the plastic nature of Th17 cells (Hirota et al., 2011). In this study a non-
dynamic L-17A fate reporter mouse model was established and allowed a permanent 
labeling of cells that are producing or have produced IL-17 cytokine at any stage. The 
authors have shown that Th17 cells had distinct capacities for alternative fates 
depending on the type of inflammation. During chronic inflammatory responses in the 
EAE model Th17 rapidly lost expression of IL-17A and switched on Ifn-γ production, 
whereas in a model of acute cutaneous Candida infection, Th17 cells did not diverged to 
an alternative fate. This study suggested that the fate of Th17 cells in vivo is determined 
by various inflammatory conditions, which allow cell-fate plasticity.  
 
1.5 Environment of T cells  
Our main interest during this PhD project was to understand how T cells sense and 
adapt to their environment. The T cell environment is composed of cytokines and 
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byproducts secreted by bystander cells, nutrients, oxygen availability and dietary 
composites such as those that are present in the gut. However, it is worth to note that 
like other cells of the body immune cells may be exposed to also pollutants. 
Understanding how T cells adapt to their environment is important since environmental 
cues received by T cells are translated to distinct signal transduction pathways, which 
lead to physiologically appropriate changes in gene expression. Subsequently, these 
changes in gene expression shape T cells programs and consequently the immune 
responses they mediate.  
 
1.5.1 mTOR signaling pathway in CD8 T cells  
1.5.1.1 Overview of mTOR signaling  
An important environmental sensor in T cells that monitors amino acid and glucose 
availability is mTOR (mammalian target of rapamycin) This is a 289kDA serine-
threonine kinase that is a member of the phosphoinositide 3-kinase related kinase 
family. mTOR kinase was initially identified as the target of a compound rapamycin, 
which was extracted from Streptomyces hygroscopicus and later was found to have 
immunosuppressive and antitumor properties (Schmelzle and Hall, 2000; Sabatini, 
2006). Rapamycin as a potent immunosuppressant is widely used in the clinic, mainly 
in transplantation procedures (reviewed in (Saunders et al., 2001) (Cutler and Antin, 
2004; Campistol et al., 2009). It is not entirely clear how Rapamycin promotes immune-
suppression. However, several studies addressed this question and showed that 
rapamycin can inhibit CD8 T cells differentiation while promoting CD8 memory 
formation (Araki et al., 2009; Rao et al., 2010). Others showed that rapamycin operates 
by promoting generation of the CD4+Foxp3+ T regulatory cells that paly a role in 
maintaining immunological tolerance (Battaglia et al., 2005; Haxhinasto et al., 2008).  
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The mTOR signaling pathway is thought to have a central role in regulating metabolic 
programs thus linking metabolism and immune function. This pathway is used by cells 
to integrate growth factor, cytokines, nutritional and energetic environmental cues such 
as the availability of amino acids in order to promote their metabolic activities (Fox et 
al., 2005a; Jones and Thompson, 2007; Pearce, 2010). Alternatively, when there is a 
shortage of nutrients, mTOR is inhibited, leading to a decrease in biosynthesis and 
increase in autophagy processes (Yu et al., 2010).  
 
mTOR signals via two distinct protein complexes (mTORc1 and mTORc2). mTOR 
complex 1 (mTORc1) contains the scaffolding protein regulatory-associated protein of 
mTOR (raptor) as well as mammalian lethal with Sec13 protein 8 (mLST8), the proline-
rich PKB substrate 40 kDa (PRAS40), and DEP-domain-containing mTOR-interacting 
protein (Deptor) (Laplante and Sabatini, 2009). The second mTOR-signaling complex 
(mTORC2) consists of mLST8, the scaffolding protein raptor-independent companion 
of TOR (rictor), mSIN1 proteins, and the protein observed with rictor (Protor). The 
assembly of mTOR with its various partner proteins to form mTORc1 and mTORc2 has 
functional and pharmacological consequences. Rapamycin and other mTOR inhibitors 
inhibit mTOR by binding to the FKBP12 domain on mTOR thus blocking RAPTOR 
assembly with mTOR and preventing mTORc1 activity (Abraham and Wiederrecht, 
1996).  
 
1.5.1.2 Upstream regulators of mTOR 
mTOR integrates four major upstream signals including growth factors, energy status, 
oxygen and amino acid availability to regulate processes that have a role in cell growth.  
In context of signaling, the closest upstream regulator of mTORc1 signaling is the Ras 
homolog enriched in brain (RHEB) (Yee and Worley, 1997; Saucedo et al., 2003). 
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RHEB is a small GTPase that is negatively controlled by the GTPase-activating protein 
(GAP) activity of a complex consisting of tuberous sclerosis complex 1 (TSC1) and 
TSC2. TSC1/2 complex phosphorylation by growth factor induced-PKB or ERk1/2, 
inhibits its GAP activity thus activating RHEB and leading to mTORc1 activation. 
Additionally, PKB can activate mTORc1 also independently of TSC1/2 by 
phosphorylation of PRAS40, thus relieving its inhibitory effect on mTORc1 (Vander 
Haar et al., 2007; Wang et al., 2007). On the other hand, phosphorylation of TSC1/2 by 
AMP-activated kinase (AMPK), promotes the ability of this complex to inhibit 
mTORc1. Hence, AMPK that is activated in response to a decreased ATP:AMP ratios, 
which are indicative of low energy stores inhibits mTORc1 activity (Tamas et al., 
2006). The hypoxia-induced factor protein regulated in the development of DNA 
damage response 1 (REDD1) also was found to inhibit mTOR by releasing TSC2 from 
its inhibitory association with 14-3-3 proteins (Brugarolas, 2004; Bottino et al., 2005; 
DeYoung et al., 2008). This ability of REDD1 to reduce mTORC1 signaling by 
disrupting the interaction of TSC2 and 14-3-3 has probably evolved to limit energy-
consuming processes under conditions of low oxygen.  
 
Amino acids are a strong signal that positively regulates mTORc1. It was recently 
shown that leucine is required for mTORc1 activation and is transported into the cells in 
a glutamine-dependent manner (Nicklin et al., 2009). Several works suggest that RAG 
proteins, a family of 4 related small GTPases interact with mTORc1 in an amino acid 
dependent manner (Kim et al., 2008; Sancak et al., 2008). For instance, Sancak et. al 
showed that the presence of amino acids induces binding of Rag proteins to the Raptor 
protein. This interaction promotes mTORc1 re-localization to a perinuclear region 
where it is localized in a closer proximity to its activator RHEB (Sancak et al., 2008).  
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Immunologically relevant signals that regulate mTORc1 activity in T cells are the T cell 
antigen receptor, cytokines and growth factor receptors. How these receptors activate 
mTORc1 has not been explored. In CD8+ mature Cytotoxic T cells IL-2 signaling 
mediated by PDK1 and not by PI3K/PKB pathways controls mTORc1 activity 
(unpublished data in our group). In Th17 cells deletion of SIGIRR which is a negative 
regulator of IL-1 signaling led to increased mTOR activity and enhanced Th17 
polarization, suggesting that IL-1 signaling is involved in mTOR stimulation (Gulen et 
al., 2010). Many models of T cell signaling assume that mTORc1 activation is mediated 
by PI3K/PKB signals. However, the criticism of experiments that support the linear 
model of PI3K/PKB/mTORc1 is that many conclusions were made after using the 
broad-specificity PI3K inhibitors such as LY294002 that has off-target effects and 
serves as a potent direct inhibitor of mTORc1 (Bain et al., 2007). Moreover, although 
the activation of PKB by PDK1 has long been thought to be critical for the activation of 
mTORc1, there are now new evidence for PDK1 dependent and PKB independent 
pathways in controlling metabolism, survival and proliferation in CD8 T cells 
(Macintyre et al., 2011). In this work it was shown that while PKB inhibition did not 
prevent mTORc1 activity, deletion of PDK1 abolished it completely. Therefore, there is 
a possibility that PKB-independent mTORc1 activity in CD8 T cells can be explained 
by redundancy with other AGC kinases. Possible candidates are serum/glucocorticoid-
regulated kinase (SGK), which shares substrate specificity with PKB (Brunet et al., 
2001) or the PIM family of Ser/Thr kinases which have a role in T cell survival, and 
they also have a substrate specificity similar to PKB (Fox et al., 2005b).   
 
1.5.1.3 Downstream targets of mTOR 
Two main mTORc1 substrates are the eukaryotic initiation factor 4E binding protein 1 
(4E-BP1) and the p70 ribosomal S6 kinase 1 (S6K1). When 4E-BP1 is phosphorylated 
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by mTORc1 it does not bind to the eIF4E, thus enabling eIF4E to promote cap-
dependent translation of mRNAs characterized by a 5’ terminal oligopyrimidine (TOP) 
motifs (Thoreen et al., 2012). The stimulation of S6K1 activity by mTORc1 leads to 
increase in mRNA biogenesis, cap-dependent translation, elongation and translation of 
ribosomal proteins (reviewed in (Ma and Blenis, 2009).  
mTORc1 regulates lipid synthesis via positive regulation of two transcription factors 
that control genes that are involved in lipid and cholesterol homeostasis: sterol 
regulatory element binding protein (SREBP1) (Porstmann et al., 2008)  and peroxisome 
proliferator-activated receptor γ (PPARγ) (Kim and Chen, 2004). mTORc1 activity has 
also been reported to have cross talk with autophagy processes. Autophagy is a 
catabolic process during which degradation of proteins and organelles occurs. This 
degradation provides biological material to support anabolic processes including energy 
production and protein synthesis. There are reports showing that mTORc1 inhibition 
under nutrient-poor conditions increases autophagy, whereas its stimulation inhibits this 
process (Korolchuk et al., 2011; Poüs and Codogno, 2011). Several studies 
demonstrated that mTORc1 represses autophagy by phosphorylating and thereby 
repressing ULK1 and ATG13. These proteins are a part of a triple complex consisting 
of ULK1, FIP200 and autophagy-related gene 13 (ATG13) and required for 
autophagosome generation and activation of autophagy-specific activity (Ganley et al., 
2009; Hosokawa et al., 2009; Jung et al., 2009). 
  
1.5.1.4  mTOR signaling guides CD4+ T cell fate and function 
T cells lacking mTOR can be activated to make the cytokine IL-2 in response to TCR 
stimulation but they cannot differentiate into Th1, Th2 or Th17 cells. Instead, mTOR 
deficient T cells increase Foxp3 and expression and become T regulatory cells 
(Delgoffe et al., 2009). In addition, pharmacological inhibition of mTOR with 
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rapamycin promotes the generation of regulatory CD4+CD25+Foxp3+ T cells 
(Battaglia et al., 2005; Sauer et al., 2008; Delgoffe et al., 2009). In order to distinguish 
between the impact of mTORc1 and mTORc2 on differentiation of CD4+, genetic 
approach of deleting either RHEB or Rictor were undertaken. Rheb-null T cells failed to 
become Th1 or Th17 cells but still could differentiate into the Th2 lineage (Delgoffe et 
al., 2011). Conversely, selective deletion of Rictor, which results in loss of mTORc2 
activity reveals that Rictor-null T cells fail to become Th2 cells in response to IL-4 but, 
unlike the Rheb-null T cells, still maintain the ability to become Th1 and Th17 cells 
(Lee et al., 2010). According to this data it was proposed that mTORc1 promoted 
differentiation of Th1 and Th17 helper T cells whereas mTORc2 activation promotes 
generation of Th2 cells. Absence of both mTORc1 and mTORc2 results in T reg 
generation.  
Recent works also link between mTOR-control of metabolism and CD4+ T cell fate 
(Dang et al., 2011; Shi et al., 2011). These two studies demonstrate that in effector IL-
17 producing CD4+ T cells the serine kinase mTORc1 can control glucose metabolism 
via regulation of hypoxia-inducible factor 1 (Hif-1α) complexes. Dang et.al showed that 
Hif-1α, which is selectively expressed in Th17 cells and to a lesser extent in T regs, Th1 
and Th2 cells orchestrates the metabolic switch from oxidative phosphorylation to 
aerobic glycolysis (Dang et al., 2011). Hif-1α deficient T cells cultured in vitro under 
Th17 skewing conditions displayed a striking reduction in IL-17 production and a 
dramatic increase in the proportion of Foxp3+ cells. The authors went on to show that 
Hif-1α transcription factor directly promoted Th17 differentiation by inducing the 
transcription of the Rorγt master regulator of Th17 lineage and inhibited T reg 
differentiation via Foxp3 degradation mechanism. Shi et. al investigated the role of 
mTORc1-regulated Hif-1α in cell fate determination between Th17 and T regs by 
examining the direct impact of glycolysis on differentiation of these lineages (Shi et al., 
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2011). Using the glucose analogue 2-deoxyglucose (2-DG), a prototypical inhibitor of 
glycolysis, the authors demonstrated how impaired glycolysis promotes T reg 
generation while dampening Th17 development. Moreover, it was shown that 
deficiency of Hif-1α diminished expression of glycolytic enzymes, which altered the 
balance between T regs and Th17. Hence, both studies propose a model in which 
mTORc1 regulates Hif-1α-dependent glycolytic pathway thus orchestrating 
differentiation to Th17 or T regulatory lineages.  
 
1.5.1.5 mTOR regulates CD8+ effector differentiation and mTOR inhibition 
promotes memory formation. 
mTOR activity regulates the  functional fate of effector CD8+ T cells. Deletion of 
mTORc1 inhibitor, TSC2 results in generation of CD8 T cells with enhanced mTORc1 
activity and increased effector functions (Rao et al., 2010), whereas CD8 T cells that 
lack mTORc1 signaling fail to become effectors cells becoming memory T cells instead 
(Araki et al., 2009; He et al., 2011). Hence Araki et. al showed that in a lymphocytic 
choriomeningitis virus (LCMV) model, low dose treatment with rapamycin during T 
cell expansion phase reduced the apoptotic death of effector cells during contraction 
thus increasing the quantity of the generated memory T cell (Araki et al., 2010). 
Furthermore, rapamycin treatment during the contraction phase promoted the protective 
capacity and thus the quality of memory T cells.  
Similarly, long-lived memory cells were generated by treating lymphocytic 
choriomeningitis virus (LCMV)-specific T cells with rapamycin and then adoptively 
transferring them into mice (He et al., 2011). Work by Rao et. al demonstrated that 
mTOR instructed a programming of a cell into an effector or memory fate by regulating 
expression of T-bet and Eomesodermin (Rao et al., 2010). Inhibition of mTOR by 
rapamycin promoted Eomesodermin expression while suppressing T-bet expression.  
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1.5.1.6 mTOR controls T cell trafficking 
During immune surveillance, naive T lymphocytes constantly recirculate from the 
blood, to the lymphatics and secondary lymphoid organs where they sample sequestered 
antigens. Lymphocytes that are stimulated by antigen are retained and proliferate while 
the majority return to the circulation (GOWANS and KNIGHT, 1964). When entering 
lymph nodes and Peyer’s patches, naïve T cells leave the blood by emigrating across 
specialized high endothelial venules (HEV). The transmigration of T cells into the 
secondary lymphoid organs through HEVs is a multi-step process: The first step 
involves a CD62L (L-selectin) dependent tethering and rolling of naïve lymphocytes 
along the blood vessel wall followed (Arbonés et al., 1994) by a subsequent binding of 
soluble or immobilized endothelial chemokines such as CCL19 and CCL21 with its 
appropriate receptor, CCR7, expressed on lymphocytes (Springer, 1995; Galkina et al., 
2007). This chemo-attractant step results in activation of the αLβ2 integrin LFA-1 on T 
cells and its interaction with ICAM-1 or ICAM-2 expressed by HEVs, leading to a firm 
adhesion of the cells and ultimately transmigration through the HEV (Stein et al., 2000; 
Förster et al., 2008).  
In the absence of an encounter with an antigen-presenting cell, T cells are not activated, 
and eventually migrate out of the lymph nodes back into the blood vasculature. This 
egress from LNs is under the control of a cyclical modulation of another receptor 
expressed on T cells, the sphingosine-1-phosphate receptor (S1P1R), which binds to the 
S1P1 ligand that is present at high concentrations within blood and body fluids (Lo et al., 
2005; Cyster and Schwab, 2012).  
In contrast to naïve T cells that express high levels of CCR7 and CD62L, effector T 
cells downregulate the expression of these molecules and upregulate expression of 
receptors that facilitate their homing to sites of inflammation, such as very late antigen 
4, P- and E-selectin ligands, and inflammatory chemokine receptors, such as CXCR3 
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and CCR5 (Mora and Andrian, 2006). Therefore, downregulation of CD62L and CCR7 
is essential to allow redirection of effector T cells to peripheral tissues while preventing 
their re-entry into the secondary lymphoid organs. There is an evidence that this 
downregulation of chemokine and adhesion molecules expression in effector T cells is 
controlled by PI3K-mTOR signaling pathway (Sinclair et al., 2008). Work performed 
by Linda V. Sinclair in our lab demonstrated that mTOR switches off CCR7 and 
CD62L expression by downregulating the cellular abundance of KLF2, which is a key 
transcription factor for CCR7 and CD62L. Naïve T cells that have low PI(3,4,5)P3 
levels and low mTOR activity express high levels of KLF2 transcription factor thus 
expressing high levels of CD62L, CCR7 and S1P1R. In contrast, effector T cells have 
high PI3K activity and high mTORc1 activity but low levels of KLF2 expression. The 
link between PI3K/mTORc1 and KLF2 expression is not purely correlative since 
effector T cells treated with PI3K inhibitors or mTORc1 inhibitors regain expression of 
KLF2 and restore expression of CD62L mRNA and plasma membrane expression of 
CD62L.  
The question is how PI3K and mTORc1 control KLF2? It was previously shown that in 
quiescent T cells, active Foxos drive expression of KLF2, whereas in effector T cells in 
response to PI(3,4,5)P3 accumulation, PKB phosphorylation of Foxos occurs, which 
causes Foxos to be exported from the nucleus, hence terminating expression of KLF2 
and its gene targets (Fabre et al., 2008; Kerdiles et al., 2009). In this context, although 
rapamycin inhibition of mTORc1 in effector CTL causes them to re-express KLF2, 
CD62L, and CCR7, it has no obvious effect on PKB activity or Foxo phosphorylation 
(Finlay and Cantrell, 2010). Therefore, how mTORc1 regulates CD62L and CCR7 is 
not entirely clear yet and remains to be elucidated.  
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1.6 The AhR and Hif-1α  in T cells 
My studies have focused on three proteins that are expressed in T cells and are known 
to act as environmental sensors: the Aryl hydrocarbon receptor (AhR), AhR nuclear 
translocator (ARNT) and Hypoxia inducible factor (Hif-1α). These proteins belong to 
the PAS (Per ARNT Sim) family of proteins that play an important role in mediating 
transcriptional responses to environmental stimuli. 
 
1.6.1 The AhR in the immune system 
The aryl hydrocarbon receptor (AhR) was discovered almost 30 years ago as a specific 
binding site for environmental pollutants collectively called polycyclic hydrocarbons, 
including the highly toxic compound 2,3,7,8 - tetrachlorodibenzo - p - dioxin (TCDD) 
(Okey, 2007). Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous compounds in 
our environment. They are formed during incomplete combustion of coal, oil, gas and 
wood and are found in diesel exhaust and cigarette smoke. Due to their biological and 
chemical stability those compounds accumulate in the environment and are believed to 
contribute to the increased prevalence of autoimmune-related diseases and allergies 
(Griem et al., 1998).  
Upon ligand binding, AhR translocates to the nucleus and allows heterodimerisation 
with the AhR nuclear translocator (ARNT). Transactivation of AhR-responsive genes is 
initiated by AhR/ARNT heterodimer binding to DREs (Dioxin-Responsive Enhancer 
elements) that are found near AhR transcriptional targets (Nebert et al., 2004). AhR 
controlled genes include those that encode xenobiotic metabolizing enzymes, such as 
cytochromes P450 (CYP1A1), CYP1A2, CYP1B1 and UDP glucoronosyltransferase 1 
family polypeptide A6 (UGT1A6). These enzymes catalyze the oxidation of 
hydrocarbons, resulting in their clearance (Schmidt and Bradfield, 1996). AhR signaling 
is also regulated on two main levels: 1. AhR activation by its ligands promotes its 
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proteasome-dependent degradation (Davarinos and Pollenz, 1999). 2. Upon AhR 
ligation with its ligands there is an induction of the AhR repressor (AhRR), which 
inhibits AhR function by competing with AhR over dimerization with ARNT as well as 
binding to dioxin response elements in the DNA (Mimura et al., 1999).  
 
AhR ligands can derive from biological systems as a result of natural processes 
(Nguyen and Bradfield, 2008). Those include plant-derived materials, such as 
flavonoids, heme metabolites, arachidonic acid metabolites, byproducts derived from 
converted dietary indoles (i.e; indole 3- carbinol) and tryptophan metabolites (reviewed 
in (Nguyen and Bradfield, 2008). One such tryptophan metabolite is the photoproduct is 
6-formylindolo [3,2-b] carbazole (FICZ). Fritsche et. al showed that FICZ is formed in 
human epidermal keratinocytes in response to physiologically relevant doses of UVB 
radiation (Fritsche et al., 2007). Other group of known endogenous ligands that activate 
the AhRs are the indigoids: indigo and indirubin are historically recognized plant 
compounds and are used for textile colouring (Adachi et al., 2001). Those compounds 
can be found in human and bovine urine and are metabolized by the CYP enzymes 
(Gillam et al., 1999). It is also important to mention the dietary compounds as a source 
of endogenous AhR ligands. Notably, the lipophilic extracts of several plant foods 
activate the AhR (Jeuken et al., 2003). Main examples are the Indole-3-carbinole (I3C) 
derivative and the natural flavonoids. I3C is a phytochemical found in Cruciferous 
plants including broccoli and brussels sprouts and it has the ability to induce the activity 
of the classical AhR-mediated monooxygenases (Loub et al., 1975). Moreover, due the 
acidic environment of the stomach I3C compound can be converted to indolo[3,2-
b]carbazole (ICZ), 3,3′-diindolylmethane (DIM), and 2-(indol-3-ylmethyl)-3,3′-
diindolylmethane (LTr-1). Those I3C derivatives were detected in intestinal contents of 
rats fed with I3C and were shown to have a higher affinity to the AhR (Bjeldanes et al., 
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1991). Similarly to I3C, flavonoids are also found in fruits and vegetables and can also 
activate AhR and CYP1A1 as it was demonstrated by using luciferase reporter systems 
in various cell lines (Zhang et al., 2003). Kynurenine is a tryptophan metabolite and was 
recently identified as an endogenous AhR ligand that is abundant in human brain 
tumours (Opitz et al., 2011). It was shown that through activation of AhR this ligand 
suppressed anti-tumour immune responses thus promoting tumour-cell survival and 
motility of malignant glioma cells.  
 
Early studies investigating the role of AhR in the immune system were commenced by 
scientists in the toxicology field who conducted in vivo and in vitro experiments using 
dioxins such as the TCDD. These early studies revealed that the immune system is a 
target of dioxin toxicity. Although, AhR-deficient mice do not have an overt 
immunological phenotype (Schmidt et al., 1996; Vorderstrasse et al., 2001), activation 
of AhR following its ligation with dioxins leads to a profound suppression of both 
humoral and cellular immune responses (Kerkvliet et al., 1990; Lawrence et al., 2000; 
Warren et al., 2000; Ito et al., 2002; Inouye et al., 2003) and results in increased 
susceptibility to infections (Kerkvliet et al., 1996; Inoue et al., 2012). For instance, 
recently a link was made between AhR activation following exposure to dioxins and 
EBV reactivation in Sjögren's syndrome (SS) patients. (Inoue et al., 2012). In contrast, 
AhR deficient mice generate normal immune response to model antigens and are 
resistant to TCDD-induced immune suppression (Vorderstrasse et al., 2001). 
Laboratory animals exposed to low doses of TCDD show altered bone marrow and 
thymic involution, associated with thymocyte loss, thymocyte proliferation arrest and 
premature emigration of T-cell progenitors (Laiosa et al., 2003; McMillan et al., 2007).   
Apart from effects on the thymus, TCDD mediated AhR activation results in defective 
immune response of CD8+ cytotoxic T cells to influenza virus infection, including their 
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suppressed expansion and differentiation together with a poor antibody response 
(Lawrence et al., 2000; Warren et al., 2000; Mitchell and Lawrence, 2003; 
Vorderstrasse et al., 2004; 2006). Moreover, it was shown that AhR activation not only 
impairs the primary CD8+ T cell response but also affects the recall response of Ag-
specific CD8+ memory T cells (Lawrence and Vorderstrasse, 2004; Lawrence et al., 
2006). CTL functions were also suppressed in a P815 tumour allograft model, in which 
allogeneic tumour cells are allowed to grow in the peritoneal cavity of recipient mice 
exposed to TCDD. In this model CD8 T cells were initially activated, but then failed to 
expand, differentiate and produce effector cytokines such as IL-2 and Ifn-γ (Kerkvliet et 
al., 1996). Several studies proposed that this TCDD driven suppression is a result of an 
increase in T regulatory T cells (Funatake et al., 2005; Quintana et al., 2008; Quintana 
and Weiner, 2009; Marshall and Kerkvliet, 2010). However, the strongest evidence 
oposing this idea is that over expression of constitutively active AhR in T cells did not 
recapitulate the activation of a regulatory T cell phenotype by TCCD (Funatake et al., 
2009). In addition TCDD induction of Foxp3+ expression in T regs cultured in vitro is 
still under a debate. Instead, other recent reports propose that dendritic cells that activate 
the indoleamine 2,3-dioxygenase (IDO) pathway generate an endogenous AhR ligand, 
kynurenine, which is required for an AhR-dependent T reg generation (Mezrich et al., 
2010). In this work it was shown that kynurenine could activate AhR downstream target 
genes such as CYP1A1 and CYP1B1 and that it did not influence T reg generation in 
AhR-null T cells. In addition, it was demonstrated that AhR synergizes with c-maf 
transcription factor in IL-27 induced Tr1 subset of cells (T regulatory cells) (Apetoh et 
al., 2010). This interaction drives IL-10 production and suppresses tissue inflammation 
and autoimmunity (Taylor et al., 2006). 
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Although studies using dioxins contributed a lot to the understanding of AhR functions, 
most of the experiments were done in in vivo whole systems, which are often 
complicated to interpret. Also in this type of experiments it is difficult to isolate the 
specific cell population responsible for the effect. In addition, there is still the thought 
that toxicity mediated by xenobiotic compounds to some extent reflects dysregulated 
endogenous functions of the AhR transcription factor. Therefore, there is a need to 
distinguish between the toxicity mediated by xenobiotic stimuli and endogenous roles 
of AhR in homeostasis in the immune system. Therefore recent studies in the field try to 
explore the relevance of AhR response to endogenous ligands and its physiological role 
in the immune system. A major progress in identifying physiological roles of AhR in 
the immune system was done thanks to the discovery of this transcription factor in in 
vitro cultured and ex-vivo isolated Th17 cells. 
   
1.6.2 AhR in Th17 cells  
Microarray analysis of transcription factors expressed in differentiated effector CD4+ T 
cell subsets, revealed a high AhR expression in Th17 cells whereas it was absent from 
Th1 and Th2 cells and only marginally present in T regulatory cells (Veldhoen et al., 
2008). Th17 cells that were described earlier on have a key role as mediators of 
inflammatory immune responses and AhR was found to promote their further but not 
initial differentiation (Veldhoen et al., 2008; 2009). Moreover, AhR activation by FICZ 
in Th17 cells enhanced expression levels of IL-17A, IL-17F and IL-22 cytokines 
(Veldhoen et al., 2009). Importantly, AhR-deficient lymphocytes can still produce IL-
17 albeit at lower levels. However they do not make IL-22. 
Examples of the importance of AhR ligands for Th17 cells include that endogenous 
AhR ligands present in culture medium (IMDM-Iscove’s modified Dulbecco medium) 
have an impact on Th17 polarization. Eg other AhR antagonist, CH-223191 (Zhao et al., 
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2010; Choi et al., 2011) that competes with endogenous ligands for binding the receptor 
inhibits Th17 polarization and IL-22 production (Veldhoen et al., 2009; Ramirez et al., 
2010). In this context, although it is established that IL-22 gene has multiple AhR 
responsive elements it is not entirely clear to what extent and how AhR supports IL-22 
production. One study showed that neither the transduction of AhR alone or together 
with Rorγt was not sufficient for IL-22 production (Veldhoen et al., 2009). Another 
study analyzing AhR functions in the intestines pointed out that Rorγt interacts with 
AhR and enhances its recruitment to the IL-22 locus (Qiu et al., 2012). It was also 
shown that Notch signaling induced AhR-dependent IL-22 production in CD4+ T cells 
via promoting the production and secretion of AhR stimulating ligands (Alam et al., 
2010). As mentioned previously IL-22 is a pro-inflammatory cytokine and is linked to 
pro-inflammatory diseases such as psoriasis, dermal inflammation, IBD and Chron’s 
disease (reviewed in (Korn et al., 2009)). Since AhR activation is a prerequisite for the 
production of IL-22 by Th17 cells and environmental factors that activate this receptor 
trigger and aggravate autoimmune diseases (D'Cruz, 2000; Naldi et al., 2005; 
Kobayashi et al., 2008), AhR is believed to act as a link between environmental factors 
and various autoimmune conditions. Studies exploring the effects of polymorphism of 
human AhR or its regulated downstream genes can shed more light on the link between 
AhR and autoimmunity.  
Nonetheless, AhR-dependent production of IL-22 can also have protective roles such as 
the protection of epithelial barriers in the gut and the production of defensins during 
cutaneous Candida infection (Wolk et al., 2004; Eyerich et al., 2011). Hepatocytes can 
respond to AhR induced IL-22 cytokine which plays a protective role in models of 
hepatitis, whereby IL-22 neutralization exacerbates pathology and IL-22 delivery 
prevents it (Radaeva et al., 2004; Zenewicz et al., 2007).  
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1.6.3 AhR function in gut lymphocytes - relevance of endogenous ligands 
Recent work has indicated that the AhR regulates immunity and tissue homeostasis in 
the gut (Kiss et al., 2011; Li et al., 2011; Lee et al., 2012; Qiu et al., 2012). The 
relevance of AhR in the immune cells of the gut is the best example of how this receptor 
links environment and immunity. Li. et al thus showed that the AhR deficiency leads to 
a specific cell loss of TCRγδ and CD8αα T cells among the intraepithelial lymphocytes, 
which resulted in an increased bacterial burden (Li et al., 2011). It is proposed that AhR 
activity in IELs is sustained by intestinal AhR ligands, which are predominantly diet-
derived, with high levels present in cruciferous vegetables such as broccoli.  
Further mechanistic insights into AhR function in the guts stem from work 
demonstrating the role of AhR in Rorγt expressing innate lymphoid cells (ILCs). ILCs 
are major producers of the IL-22 cytokine, which is important for immunity and tissue 
homeostasis at barrier surfaces such as the gut (Sonnenberg et al., 2011a; 2011b). 
Studies by Lee et. al and Qiu et. al showed that the generation of ILC cells in the 
intestinal lamina propria required AhR expression in the hematopoietic compartment 
(Lee et al., 2012). In the absence of the AhR, the reduction in ILCs numbers affected 
the formation of isolated lymphoid follicles and cryptopatches in the gut. It was thus 
hypothesized that AhR activation by endogenous ligands is required for the survival of 
ILCs. The initial idea was that the microbiota residing in the lamina propria is the main 
source of the AhR endogenous ligands. However, neither maintenance of mice under 
germ-free conditions nor treatment with antibiotics effected the homeostasis of Rorγt+ 
AhR-/- ILCs (Kiss et al., 2011; Lee et al., 2012). There is however evidence for a role 
of diet derived AhR ligands for ILCs.  
An important question of how does AhR activation by its endogenous ligands affect 
Rorγt+ ILC homeostasis? One observation was that AhR ablation resulted in lower 
expression of IL-7R in Rorγt+ ILCs. Lower IL-7R expression decreased IL-7-induced 
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Bcl-2 expression thus leading to increased apoptosis of ILCs (Qiu et al., 2012). 
Moreover, both AhR and Rorγt were found to bind to their corresponding responsive 
elements in the IL-22 locus thus directly driving production of the IL-22 cytokine. 
Using chromatin immunoprecipitation technique Qiu et. al found that Rorγt facilitates 
AhR binding at the IL-22 locus, suggesting a coordinated function between these two 
transcription factors in promoting IL-22 expression (Qiu et al., 2012). Collectively the 
studies described above demonstrate expression and function of AhR in IELs and the 
innate cells of the gut, highlighting the importance of AhR as a mediator of 
environment and gut immunity. 
 
1.7 Hypoxia inducible factor (Hif-1α) and Aryl Hydrocarbon Nuclear 
Translocator (ARNT)  
1.7.1 Discovery and function of Hif-1α   
The Hif-1α transcription factor was discovered by Gregg L. Semenza and G.L Wang in 
a project that explored how hypoxia induces expression of the EPO gene (Semenza and 
Wang, 1992; Wang et al., 1995). Hif-1α forms a heterodimeric complex with Hif-1β, 
which is a nuclear protein also known as AhR nuclear translocator (ARNT). To date, 
three Hif-α isoforms (Hif-1α, Hif-2α and Hif-3α) have been described whereas Hif-1α 
and Hif-2α are the best characterized. Hif-2α is predominantly expressed in lungs, 
endothelium and the carotid body (Wiesener et al., 2003). The discussion of this section 
will focus on the Hif-1α isoform since T cells and other immune cells specifically 
express this isoform.  
Both Hif-1α and ARNT are members of the basic helix- loop- helix Per/ARNT/Sim 
(bHLH-PAS) transcription factor family (Wang et al., 1995). Hif-1α dimerises with 
ARNT via its bHLH and part of the PAS domain, whereas the bHLH domain is required 
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for the DNA binding (Jiang et al., 1996). Two transactivation domains in the N-terminal 
(N-TAD) and C-terminal (C-TAD) halves of Hif-1α interact with co-activators such as 
CBP/p300 and mediate transcriptional activation of Hif-1α target genes (Sang et al., 
2002). ARNT was shown to be absolutely required for Hif-1α mediated gene activation 
in hypoxia (Salceda et al., 1996).  
The first Hif-1α target genes identified were genes involved in erythropoiesis and 
angiogenesis eg EPO and vascular endothelial cell growth factor (VEGF). VEGF is the 
most potent endothelial-specific mitogen, which recruits endothelial cells into hypoxic 
and avascular areas and drives their proliferation, thus leading to an increase in the 
vascular density (Jośko et al., 2000). It was subsequently discovered that Hif-1α was 
important in regulating expression of molecules important for glycolysis. Hence under 
low oxygen levels, cells switch their metabolism from oxygen dependent to anaerobic 
glycolysis. This switch is achieved by Hif-1α mediated upregulation in the expression 
of glycolytic enzymes and glucose transporters (Chen et al., 2001; Wenger, 2002). In 
this context, Hif-1α mediates the cellular adaptation to hypoxia in a tumor 
microenvironment.  
 
1.7.2 Hif-1α  regulation 
Hif-1α protein is unstable under normoxia since it is ubiquitinated and subjected to 
proteasomal degradation by the von Hippel Lindau protein (pVHL) pathway (Maxwell 
et al., 1999). In contrast, under hypoxic conditions (O2 <5%) the fraction of the 
ubiquitinated Hif-1α is decreased, resulting in its stabilization and subsequent 
accumulation.  
Under aerobic conditions Hif-1α is hydroxylated by specific prolyl hydroxylases 
(PHD1, PHD2 and PHD3) at two conserved proline residues (Pro402 and Pro564), 
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which are localized within the ODD (oxygen dependent degradation) domain of the 
protein. All three PHDs are capable of hydroxylating Hif-1α, however PHD2 is the key 
limiting enzyme that regulates Hif-1 turnover (Huang et al., 2002; Berra et al., 2003). 
PHD mediated hydroxylation is oxygen, 2-oxoglutarate and ascorbate-dependent 
reaction (Jaakkola et al., 2001) and PHDs require Fe2+ (iron) for their function (Masson 
and Ratcliffe, 2003). Following Hif-1α hydroxylation, pVHL captures Hif-1α via a 
specific pocket that fits its hydroxyproline and recruits additional proteins with which it 
forms the E3 ligase complex (Ivan et al., 2001). Subsequently, E3 complex causes 
polyubiquitination of Hif-1α, resulting in its degradation in the proteasome.  
pVHL was first identified as a tumor suppressor since its loss resulted in VHL human 
cancer syndrome (Ivan and Kaelin, 2001). In this syndrome the loss of pVHL leads to 
stabilization and activity of Hif-1α and Hif-2α under normoxia, resulting in over-
activation of hypoxia induced genes such as the ones that encode angiogenic factors 
(Iliopoulos et al., 1996; Ivan and Kaelin, 2001). Since hydroxylation requires O2, under 
hypoxic conditions Hif-1α hydroxylases can no longer function. Subsequently, Hif-1α 
is no longer targeted by VHL but instead accumulates in the cell, translocates to the 
nucleus where it dimerises with ARNT and binds to Hypoxia responsive elements 
(HRE) in target gene promoters.  
Apart from oxygen, PHD enzymes can be also regulated by a variety of inhibitors and 
byproducts of metabolic processes in the cellular environment such as nitric oxide, 
metabolic intermediates of the TCA cycle including fumarate and succinate and reactive 
oxygen species (ROS) (reviewed in (Kaelin and Ratcliffe, 2008). In this context, there 
are reports suggesting that mitochondria is involved in oxygen signaling and Hif-1α 
regulation by increasing ROS generation in hypoxia. Since ROS were found to inhibit 
the function of PHD enzymes, ROS have a role in Hif-1α stabilization (Pan et al., 
2007). On the other hand, mitochondria also express a deacetylase sirtuin-3 (SIRT3), 
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which was described to inhibit ROS production, thereby promoting maximal activity of 
PHDs and subsequent HIf-1α degradation (Finley et al., 2011). Therefore, the 
relationship between ROS production and Hif-1α stability are complex and not 
completely clear yet.  
 
Although many studies investigate the control of HIf-1α stability, not much is known 
about the mechanisms that control Hif-1α translation under normoxic and hypoxic 
conditions. The notable pathways that were reported to activate Hif-1α translation under 
normoxia are the mTOR (Laughner et al., 2001; Hudson et al., 2002) and the MAPK 
(mitogen-activated protein kinase) pathways (Fukuda, 2002). Both pathways 
phosphorylate the translational repressors eukaryotic initiation factor eIF4E-binding 
proteins (4E-BP1, 4E-BP2 and 4E-BP3) and the ribosomal kinase S6K. The initial 
hypothesis was that hypophoshorylated 4E-BP1 binds to eIF4E with high affinity and 
prevents it from translating 5’ capped mRNAs. When 4E-BP1 is phosphorylated by 
mTORc1 it does not bind to the eIF4E, thus enabling eIF4E to promote cap-dependent 
translation of mRNAs characterized by a 5’ terminal oligopyrimidine (TOP) motifs 
(Thoreen et al., 2012). However, it is now believed that the 5’ TOP motif is not present 
in Hif-1α mRNA (van den Beucken et al., 2006), and therefore the exact regulation of 
Hif-1α translation by mTOR pathway under normoxia remains to be elucidated.  
 
NF-κB is another interesting and relevant to immune cells factor that plays a role in 
regulation of basal Hif-1α and ARNT expression (van Uden et al., 2008; 2011).  
Van Uden et. al showed that TNF-α- induced NF-κB subunits could bind to and 
activate Hif-1α promoter thus modulating basal levels of Hif-1α mRNA (van Uden et 
al., 2008). Moreover, knockdown of NF-κB resulted in reduction of Hif-1α protein and 
its overexpression led to increase in Hif-1α protein levels and subsequent activation of 
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Hif-1α target genes: Glut1 and Glut3. In a later study van Uden also showed the 
requirement of IKK and NF-κB for the induction of ARNT mRNA and protein (van 
Uden et al., 2011). Importantly, the authors showed that this mechanism of NF-κB-
dependent regulation of ARNT is conserved in Drosophila and mice.  
 
1.7.3 Physiological consequences of Hif-1α  activity  
Various germline Hif-1α KO and conditional KO mice were generated. Components of 
the Hif-1α system play crucial roles in embryonic development and physiology. 
Germline deletion of either Hif-1α (Iyer et al., 1998; Ryan et al., 1998; Kotch et al., 
1999; Compernolle et al., 2003) or ARNT (Kozak et al., 1997; Maltepe et al., 1997) 
resulted in abnormal vascular development, cardiac malformations and subsequent 
lethality in mice. In wild type mouse Hif-1α and ARNT expression is induced between 
E8.5 and E9.5 and embryos that are deficient for one of these transcription factors die 
between E9.5 and E10.5 mainly as a consequence of lack of blood vessel formation. 
Heterozygous Hif-1α+/- mice developed normally. However they displayed impaired 
physiological responses including when challenged by chronic hypoxia (Yu et al., 1999; 
Kline et al., 2002).  
 
1.7.4 What is known about Hif-1α  in T cells? 
There are only few publications about the role of Hif-1α in T cells. The main 
motivation to study T lymphocytes responses to hypoxia is that oxygen tensions in the 
lymph organs are between 0.5 and 4.5% (Neumann et al., 2005), meaning that the 
natural environment of T lymphocytes is hypoxic. It was shown that T cells express 
Hif-1α mRNA only following a TCR mediated activation under hypoxic conditions 
(Lukashev et al., 2001; Makino et al., 2003). Moreover, TCR mediated-Hif-1α 
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expression in T cells was required to repress the activation-induced death (AICD) of T 
cells, thus promoting their survival (Makino et al., 2003). Surprisingly, TCR activated 
Hif-1α deficient T cells produced more pro-inflammatory cytokines including IFN-γ, 
TNF-α, IL-2, IL-4, and IL-13 both under normoxic and hypoxic conditions (Lukashev 
et al., 2006). These studies imply that Hif-1α is important for negative regulation of 
activated T cells thus having an anti-inflammatory function. However, the precise 
function of Hif-1α in this negative regulation remains to be elucidated. An additional 
study examined the role of Hif-1α in cytotoxic T cells cultured in vitro (Neumann et al., 
2005). In this study it was shown that CD8+ T cells cultured under low oxygen tensions 
had higher levels of CD25 (IL-2 Receptor), TCR and LFA-1 surface markers but 
produced same amounts of IL-2 and IFN-γ cytokines. Most importantly, due to higher 
levels of lymphocyte-associated antigen 1 (LFA-1) expression, which is important in 
CTL-mediated direct cell lysis (Rutigliano et al., 2004), cells cultured under hypoxia 
were much more lytic than CD8+ CTLs differentiated under normoxic conditions.  
Finally, two recently published papers demonstrated the role of Hif-1α in the glycolytic 
switch in Th17 cells, which also determined the balance between Th17 and T regs 
development (Dang et al., 2011; Shi et al., 2011). The main findings about the role of 
Hif-1α in Th17 cells were described in section 2.8.7, which dealt with mTOR signaling 
pathways in T cells. As discussed Hif-1α partners with ARNT but the role of ARNT in 
T cells has only been investigated in context of its requirement for the AhR-mediated 
response to dioxins (Tomita et al., 2003). Mice that had ARNT deficient T cells 
displayed resistance to 2,3,7,8-Tetrachlorodibenzo-p-dioxin induced thymic involution. 
Additionally, ARNT-deficient T cells showed normal development in the thymus but an 
impaired response to hypoxia in vitro (Wood et al., 1996; Tomita et al., 2000).  
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1.8 Thesis Aims 
As described in the introduction, multiple studies show defective immune response of 
CD8+ cytotoxic T cells to viral infection such as influenza virus infection, including 
suppressed expansion and differentiation following TCDD mediated AhR activation. 
Most of the experiments that explored the role of AhR in CD8 T cells were performed 
in an in vivo context and using exposure to exogenous toxic AhR ligands. This type of 
experiments cannot address how much of the CTL pathology is actually caused by 
direct effects of dioxins on CTLs. Also, the mechanism by which AhR alters CD8+ T-
cell functions remained unclear. On the other hand, a great deal of work was done to 
understand the function of AhR in the differentiation of Th17 cells in vivo and in vitro. 
Still, it has not yet been explored whether all Th17 cells express a functional AhR 
uniformly. Also, although there is a growing number of studies that describe and 
characterise a variety of naturally occurring dietary chemicals that can directly activate 
and/or inhibit the AhR signaling pathway, it is still not known whether T cells of the 
immune system are exposed to any endogenous physiological ligands. 
 Accordingly, the aim of the first part of our study was to investigate what signals 
induce AhR expression in CD8 T cells and to explore the role of AhR in CD8 T cell 
physiology. In addition, we wished to understand whether there are endogenous ligands 
for the AhR in T cells. Another goal was to understand whether different AhR 
expression levels observed in various T cell subsets are translated to different levels of 
AhR signaling. Experiments using a reporter CYP1A1Cre X R26REYFP mouse model that 
tagged cells with functional AhRs addressed the questions outlined above and provided 
new insights into the expression and function of AhR in T cells. 
  
The objective of the second part of this thesis was to understand the role of AhR nuclear 
translocator as a binding partner of AhR in Th17 cells. Whereas many studies focused 
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on AhR in effector Th17 cells not much information exists about the requirement of 
ARNT for the canonical AhR signaling pathway. Using conditional ARNT KO mice, 
we were the first to address the role of ARNT as a part of the AhR/ARNT 
transcriptional complex in the differentiation of effector Th17 cells.   
 
Finally, the objective of the last part of this project was to explore the molecular 
pathways that mediate mTORc1 control of effector CD8 T cell differentiation.  
The knowledge that mTORc1 activity is needed for CD8 T cells to initiate and sustain a 
switch to a glycolytic metabolism and to control the expression of adhesion molecule 
CD62L and the chemokine receptor CCR7 existed in our lab for a long time, however, 
the exact mechanism was not completely uncovered. From the literature it is known that 
ARNT/Hif-1α transcriptional complex is involved in the regulation of Glut1 and other 
glycolytic enzymes. Therefore, the hypothesis was that mTORc1 regulation of this 
complex could partially explain how mTORc1 controls glycolysis and migratory 
properties of CTLs. In order to test this hypothesis we used ARNT-null mice in which 
mTORc1 pathway is intact whereas ARNT/Hif-1α function is lost specifically in T 
cells.  
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Chapter 2 Materials and Methods 
2.1 Transgenic mice 
2.1.1 CYP1A1Cre+/-  X R26REYFP  mice 
Reporter CYP1A1Cre+/- X R26REYFP mice were generated by backcrossing CYP1A1Cre+/- 
mice to R26R EYFP mice. The R26R EYFP mice have a knock-in of a gene encoding EYFP 
into the ubiquitously expressed Rosa26 locus preceded by a loxP flanked floxed stop 
sequence (Srinivas et al., 2001). In the CYP1A1KIN (CYP1A1Cre) mouse, cDNA 
encoding Cre recombinase is ‘knocked in’ to the endogenous mouse CYP1A1 locus, 
thus replacing one copy of the CYP1A1 gene (Colin Henderson and Roland Wolf, 
manuscript in preparation). CYP1A1 is a direct Aryl Hydrocarbon receptor (AhR) target 
gene. Therefore, following AhR activation by its ligands, CYP1A1 promoter drives the 
expression of the Cre recombinase. Expression of Cre in a cell/tissue results in deletion 
of the floxed stop sequence and leads to the expression of the EYFP. The CYP1A1Cre 
mouse has been produced and kindly provided to us by Professor Roland Wolf in the 
Cancer Research UK Molecular Pharmacology unit at the University of Dundee. 
 
2.1.2 ARNTfl/fl  X CD4Cre+/- mice 
ARNTfl/fl mice in which LoxP sites flank exon 6 of the Arnt gene were kindly provided 
to us by Dr. Andrey Panteleyev from the Nine wells hospital (Geng et al., 2006). 
ARNTfl/fl mice were backcrossed with mice expressing Cre recombinase under the 
control of the CD4 promoter thus generating ARNTfl/fl X CD4Cre mice. CD4 promoter 
induces the expression of Cre recombinase, which results in a specific deletion of 
ARNT in T cells. All mice were bred and maintained in the Transgenic Unit at the 
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Wellcome Trust Biocentre, University of Dundee in compliance with UK Home Office 
Animals (Scientific Procedures) Act 1986 guidelines. 
 
2.1.3 AhR KO mice 
AhR deficient mice on a B6 background (B6 BRA AHRKO) mice were generated as 
described in (Schmidt et al., 1996) and purchased from Jackson Laboratory. 
 
2.2 Cell Culture 
2.2.1 Reagents 
2C11 (hamster anti-mouse CD3), R&D Systems/CRUK hybridoma unit 
CD28 antibody, Invitrogen 
Recombinant human IL-2, Proleukine/Aldesleukine, Chiron B.V 
Recombinant human IL-15, IL-7, Peprotech 
Recombinant mouse IL-6, mouse IL-1β, human TGF-β, Peprotech 
RPMI 1640+ L-glutamine + glucose/RPMI glucose free, Gibco 
Foetal bovine serum (FBS), Gibco 
Heat inactivated dialysed FBS (dFBS), Gibco 
Hepes, Sigma 
EDTA, Sigma 
Collagenase D, Sigma 
DNAseI, Roche 
IMDM (Iscove’s Modified Dulbecco’s Medium), Gibco 
β mercaptoethanol, Invitrogen 
D (+) glucose, Sigma 
Penicillin/Streptomycin (pen/strep), Gibco 
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FICZ (6-Formylindolo [3,2-b] carbazole), Biomol, Enzo Life Sciences 
CH-223191, AhR inhibitor, Biomol Enzo Life Sciences 
Phorbol-12,13-dibutyrate (PdBu), Calbiochem 
Golgi Plug, BD Biosciences 
CD4+ and CD8+ T cell isolation Kits, Miltenyi Biotec 
Ficoll Paque Premium 1.084, GE Healthcare 
 
2.2.2 Isolation and preparation of cells from lymphoid organs 
Spleens and lymph nodes were obtained from mice up to three months of age. The 
tissue was passed through a 70µm mesh to obtain a single cell suspension. In order to 
lyse the red blood cells, splenocytes were treated with ACK lysis buffer (0.15 M 
NH4Cl, 1.0 mM KHCO3, 0.1 mM EDTA, pH 7.8) for 2 min in room temperature, or 15 
min on ice. The cells were then washed thoroughly with RPMI and the cell pellet was 
resuspended in complete medium (RPMI 1640 + 10% FBS + 50 µM β-Mercaptoethanol 
and streptomycin/penicillin 100U and 100 µg/ml, respectively).  
 
2.2.3 In vitro cell activation 
Single cell suspensions from lymph nodes or spleens, or MACS purified CD4+ or CD8+ 
T cells were adjusted to 5x106 or 2x106 cells per ml. Cells from wild type mice were 
stimulated with 5µg/ml CD3 antibody (2C11-hamster anti-mouse CD3) and CD28 
antibody (2ng/ml) to trigger the T Cell Receptor. Cells isolated from P14 LCMV or OTI 
mice were stimulated with soluble LCMV specific peptide gp 33-41 or SIINFEKL 
peptide (1nM), respectively. Cells kept with 5µg/ml of IL-7 cytokine were maintained 
as negative control to TCR stimulated T cells were. The periods of TCR stimulation 
were set according to the aim of the experiment. 
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2.2.4 In vitro T lymphoblast generation 
T lymphoblasts were generated from splenocytes or T cells extracted from lymph nodes. 
Cells adjusted to a concentration of 5x106 cells per ml were stimulated with 0.5µg/ml 
CD3 antibody (clone 2C11) and were cultured in RPMI containing 10% heat inactivated 
FBS, 50 µM β-Mercaptoethanol and streptomycin/penicillin (100U and 100 µg/ml, 
respectively) for 48 hours. After 48 hours the cells were washed and resuspended at 1-
3x105 per ml with IL-2 or IL-15 cytokines at a final concentration of 20 ng/ml. Cells 
were incubated at 37ºC with 5% CO2. Where indicated the lymphoblasts were incubated 
with specific kinase inhibitors. To inhibit mTORc1, Rapamycin (Calbiochem) was used 
at a concentration of 20 nM, to inhibit PKB, Akti1/2 (Calbiochem) was used at 
concentration of 1 µM and PI3K inhibitor, IC87114 (synthesised in-house) was used at  
a final concentration of 10 µM. When hypoxia affect was measured, cytotoxic T cells or 
Th17 were split to 0.3x106 cells/ml, IL-2 was refreshed in CTLs cultures and the cells 
were incubated in hypoxia chamber (Galaxy 48R model, New Brunswick) under 
conditions of 1% O2 and 5% CO2 for the indicated periods of time.  
 
2.2.5 auto MACS purification of T cells 
CD4+ or CD8+ T cells were purified from lymph nodes cell suspension using the auto 
MACS CD4+ or CD8+ T cell Isolation kit (Miltenyi Biotec). Using this kit, mouse CD4+ 
or CD8+ T cells were isolated by depletion of non-CD4+ T cells or non-CD8+ T cells, 
respectively (negative selection). In both separations, whole suspension of cells was 
indirectly magnetically labelled with a cocktail of biotin-conjugated monoclonal 
antibodies binding to the unwanted/depleted cells in the suspension. Using MACS 
columns and a MACS Separator, magnetic separation was performed. During the 
separation the magnetically labelled non-CD4+/CD8+ T cells were depleted by their 
retention on a MACS Column in the magnetic field of a MACS Separator, while the un-
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labelled CD4+/CD8+ T cells pass through the column. The purity was tested using Flow 
cytometry analysis. 
 
2.2.6 In vitro Th17 generation 
In order to generate Th17, CD4+ MACS purified cells or CD8+ depleted-T cells (see 
2.2.5) were resuspended at 0.3x106 cells/ml in IMDM (Iscove`s modified Dulbecco`s 
medium) and stimulated with CD3 (2µg/ml)/CD28 antibodies (3ng/ml) in presence of a 
cytokine cocktail including 50 ng/ml IL6, 10 ng/ml IL-1β and 1 ng/ml of TGF-β 
(Peprotech) for four days. Where indicated, cells were incubated in presence of FICZ 
(300nM) in order to activate AhR or in presence of CH-223191 (10µM) to inhibit AhR 
signaling pathway from start or for the indicated periods of time. 
 
2.2.7 In vitro culture of Dendritic cells 
Tibias and femurs were removed from mice and cleaned using a petri dish. Both ends 
(epiphyses) of the bones were cut and the marrow was obtained by flushing out each of 
the shafts with 2 ml RPMI-1640 using a syringe. The suspensions were passed through 
a 70µm mesh into a 15 ml collection tube. Red blood cells were lysed using ACK buffer 
and the cell suspension was subsequently centrifuged for 10 min at 280 x g at room 
temperature followed by removal of the supernatant. The cells were then resuspended in 
complete RPMI medium containing 10 ng/ml of recombinant mouse GM-CSF 
(Peprotech) and 1ng/ml recombinant human TGF-β (Peprotech) at a density of 0.5x106 
cells/ml and plated into low-attachment 24-well plates (Corning - Costar) at 1.5 ml/well. 
After four to five days of culture at 37°C with 5% CO2, medium was carefully removed 
from each well and replaced with 1 ml of fresh complete RPMI containing GM-CSF 
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and TGF-β. Dendritic cells were cultured for 14 days in total and then protein lysates 
were prepared. 
 
2.3 Isolation of (Intraepithelial lymphocytes) IELs 
Small intestines were removed and kept in complete medium on ice until the washing 
step. The intestines were flushed with 20 ml of HBSS using a syringe and a small 
needle and the mucous was removed using forceps. Subsequently the intestinal tube was 
cut longitudinally and then the opened tube was cut into 0.5-1 cm pieces using scissors. 
The pieces from one intestine were placed into 25 ml IEL buffer (500 ml of MgCl and 
CaCl free PBS, 10% FCS, 5.5 ml of 100xSodium Pyruvate, 11 ml Hepes (1M), 11 ml 
EDTA (0.5M), 5.5 ml Pen/Strep and 110 Polymyxin B (50mg/ml)) and incubated for 35 
min while shaking in 37°C at 220-240 rpm speed. Next, the pieces were filtered through 
70µm cell strainer and the supernatant containing the cells was collected and 
centrifuged at 500g for 8 min at RT. To separate cells from fat and debris cell pellets 
were resuspended in 20 ml of 37.5% isotonic percoll (Sigma) and centrifuged at 700g 
for 10 min at RT. The percoll layer was then carefully removed and cells were washed 
with RPMI media supplemented with 1% Pen/Strep and 0.5% FCS and analysed by 
Flow cytometry. 
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2.4 Isolation of lamina propria lymphocytes 
After lymphocytes were extracted from intraepithelial layer using IEL buffer, the 
remaining pieces retained on the cell strainer were collected and washed in complete 
RPMI medium twice. The pieces were then suspended in complete RPMI medium 
supplemented with collagenase D (0.5 mg/ml final) and DNAase I (60 µg/ml final) and 
stirred for 45 min at 37˚C. Digested pieces were filtered using 70µm cell strainer, 
washed and centrifuged (5 min, 1200 rpm, 4˚C), resuspended in fresh complete RPMI 
medium and filtered again through 40µm cell strainer. Cells resuspended in 8 ml of 
fresh complete RPMI media were gently pipetted on the ficoll layer (4 ml, Ficoll-Paque 
TM PREMIUM 1.084, GE Healthcare) and centrifuged for 30 min at 400g at RT. Then, 
the interphase containing cells was collected and cells were washed with fresh complete 
RPMI medium and analysed by FACS. 
 
2.5 Isolation of liver lymphocytes 
Livers were mashed through a sieve in 5 ml of 0% RPMI, then passed through a filter 
cup. In a 50 ml Falcon tube 15 ml of 40% percoll was underlayed with 15 ml of 60% 
percoll. Liver suspension was then carefully added on top of the gradient, which was 
centrifuged at RT for 30min, 1000g. After the centrifugation process lymphocytes 
appear at the interface of 40% and 60% percoll. Lymphocytes are collected and washed 
in FACS buffer (RPMI + 1% FCS). 
 
2.6 Flow cytometry 
Flow cytometric data was obtained using either a FACS Calibur and LSR II Fortessa . 
Data was analysed using FlowJo data analysis (Tree star inc.). 
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2.6.1 Flow Cytometry Reagents 
Methanol, Sigma 
Paraformaldehyde, Sigma 
PBS tablets, Sigma 
Bovine Serum albumin (BSA)  
2.6.2 Flow Cytometry solutions 
FACS Buffer: RPMI + 1% FCS 
BSA Buffer: 0.5% BSA in PBS 
Paraformaldehyde w/v 1% in PBS for fixation 
Fixation and permeabilization buffers, eBiosciences 
 
2.6.3 Cell counting by Flow cytometry 
Cells were counted using Caltag cell counting beads (Invitrogen). Caltag beads are 
fluorescent beads. A known volume of beads is added to the same known volume of 
cells that are counted. The beads and cells are mixed and the beads are counted along 
with cells using FACS Calibur. Live cells and beads were identified by forward and 
side light scatter profiles and by fluorescence at 564-606 nm. Since the concentration of 
beads is known, the number of cells per µL (the absolute count) is calculated by relating 
the number of cells counted to the total number of fluorescent bead counts. The cell 
number is then multiplied by the number of total fluorospheres per unit of volume.  
(Final absolute count = number of cells/total number of beads*number of beads per 
µL.) 
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2.6.4 Antibodies 
Fluorescein Isothiocyanate (FITC), R-Phycoerythrin (PE), Allophycocyan (APC) 
directly conjugated antibodies for flow cytometry.  
 
Table 2.1: Flow cytometry antibodies and their conjugates. 
Antibodies and working dilution clone Supplier 
CD8a (Fitc, PE, PerCP Cy5.5, 
PECy7, APC-Cy7, APC) 1:200 
53-6.7 BD Biosciences 
CD8β (PE) 1:200  H35-17.2 BD Biosciences 
CD4 (PE, APC, PerCP-Cy5.5, PE-
Cy7, APC-Cy7) 1:200  
RM4-5 BD Biosciences 
B220 (PE, Fitc, APC) 1:200 RA3-6B2 BD Biosciences 
B220 (V500) 1:200 RA3-6B2 BD Horizon 
Thy1.2 (Fitc, APC) 1:1000 5E10 BD Biosciences 
TCRβ (PerCP Cy5.5, APC, v450) 
1:200  
H57-597 PD Pharmingen, BD 
Horizon 
CD45 (Fitc, PE)  30-F11 BD Biosciences 
CD25 (PECy7, Fitc) 1:200,1:100 7D4, PC 61 BD Biosciences 
CD44 (Fitc, PE, APC,PE-Cy7, 
APC-Cy7) 1:200 
IM7 BD Biosciences 
CD62L (PE) 1:200 MEL-14 BD Biosciences 
CD71 (PE) 1:100 C2 BD Pharmingen 
CD98 (PE) 1:100 UM7F8 BD Biosciences 
TCRγδ (PE, APC) 1:200 GL3 BD Biosciences 
KLRG1 PE - Cy7 (1:200) 2F1 eBiosciences 
IL-17A (PE, PE Cy7) 1:100 eBio17B7 eBiosciences 
Ifn-γ (APC) 1:200 XMG1.2 BD Pharmingen 
Granzyme B (PE), 1:100 16G6 eBiosciences 
Pro5 MHC class I Pentamer 
complex 
 Proimmune 
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2.6.5 Live cell staining 
Cells were stained at 1-2x106 cells per ml at previously determined saturating 
concentrations of antibody at 4ºC for 20 min in FACS buffer. Cells were washed and 
resuspended in RPMI + 1% FCS prior to acquisition on a FACS Calibur (Becton 
Dickinson, San Jose, CA). A minimum of 10,000 relevant events were collected, stored 
ungated and the data were analysed with FlowJo software. Live cells were gated 
according to their forward light scatter (FCS) and side scatter (SSC) or when analysing 
small intestines using LSRII, live cells were identified as DAPI negative population. 
 
2.6.6 Fixed cell staining for intracellular IL-17/Ifn-γ  staining 
Th17 cells were stimulated with 20 ng/ml PdBu and 1 µg/ml Ionomycin in presence of 
‘Golgi plug’ for 4 hours followed by staining of cell-surface markers: CD4 and CD8. 
Next, cells were washed and fixed using a fixation buffer (eBiosciences) while 
vortexing the tubes and followed by incubation in the dark at room temperature for 20 
min. After fixation, cells were permeabilized using 1 ml of permeabilization buffer 
(eBioscience). Cells were centrifuged and the supernatant discarded. Permeabilization 
step was repeated, followed by resuspension of cells in 100 µl of permeabilization 
buffer. The cells were incubated with 0.5 µg/ml of mIL-17A and Ifn-γ antibody in a 
volume of 100 µl for 20 min at room temperature in the dark. Cells were then washed 
twice with 1 ml of permeabilization buffer and pelleted. The supernatant was discarded, 
and cells were subsequently resuspended in 0.5 ml of FACS buffer and analysed by 
flow cytometry. 
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2.7 RNA measurements 
2.7.1 Reagents for RNA measurements 
Rneasy minikit (Qiagen) 
Nuclease free water (Sigma) 
iQ SYBR Green supermix (BioRad) 
iScript cDNA synthesis kit (BioRad) 
 
2.7.2 cDNA Primers 
All sequences are from 5’ to 3’. 
18S:  Forward  ATC AGA TAC CGT CGT AGT TCC G 
Reverse  TCC GTC AAT TCC TTT AAG TTT CAG C 
HPRT: Forward TGA TCA GTC AAC GGG GGA CA 
Reverse TTC GAG AGG TCC TTT TCA CCA 
GAPDH: Forward CAT GGC CTT CCG TGT TCC TA 
Reverse CCT GCT TCA CCA CCT TCT TGA T 
AhR: Forward GAG CAG CGG CGC CAA CATCAC 
Reverse CAG GCT GGC CAG GCG GTC TAA CTC 
CYP1A1: Forward TGC CTA ACT CTT CCC TGG ATG CCT T 
Reverse CCG GAT GTG GCC CTT CTC AAA TGT 
IL17: Forward AGC TCC AGA AGG CCC TCA GAC TAC C 
Reverse CAG CTT TCC CTC CGC ATT GAC AC 
KLF2: Forward TGT GAG AAA TGC CTT TGA GTT TAC TG 
Reverse CCC TTA TAG AAA TAC AAT CGG TCA TAG TC 
IL-22: Forward CAA ATG CGC TGC CCG TCA ACA 
Reverse GCA CTG ATC CTT AGC ACT GAC TCC TCG 
ARNT: Forward ACA CAA GCA CAA GCA CCT AG 
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Reverse CTT CAT TGT TGT AGG TGT TGC 
CCR7: Forward CAG GCT TCC TGT GAT TTC TAC A 
Reverse ACC ACC AGC ACG TTT TTC CT 
S1P1R: Forward GTG TAG ACC CAG AGT CCT GCG 
Reverse AGC TTT TCC TTG GCT GGA CAG  
CD62L: Forward ACG GGC CCC AGT GTC AGT ATG TG 
Reverse TGA GAA ATG CCA GCC CCG AGA A 
Ifn-γ: Forward TTA CTG CCA CGG CAC AG T C 
Reverse AGA TAA TCT GGC TCT GGC TCT GCA GG 
Perforin: Forward CGT CTT GGT GGG ACT TCA G 
Reverse GCA TTC TGA CCG AGG GCA G 
Glut1: Forward GCT CAG TGT CAT CTT CAT C 
Reverse ACC CTC TTC TTT CAT CTC C 
T- bet: Forward GAT CAT CAC TAA GCA AGG ACG 
Reverse GGT CCA CCA AGA CCA CAT C 
YFP: Forward GTG CAG CTC GCC GAC CAC TAC CA 
Reverse CGG CGG CGG TCA CGA ACT CCA 
Cre: Forward CGT ACT GAC GGT GGG AGA AT 
Reverse: CCC GGC AAA ACA GGT AGT TA 
 
2.7.3 RNA Purification 
RNA was purified from cell pellets using the RNeasy RNA purification minikit 
following the manufacturer’s instructions (Qiagen). RNA purification included a step of 
15 min on column DNaseI digest in order to remove contaminating genomic DNA. 
RNA concentrations were determined using a Nanodrop spectrophotometer (Thermo 
Scientific) by measuring absorbance at 260 and 280nm. 
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2.7.4 cDNA production 
1 µg of isolated RNA was reverse transcribed to cDNA using iScript cDNA synthesis 
kit (BioRad), which contains an MMLV-derived and modified H+ RNAse reverse 
transcriptase, which has been optimised by pre-blending with RNAse inhibitor and 
contains a unique blend of oligo (dT) and random hexamer primers. 0.3-1 µg RNA was 
diluted into 15 µl nuclease-free water plus 4 µl iScript reaction mix and 1 µl iScript 
reverse transcriptase and run at 25ºC for 5 min, 45ºC for 20 min and 85°C for 5 min. 
 
2.7.5 Quantitative PCR 
Quantitative PCR was performed in 96 well plate format using iQ SYBR Green based 
detection (BioRad) in a BioRad iCycler with each 20 µl reaction containing: 1µl cDNA, 
0.8µl (10 µM) sense primer and antisense primer, 10 µl iQ SYBR Green supermix, 7.4 
µl nuclease free water. The plate was sealed with iCycler iQ optical foil (Biorad) and 
run under the following conditions: 95ºC for 3min followed by 40 cycles of 95ºC for 20 
seconds and 57ºC for 45 seconds; then 95ºC for one min, 55ºC for one min followed by 
80 cycles stepwise to 95ºC at 0.5ºC increments for 10 seconds at each temperature to 
determine the melt curve. Each reaction was performed in duplicate. 18S, HPRT or 
GAPDH levels were used for normalization and the relative mRNA levels calculated 
using the equation:  
 
Where ct is the threshold cycle, u is the mRNA of interest, r is the reference gene, s is 
the sample and c is the unstimulated control sample.  
When new primers were used, amplified products were run on agarose gel, purified 
using a QIAquick Gel Extraction kit (Qiagen) and sequenced by the Sequencing Service 
(Dundee University). 
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2.8 ELISA 
2.8.1 Reagents 
DuoSet Elisa kit for IL-17 and IL-22 (R&D systems) 
PBS - 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.2-7.4 
Wash Buffer - 0.05% Tween 20 in PBS, pH 7.2-7.4 
Reagent Diluent - 1% BSA in PBS, pH 7.2-7.4 
Substrate solution  
Stop solution - H2SO4 1M 
 
2.8.2 General ELISA protocol for IL-22 and IL-17A cytokines 
Th17 cells were incubated at a density of 1x106 per ml in IMDM with 10% heat 
inactivated FCS, 50 µM-β-Mercaptoethanol and Pen/Sterp with or without 
PdBu/Ionomycin for four hours. Subsequently, the supernatants were collected. A 96- 
well plate was coated with a capture antibody (2 µg/ml), sealed and incubated over 
night at room temperature for IL-22 and 4°C for IL-17. The next day, capture antibody 
was aspirated and the plate was washed twice with a wash buffer. The plate was then 
blocked for 1 hour in room temperature by adding 300 µl of Reagent Diluent to each 
well. Following reagent diluent aspiration, 100 µl of standards and cell supernatants 
samples were added into each well. The plate was covered with an adhesive strip and 
incubated two hours at room temperature. After two hours of incubation, the samples 
were aspirated and the plate was washed with a wash buffer. A volume of 100 µl of 
detection antibody at concentration of 400 ng/ml was incubated for 20 min at RT in 
each of the wells. Following this incubation step, the plate was washed with a wash 
buffer and 50 µl of substrate solution was incubated for 20 min in each well. Once the 
colour reaction was complete, 50 µl of stop solution was added and the optical density 
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of each well was determined immediately using a microplate reader set to 450 nm. IL-
17 and IL-22 cytokine production was determined using a recombinant mouse IL-17 or 
IL-22 standard curve. 
 
2.9 Western blot 
2.9.1 Reagents 
Lamelli sample buffer, Invitrogen 
NuPAGE anti-oxidant, Invitrogen 
20 x NuPAGE MOPS running buffer, Invitrogen 
20 x NuPAGE transfer buffer, Invitrogen 
Powdered milk, Marvel 
 
2.9.2 Solutions 
F buffer: 50mM NaCl, 10 mM Tris pH 7.05, 30mM sodium pyrophosphate, 50mM 
NaF, 5µM ZnCl2, 10% glycerol, 0.5% Triton with 1µM DTT and protease inhibitors 
(Roche) being added freshly to the buffer prior to lysis. 
PBS-T: Phosphate buffered saline, 0.5% Tween-20 (Sigma) 
Poncaeu S:  0.1% Poncaeu S, 0.5% acetic acid (BDH) 
Stripping buffer: 0.7% β- Mercaptoethanol, 2% SDS, 62.5mM Tris (pH7.4) 
Hypotonic lysis buffer: 10 mM HEPES, pH 7.9, 4 mM MgCl2, 15 mM KCl, 10 mM 
NaF, 0.1 mM EDTA, 0.15% (vol/vol) Nonidet-P40, 1 mM phenylmethylsulfonyl 
fluoride, 1 mM Na3VO4 and 1 mM dithiothreitol 
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2.9.3 Antibodies 
AhR, Biomol, Enzo Life Sciences 
ARNT (sc-8076), Santa Cruz 
Hif-1α (clone 241809), R&D systems 
SmC1 (A300-055A), Bethyl labs  
IκB (sc-371), Santa Cruz 
Glut1 (the antibody was raised against a C-terminal peptide EELFHPLGADSQV and 
originally made by Geoffrey D. Holman in the university of Bath (Holman et al., 1990), 
UK, given to us by Carol MacKintosh, MRC protein Phosphorylation Unit). 
PKB, Cell Signaling Technologies (CST) 9272 
pPKB (Thr 308), CST 4056 
pPKB (Ser 473), CST 4058 
pS6 (Thr235/236), CST 2211 
S6, CST 2217 
S6K, CST 9202 
S6K (Thr 389), CST 9206 
Perforin, Gift from G.M Griffiths 
T-bet (sc-21003), Santa Cruz 
Blimp1 (6D3), Santa Cruz 
MAPK, CST 9212 
Foxo3a, DSTT (Division of Signal Translation Therapy) 
pFoxo1/3a (Thr24/32), CST 9464 
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2.9.4 Cell Lysis 
Cells at concentration of 20x106/ml were lysed for 20 min on ice in F Buffer. Lysates 
were centrifuged at 4°C, 1600g for 10 min. In some cases, total soluble protein content 
was determined using Bradford assay reagent (Sigma) according to manufacturer’s 
instructions. Protein samples were mixed with LDS sample buffer (1x) and DTT (5 
mM) and denatured by boiling for 5 min at 100°C.  
For Cytoplasmic Nuclear fractionation: Cells were lysed at a density of 20x106 
cells/ml in hypotonic lysis buffer and centrifuged at 4˚C for 1 min at 10,000g. Cytosolic 
fractions were removed and nuclear-membrane fractions were suspended in F buffer 
described above. 
 
2.9.5 Western Blot procedure 
Protein samples were then separated at 200V using NuPAGE 4%-12% bis-tris gradient 
gel electrophoresis in MOPS running buffer. Separated proteins were transferred to 
Hybond-C Extra membranes (Amersham) for 2.5 hours on ice. Transfer and equal 
loading was confirmed by Poncaeu S, washed with water and were blocked with 5% 
milk fat in PBS-Tween 20 for 1 hour in RT. Blots were probed with primary antibodies 
at optimized concentrations in 5% milk PBS-T or in 5% BSA PBS-T for over night at 
4°C. Membranes were then washed in PBS-T (3x5min) at room temperature followed 
by incubation with HRP tagged secondary antibody diluted in 5% milk PBS-T (1:5000) 
for 1 hour at room temperature. Membranes were then washed 3x5 min and visualized 
via enhanced chemiluminescence (ECL). 
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2.10 Glucose uptake 
2.10.1 Reagent 
Glucose free RPMI, Gibco 
D(+) Glucose, Sigma 
2-Deoxy-D-[1-3H]glucose ([3H]2DOG), GE Healthcare 
Heat inactivated dialysed FBS (dFBS), Gibco 
 
2.10.2 Measurements of Glucose Analogue Uptake 
T cells activated with 2C11 and cultured in presence of IL-2 for 6 days or naïve CD8 T 
cells extracted from lymph nodes of P14 TCR transgenic mice and stimulated with 
gp33-41 (100 ng/ml) and CD28 (3 ng/ml) for 20 hours were left untreated or treated 
with 20 nM rapamycin for indicated periods of time. Total number of 7x106 (per 
triplicate) of IL-2 cultured cytotoxic T cells or 3x106 of TCR-activated CD8 T cells 
were pelleted and suspended in 700 µl or 600 µl of Glucose free, FCS free medium 
(Gibco). A total of 2x106 of IL-2 cultured cytotoxic T cells or total of 1x106 of TCR-
activated T cells in 200 µl were loaded on top of 500 µl phthalsäurediisononylester oil 
(Sigma Aldrich) mixed in 1:1 ratio with poly (dimethyloiloxane-co-methyl-phenyl 
siloxane) oil (Sigma Aldrich) containing 200 µl of 1 µCi/ml 2-Deoxy-D-[1-3H] glucose 
([3H] 2DOG) (GE healthcare) in glucose-free medium. Glucose uptake was for 3 min 
for IL-2 cytotoxic T cells and 10 min for TCR stimulated CD8 T cells. Cells were then 
spun for 3 min at 9000 rpm and washed twice with MilliQ water to remove excess oil. 
Cell pellets were lysed over night with 200 µl of 1M NaOH and the incorporated 3H 
radioactivity was quantified via liquid scintillation counting. Measurements were 
performed in triplicates per condition. 
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2.11 Lactate production assay 
2.11.1 Reagents 
Glycine, Sigma 
Hydrazine monohydrate, Sigma 
β- Nicotinamide adenine dinucleotide hydrate (NAD+), Sigma 
Rabbit muscle lactate dehydrogenase VII (LDH), Sigma 
L-Lactate, Sigma 
 
2.11.2 Measurement of Lactate  
The lactate assay is based on a colorimetric reaction in which L(+)-lactate is oxidised by 
lactate dehydrogenase (LDH) which exhibits an absorbance maximum at 450 nm. For 
measuring lactate output, 2x106 of IL-2 cultured cytotoxic T cells/ml or 10x106 TCR-
activated T cells/ml were cultured for 4 hours in RPMI 1640 containing 10% dialysed 
heat inactivated foetal calf serum (FCS). Following 4 hours of culture, cells were 
pelleted and the supernatants were collected. For lactate standard curve, sodium lactate 
(Sigma) at concentration of 40 mM was used to make 2-fold serial dilutions. Volumes 
of 100 µl of cell supernatants and standards were added in triplicates into 96-well plate 
and mixed with 100 µl of master-mix reaction containing 1M glycin, 20M hydrazine 
monohydrate, ddH2O, 0.1M NAD and 2 units of Lactate dehydrogenase enzyme. The 
plate was then incubated for 10 min at 25˚C and the absorbance was read in Cytofluor at 
settings of 360/340 nm excitation and 460/440 nm emission. 
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2.12 Adoptive transfer 
Spleens from ARNTfl/fl x CD4Cre+/-  (KO) mice or ARNTfl/fl  (WT) mice were activated 
with 2C11 antibody for 48 hours and cultured in IL-2 for 4 days. Cells were then 
labeled either with CFSE (Invitrogen) or with CellTracker Orange (CMTMR; 
Invitrogen) for 15 min in 37˚C, washed, mixed at 1:1 ratio and suspended in sterile 
PBS. Mixed cell suspension of ARNTfl/fl X CD4Cre+/-  (KO CTLs) and ARNTfl/fl (WT 
CTLs), containing total of 5x106 cells in 150 µl was injected into the tail vein of 
C57/BL6 host mice and allowed to home. After 4 hours mice were sacrificed and lymph 
nodes, spleen and blood were analysed for the quantification of CFSE- and CMTMR- 
labeled T cells. Values indicate recovery of ARNTfl/fl x CD4Cre+/- (KO) or ARNTfl/fl 
(WT) T cells as a percentage of the total recovered transferred cells. 
 
2.13 Candida albicans infection 
Infection experiments with Candida albicans were performed in NIMR-National 
Institute of Medical Research, London in Prof. Brigitta Stockinger lab according to a 
protocol described in (Hirota et al., 2011). C. albicans strain SC5413 was obtained from 
the Institute of Medical Sciences of the University of Aberdeen. For hyphae 
preparation, cells were cultured for 2 hours at 37 °C in 5% CO2 in RPMI. Ventral skin 
of mice (~2 cm2) was shaved and scratches were made using a needle. Candida albicans 
hyphae (2 x 105) were then applied to the skin surface. Mice were culled on day 5 post 
infection and area of 1 cm2 of infected skin was excised and mashed. Subsequently skin 
pieces were digested for 1 hour at 37 °C in Iscove's modified Dulbecco medium 
containing liberase (400 µg/ml; Roche) and collagenase D (1 mg/ml; Roche) with 
constant stirring. Cells were then pelleted, washed and stained for surface markers.  
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2.14 Listeria monocytogenes infection 
Attenuated recombinant Listeria monocytogenes strain that secrets OVA protein (ΔactA 
rLM-OVA) was kindly provided by Prof. Klaus Okkenhaug (Babraham Institute, 
Cambridge). Bacteria were grown in brain-heart infusion containing 5 µg/ml 
erythromycin and glycerol stocks were frozen in aliquots in -80°C. On the day of the 
experiment ΔactA rLM-OVA frozen aliquots were thawed and used to infect mice by 
i.v. injection with 1 x 106 CFU for a primary infection and 1 x 107 for secondary 
infection in the lateral tail vein in a volume of 150 µL. To access CD8+ effector T cells 
generated following Listeria monocytogenes infection, mice were culled on day 7-post 
infection. To detect secondary effector CD8+ T cells, mice were re-challenged on day 
28 and sacrificed on day 6-7 after secondary challenge. To detect OVA-specific CD8+ T 
cells spleens, livers and lymph nodes were harvested. Tissues were mashed and 
extracted cells were stained with Pro5 MHC class I pentamer loaded with SIINFEKL 
(Proimmune) in combination with other surface markers. In addition, intracellular 
staining of Ifn-γ cytokine was performed following T cell stimulation with (1 µM) 
SIINFEKL peptide and Golgi plug for 5 and 3 hours, respectively. 
 
2.15 Treatment with 3-Methylcholanthrene (3-MC)  
3-Methylcholanthrene (Sigma-Aldrich) was administered to animals (at least 8 weeks of 
age) as a suspension in corn oil by intraperitoneal (i.p) injection. Dosage consisted of 
40mg/kg body weight for three days at 24 hourly intervals. Control animals were 
injected with an equal volume of carrier corn oil only. Animals were culled and tissues 
were analysed on day 4.  
  
 112 
2.16 NP(OVALBUMIN) Immunization and Ig and IgM ELISA 
NP(13)OVALBUMIN (Biosearch Technologies) was diluted in PBS and mixed with an 
equal volume of alum (Thermo Scientific). The solution was incubated for 1 hour on 
rotating wheel at RT to allow the antigen to from precipitates with alum. Age-matched 
mice at 8-12 weeks of age were then immunized subcutaneously with 
NP(13)OVALBUMIN + alum at a dose of 100 µg/mouse. 
Mice were bled on day 0, 7, 14, 28 and 42 after primary infection and sera were 
collected into MiniCollect tubes (GreinerBioOne) that were spun down at 8000 rpm for 
5 min (benchtop centrifuge). On day 42 mice were boosted with a secondary challenge 
of NP(13)OVALBUMIN in PBS (no alum) at a dose of 50 µg/mouse. On day 49 (day 7 
after secondary boost) terminal bleeds were collected.  
Basal and NP-specific Ig levels were determined by ELISA. In brief: Elisa plates were 
coated with 100µL/well of 10µg/mL of NP(X)BSA diluted in 50mM Carbonate buffer 
(pH 9.5) over night at 4°C. NP(X)BSA used for coating was either NP(2)BSA for 
detection of high affinity and/or NP(32)BSA for the detection of low affinity antibodies. 
The plates were then washed three times in PBS/0.05% Tween 20 and blocked with 200 
µL/well of BSA/PBS for 1 hour at RT followed by additional three washes in 
PBS/0.05% Tween 20. Serum samples were then added starting from a 1:400 and 1:200 
dilutions for IgG and IgM, respectively, with subsequent 4-fold serial dilutions. The 
plates with the sera were incubated for 2 hours at RT or over night at 4°C. Following 
incubation step with the sera, the plates were washed 3 times in PBS/0.05% Tween 20 
followed by incubation with biotin conjugated anti IgG and anti IgM antibodies diluted 
at 1:1500 in 0.1% BSA/PBS (0.5mg/ml, BD Biosciences) for 1 hour at R.T. At the end 
of the incubation step the plates were washed again three times in PBST and 
streptavidin HRP 100µL/well was added for 30 min-1 hour at R.T. Following a washing 
step with PBST, the reaction was revealed by adding a TMB (3,3',5,5"-
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tetramethylbenzidine) substrate (eBiosciences) until a signal was developed. The 
reaction was stopped using 50µL/well of H2SO4 (1M) and the absorbance was read at 
450 nm. Endpoint titers were calculated to give a measure of relative antibody 
concentration.  
 
2.17 Data analysis and statistical evaluation 
All quantified data were processed in Microsoft EXCEL 14.2.2 (MAC 2011). Statistical 
evaluation was done using Prism version 4 for Macintosh. Using Prism bar and line 
graphs, dot plots and column graphs were generated. Statistical tests used to determine 
significant differences were two-tailed t-tests and one-way ANOVA. Differences were 
considered significant when p<0.05.  
All experiments were repeated at least 3 times unless stated otherwise. 
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Chapter 3 Exploring Aryl Hydrocarbon Receptor expression 
in T lymphocytes 
3.1 Introduction  
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription regulator that 
binds to the environmental pollutants such as the 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD) (Bohonowych and Denison, 2007) and endogenous ligands e.g kynurenine, the 
first breakdown product in the IDO-dependent tryptophan degradation pathway 
(Mezrich et al., 2010). Ligand binding drives AhR translocation to the nucleus and 
allows its heterodimerisation with the AhR nuclear translocator (ARNT) (Esser et al., 
2009). The immune system is recognized as a target of dioxin toxicity reflecting that 
subpopulations of immune cells express the AhR. In particular, although AhRs are not 
expressed by naïve T cells extensive work has showed that the AhR is highly expressed 
in IL-17 producing CD4 T cells and acts as one of the three master transcription factors, 
which drive the differentiation of Th17 cells. AhR ligands thus induce the transcription 
of AhR target genes and enhance Th17 differentiation (Veldhoen et al., 2009). AhR-null 
T cells show impaired Th17 differentiation and complete loss of IL-22 cytokine 
production (Kimura et al., 2008; Veldhoen et al., 2008). The expression of AhRs by 
other CD4 T cell subpopulations has not been extensively explored although it has been 
described that Th1 cells do not express the AhR. Since in numerous studies TCDD was 
shown to suppress cell mediated immune responses (Holsapple et al., 1991; Kerkvliet, 
2002), it is believed that these suppressive effects are due to increase in the percentages 
of T regulatory cells. Hence, several reports imply that AhR is expressed in T regulatory 
cells (Funatake et al., 2005; Quintana et al., 2008; Marshall and Kerkvliet, 2010), thus 
responsible for mediating these suppressive effects. However, when actual levels of 
AhR mRNA in T regs were measured, they appeared to be above background when 
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compared with non-polarised activated Th0 and Th1 T cells but 50-100 fold lower when 
compared with Th17 cells (Hill et al., 2007; Quintana et al., 2008; Veldhoen et al., 
2008). Furthermore, forced expression of constitutively active AhR in T cells did not 
seem to recapitulate the activation of a regulatory T cell phenotype by TCCD (Funatake 
et al., 2009). Based on the effects of TCDD it is also assumed in the field that AhRs are 
expressed in innate immune cells such as macrophages, dendritic cells and NK cells. 
However, no solid and cell type-specific expression data has been provided yet. The 
only clear data originates from gene array studies that show high AhR expression in 
dendritic cells in comparison to other immune cell subsets (Frericks et al., 2007). 
Nonetheless, some evidence for AhR expression in certain innate immune cells are 
supported for instance by studies that show a direct and cell intrinsic functional role of 
AhR in maturation of Langerhans cells (Jux et al., 2009), AhR-dependent IL-22 
production by γδ T cells in response to Mycobacterium and Candida albicans infections 
(Martin et al., 2009) and the requirement of AhR expression for the maintenance of  γδ 
T cells on the skin dermis and among the intraepithelial lymphocytes in the small 
intestines (Li et al., 2011). AhR expression was also described in a population of NK 
cells in the gut (Hughes et al., 2010). 
The recent focus on AhR function in lymphocytes has been its role in CD4 T cells 
and intraepithelial lymphocytes of the gut (Kimura et al., 2008; Veldhoen et al., 2008; 
Stockinger, 2009; Li et al., 2011; Qiu et al., 2012). However, the response of CD8+ T 
cells to influenza virus is very sensitive to modulation by aryl hydrocarbon receptor 
(AhR) agonists. For example, in the context of CD8 cytotoxic T cell exposure of mice 
to TCDD suppressed the clonal expansion of influenza virus-specific CD8+ T cells 
(Mitchell and Lawrence, 2003), and also impaired memory T cell production (Warren et 
al., 2000; Lawrence and Vorderstrasse, 2004). How much of the CTL pathology in 
dioxin treated mice is caused by direct effects of dioxins on CD8 T cells is not known. 
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Moreover, whether the AhR has a role in normal CTL physiology is not clear. Here it is 
noteworthy that effector CD8 T cells that produce high levels of IL-17 are found in the 
lung following influenza challenge. These CD8 positive Tc17 cells can protect against 
lethal influenza challenge in mouse models. In CD4 T cells the AhR has a clear role in 
controlling the production of Th17 cells and cells that produce IL-22 (Veldhoen et al., 
2008). It has not yet been explored whether the AhR has a similar role in determining 
the balance between the production of CTL, memory T cells and Tc17 cells. In this 
respect, in the literature, there are opposing opinions regarding whether the immuno-
suppressive effect of dioxins on CD8 T cell mediated immune responses is a direct 
effect of dioxins on the CD8 T cells. For example, studies using in vivo acute graft 
versus host (GVH) model of T cell immunity argue that direct AhR-dependent effects of 
TCDD occur in both CD4+ and CD8+ T cell subsets and both T cell subsets contribute 
to the full suppression of the CTL response by TCDD (Kerkvliet et al., 2002). However, 
dendritic cells can express AhRs (Vogel et al., 2008; Bankoti et al., 2010). In fact, there 
are studies that showed that AhR expressed in DCs is required to induce indoleamine 
2,3-dioxygenase (IDO) expression, an immunosuppressive enzyme that converts 
tryptophan into kynurenine. This latter molecule is an AhR ligand and can promote the 
differentiation of naïve T cells into T reg cells (Nguyen et al., 2010; Quintana et al., 
2010). Hence, any effect of AhR ligands on CD8 T cell mediated immune responses 
could be indirect. In this regard, it is not known whether CD8 T cells express the AhR 
or its transcriptional partner ARNT. Accordingly, the present chapter uses western blot 
analysis with AhR and ARNT selective antibodies to address this issue.  
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3.2 Results 
3.2.1 AhR expression in naïve CD4 T cells versus IL-17 CD4 effector T cells 
In initial experiments we monitored AhR and ARNT expression in CD4 T cells induced 
to differentiate to Th17 cells. The rationale for these first experiments was that it is well 
established that AhRs are expressed in Th17 cells and accordingly these are an 
important reference population. To produce Th17 cells we used the previously 
described protocol (Veldhoen et al., 2009). CD4 T cells were activated with CD3 and 
CD28 antibodies in the presence of IL-6, IL-1β and TGF-β and then maintained in 
culture for the indicated time. Quantitative RT PCR (Figure 3.1A) and western blot 
analysis (Figure 3.1B) show that naïve CD4 T cells do not express AhR mRNA or its 
protein. In contrast, IL-17 producing CD4 effector T cells generated in vitro express 
both AhR mRNA (Figure 3.1A) and protein (Figure 3.1B). To assess the specificity of 
the AhR antibody used in these experiments we used AhR-null CD4 Th17 cells. (Figure 
3.1C). The well established AhR signaling pathway holds that ligand binding to the 
cytosolic AhR results in the translocation of AhR to the nucleus and its dimerization 
with its binding partner ARNT (AhR Nuclear Translocator). Ultimately, the 
transactivation of AhR target genes requires the recognition of DRE (dioxin responsive 
enhancer) sequences by the AhR/ARNT complex. It is frequently described that ARNT 
expression is ubiquitous. However, we noted that ARNT is not expressed in naïve CD4 
T cells but is expressed in effector Th17 cells. (Figure 3.1D). The specificity of the 
ARNT antibody is shown by its inability to detect proteins in Th17 differentiated from 
T cells selectively deleted of ARNT (Figure 3.1E).  
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Figure 3.1 AhR and ARNT expression in effector Th17 cells versus naïve CD4 T cells. 
 
(A) qRT PCR analysis of AhR mRNA expression in naïve CD4 T cells versus Th17 
cells generated by activating CD4 T cells with CD3 and CD28 antibodies and culturing 
cells in presence of IL-1β, IL-6 and TGF-β for 5 days (n=3). (B) Western blot analysis 
with AhR and SmCI antibodies of naïve CD4 T cells and day 5 Th17 cells (n=3). (C) 
Western blot analysis with AhR antibody in WT Th17 cells and AhR-null Th17 cells 
(n=2). (D) Western blot analysis with an ARNT antibody of naïve CD4 T cells and 
Th17 effector cells (n=3). (E) Western blot analysis of ARNT expression in (WT) 
ARNTfl/fl Th17 cells and ARNT-deficient Th17 cells differentiated from ARNTfl/fl X 
CD4Cre +/- (KO) mice. mRNA levels were normalized to HPRT expression and shown as 
mean +/- SD values of three independent experiments. Probing with SmCI antibody 
controlled equal loading on the gel (n=3). 
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Time course analysis performed by us and other groups shows that there is a gradual 
induction in the expression of AhR and ARNT proteins during the differentiation 
process of CD4 T cells in vitro in the presence of Th17 polarizing conditions (Figure 
3.2A and B), reaching their highest level of expression at 96 hours time point when 
Th17 cells are a fully differentiated effectors.  
Western blot analysis showing expression of AhR and ARNT does not inform if cells 
express sufficient AhR receptors to induce transcription of AhR responsive genes. 
Hence, to assess AhR functional capacity in T cells as they differentiate to Th17 cells 
we examined the expression of mRNA encoding expression of an AhR/ARNT target 
gene CYP1A1. In these experiments we assessed CYP1A1 mRNA expression in cells 
cultured in the presence and absence of the AhR ligand 6-formylindolo [3,2-b] 
carbazole, (FICZ). This compound is a high affinity AhR ligand and effectively 
activates AhR signaling pathways (Veldhoen et al., 2009; Wincent et al., 2009). The 
data show that CYP1A1 expression is expressed at low levels within 12-24 hours of 
immune activation in the CD4 T cells cultured Th17 polarizing cultures in the absence 
of FICZ. There was however a striking increase in expression of CYP1A1 mRNA in 
CD4 T cells cultured in Th17 polarizing cultures in the presence of FICZ. This was 
apparent at the 18-24 hour time point but continued to increase to a maximum level of 
expression in cultures maintained for 36-42 hours (Figure 3.2C).  
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Figure 3.2 AhR and ARNT expression is induced during Th17 differentiation in vitro. 
 
(A) Western blot with AhR and PKB antibodies of CD4 T cells activated with CD3 and 
CD28 antibodies and cultured in presence of IL-1β, IL-6 and TGF-β for the indicated 
periods of time (n=2). (B) Western blot with ARNT and SmCI antibodies of CD4 T 
cells cultured under Th17 polarizing conditions for the indicated periods of time (n=2). 
(C) Representative qRT PCR kinetic analysis of CYP1A1 mRNA expression in CD4 T 
cells differentiated under Th17 conditions for indicated time points in the presence or 
absence of FICZ (300nM). mRNA levels were normalized to 18S expression and shown 
as mean +/- SD values (n=3). Probing with SmCI and PKB antibodies controlled equal 
loading on the gel. 
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3.2.2 AhR and ARNT expression in CTLs versus Th17/Tc17 T cells 
Several studies describe AhR-dependent effects on CD8+ T cell subpopulations 
following exposure of mice to TCDD in vivo but it is unclear whether the effects of 
AhR ligand on CD8 T cells is direct. To study the expression of AhR in CD8 T cells we 
looked at its mRNA expression by RT PCR and by western blot analysis. Figure 3A 
shows that naïve CD8 T cells do not express AhR mRNA (Figure 3.3A) and do not 
express AhR protein (Figure 3.3B). Similarly, naive CD8 T cells do not express ARNT 
protein (Figure 3.3C). We then looked at AhR and ARNT expression in immune 
activated CD8 T cells. In these experiments CD8 T cells expressing the P14 TCR 
transgene were activated with a peptide of the lymphocytic choriomeningitis virus 
(LCMV), glycoprotein gp33-41, presented by the MHC class I molecule H-2Db, 
followed by clonal expansion in IL-2. This generates a homogenous population of CTLs 
that express the P14 TCR transgene. The data in Figure 3 show that T cells activated 
with gp33-41 peptide and subsequently cultured in IL-2 for six days express AhR 
mRNA (Figure 3A) and induce the expression of AhR protein (Figure 3.3B). The data 
(Figure 3.3C) also show that ARNT is not expressed in naive CD8 T cells but is 
expressed in CD8 cytotoxic T cells activated with gp33-41 ad cultured with IL-2. 
Moreover, induction of both AhR and ARNT expression in CD8+ T cells was TCR 
dependent as shown by expression of AhR and ARNT following 20 hours stimulation 
of purified CD8+ T cells with a gp33-41 peptide (Figure 3.3D and E).  
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Figure 3.3 AhR and ARNT are expressed in effector CTLs maintained with IL-2 
cytokine. AhR and ARNT expression is induced in CD8 T cells following TCR 
stimulation.  
 
(A) qRT PCR analysis of AhR mRNA expression in naïve purified P14 CD8 T cells and 
effector P14 CD8 T cells activated with gp33-41 and maintained in presence of IL-2 for 
6 days. mRNA levels were normalized to HPRT expression and shown as mean +/- SD 
values (n=3) (B) Western blot analysis with AhR and SmCI antibodies of purified naïve 
P14 CD8 T cells versus P14 effector cytotoxic T cells cultured in presence of IL-2 for 6 
days (n=3). (C) Western blot analysis with ARNT and SmCI antibodies of purified 
naïve P14 CD8 T cells and P14 effector cytotoxic T cells (n=3). (D) Western blot 
analysis with AhR and SmCI antibodies of naïve purified P14 CD8 T cells stimulated 
with gp33-41 and cultured in presence of IL-2 cytokine for 20 hours (lane 1), P14 CD8 
T cells stimulated with gp33-41 and cultured in presence of IL-7 cytokine for 20 hours 
(lane 2) or naïve purified CD8 T cells (lane 3). (E) Western blot analysis with ARNT, 
pS6K (Thr389) and SmCI antibodies of P14 CD8 mature cytotoxic T cells maintained 
in presence of IL-2 for 6 days (lane 1), P14 CD8 T cells stimulated with gp33-41 for 
20h (lane 2) and naïve purified P14 CD8 T cells (lane 3). Probing with SmCI antibody 
controlled equal loading on the gel. (n=3). 
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Interestingly, a semi quantitative western blot comparison of AhR protein levels in CD4 
Th17 cells versus CTLs reveals that AhR levels in Th17 cells and in dendritic cells are 
much higher than in CTLs on a per cell basis (Figure 3.4).  
 
 
Figure 3.4 Comparison of AhR expression levels in Th17 T cells, dendritic cells and 
cytotoxic T cells.  
 
Western blot analysis with AhR and PKB antibodies of effector Th17 cells, P14 mature 
CTLs and bone marrow-derived dendritic cells (lysed at 3x107 cells/mL). All protein 
extracts were similarly titrated in 2-fold serial dilutions as indicated. Blotting with PKB 
antibody was used to confirm two-fold dilution of loading (n=2). 
 
 
We also compared AhR levels in immune activated T cells cultured under different 
conditions: immune activated CD8 T cells grown in presence of IL-6, IL-1β and TGF-β 
to polarize to Tc17 cells; immune activated CD8 T cells cultured in the presence of IL-
15, a well characterized in vitro model to produce memory CD8 T cells and CD8 
effector CTLs. The data in Figure 5A show that Th17 and Tc17 cells express relatively 
high levels of AhRs compared to CD8 effector CTL and ‘memory’ CD8 effector cells. 
We noted however that ARNT levels were comparable in Tc17 cells and CTLs although 
immune activated T cells cultured in vitro with IL-15 to generate memory like CD8 T 
cells express low levels of ARNT (Figure 3.5B). The western blot analysis in Figure 
3.5B also shows that Th17 cells and Th1 cells express relatively high levels of ARNT. 
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Figure 3.5 AhR and ARNT expression in T cell subsets  
(A) Western blot analysis with AhR and SmCI antibodies of effector CD4+ cells 
cultured under Th17 conditions for 4 days, Tc17 cells generated by TCR activation of 
P14 CD8 T cells with gp33-41 and cultured with combination of IL-1β, IL-6 and TGF-β 
cytokines for 4 days and P14 CD8 T cells activated with gp33-41 and cultured with 
either IL-15 or IL-2 cytokines for 6 days (n=2). (B) Western blot analysis with AhR, 
ARNT and SmCI antibodies of Th1 effector cells, which were generated by activating 
naïve purified CD4 T cells with CD3 and CD28 antibodies and cultured with IL-12 and 
IL-2 for 6 days, Tc17 cells and P14 CD8 T cells cultured with either IL-15 or IL-2 
cytokines for 6 days (n = 3).  
 
 
Another question we asked was what signals are required to re-induce and maintain 
AhR expression in Tc17 and CTLs? Our initial experiment on AhR expression in CD8 
T cells polarized under Tc17 culture conditions (Figure 3.6A, lane 1) looked at TCR 
activated CD8 T cells cultured for 4 days with IL-6, TGF-β and IL-1β. However, if the 
cell cultures were continued for 3 more days, until day 7 the expression of AhRs 
declined (Figure 3.6A, lane 2) despite the continued presence of cytokine (Figure 3.6A, 
lane 5). The expression of the AhR could be re-induced by triggering of TCR 
complexes with cognate peptide (Figure 3.6A, lane 4). On the other hand, we could 
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maintain AhR expression in Tc17 cells if from day four onwards the cultures were 
supplied with IL-2 cytokine (Figure 3.6B, lane 3) in contrast to no-cytokines conditions 
in which AhR expression was lost (lane 2). It is noteworthy, that although IL-2 
maintained AhR expression in Tc17, its levels were still lower than in day 4 fully 
differentiated Tc17. Interestingly, IL-2 was also essential for the maintenance of AhR 
and ARNT expression in CTLs. Day 5 CTLs, which were maintained with IL-2 were 
washed from IL-2 and further cultured for 24 hours in the absence of this cytokine. A 
Western blot analysis showed that AhR and ARNT expression were downregulated in 
CTLs upon IL-2 withdrawal in comparison to control cells grown in the presence of IL-
2 (Figure 3.6C).  
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Figure 3.6 AhR expression in Tc17 cells and CTLs requires IL-2 and AhR expression 
and can be re-induced in Tc17 by TCR stimulation  
 
(A) Western blot analysis with AhR, SmCI and PKB antibodies showing AhR 
expression of day 4 differentiated Tc17 cells (lane 1- from right), day 7 and day 9 Tc17 
cells kept with no cytokines (lane 2 and 3), day 9 Tc17 cells triggered with gp33-41 
peptide and cultured in presence of Th17 polarizing cytokines for the last 48 hours (lane 
4) and AhR expression in day 9 Tc17 cells maintained only with Th17 polarizing 
cytokines (IL-1β, IL-6 and TGF-β) for the last 48 hours (n=2). (B) Western blot 
analysis with AhR and MAPK antibodies of day 4 Tc17 (lane 1-from right), day 7 Tc17 
maintained with no cytokines and day 7 Tc17 cultured in presence of IL-2 for the three 
last days (n=1). (C) Western blot analysis with AhR and ARNT antibodies showing a 
decrease in AhR and ARNT expression in CTLs upon IL-2 withdrawal from the 
cultures for 24 hours (n=1 for AhR and n=2 for ARNT). 
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CTL seem to express low levels of AhRs and to understand whether the AhR detected 
in CTLs are functional, we examined the impact of the AhR ligand FICZ on CD8 T 
cells. Previous studies have showed that following ligand binding to the AhR, its N-
terminal nuclear localization signal is exposed which allows its translocation to the 
nucleus (Davarinos and Pollenz, 1999). In addition, the AhR is rapidly depleted via its 
proteosomal degradation in vitro and in vivo following its exposure to ligands (Pollenz, 
2002; Song and Pollenz, 2002; Pollenz et al., 2005). Western blot analysis of cytosolic 
and nuclear extracts of control and FICZ stimulated CTLs indicated that the 
cytoplasmic AhR translocates to the nucleus following ligand stimulation (Figure 3.7A).  
Moreover, AhR translocation following FICZ treatment induced the expression of the 
AhR target gene, CYP1A1 (Figure 3.7B). Furthermore, time course analysis 
demonstrated that within 2 hours of FICZ exposure there was a decrease in levels of 
AhR protein (Figure 3.7C). This depletion of the AhR protein could be blocked by the 
addition of a proteasome inhibitor, MG132, (Figure 3.7D) confirming previous 
observations of AhR proteasome-dependent degradation upon its activation with 
exogenous ligands. 
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Figure 3.7 AhR is functional in IL-2 maintained CTLs  
 
(A) Western blot analysis with AhR antibody showing subcellular AhR expression in 
nuclear and cytosolic extracts of P14 CTLs left untreated (-) or treated (+) with FICZ 
for 12 hours. Probing with antibodies to IκB and SmCI serve as controls for fraction 
purity (the arrow points at the band correlating to the AhR protein) (B) qRT PCR 
kinetic analysis of CYP1A1 mRNA expression in IL-2 maintained CTLs in the presence 
or absence of FICZ for the indicated periods of time. mRNA levels were normalized to 
HPRT expression and shown as mean +/- SD values (n=3) (C) Western blot analysis 
with AhR antibody of P14 CTLs left untreated or treated with Ficz for 2, 4, 6 and 10 
hours (n=4). (D) Western blot analysis with AhR and PKB antibodies showing AhR 
expression in IL-2 cultured P14 CTLs treated or untreated with Ficz (lanes 1 and 2 left 
to right) or treated with combination of FICZ (300nM) and MG-132 (25µM) (lane-3) 
(n=2).  
 
 
The experiments with FICZ demonstrate that AhRs are functional in CTLs and that 
AhR engagement with FICZ can induce expression of CYP1A1. However, it is striking 
that CYP1A1 induction in CTLs, is almost 1000 fold lower that the level of CYP1A1 
induction in FICZ treated Th17 or Tc17 cells (Figure 3.8A and B).  
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Figure 3.8 Basal and FICZ-induced CYP1A1 mRNA levels in CTLs versus Th17 or 
Tc17 cells. 
  
(A) qRT PCR analysis of CYP1A1 mRNA expression in differentiated CTLs versus 
Th17 cells both either treated or untreated with FICZ for 6 hours. mRNA levels were 
normalized to HPRT expression and shown as mean +/- SD values (n=3) (B) qRT PCR 
analysis of CYP1A1 mRNA expression in P14 CTLs versus differentiated Tc17 cells 
treated or untreated with FICZ for 6 hours (n=2). mRNA levels were normalized to 18S 
expression and shown as mean of 3 experiments +/- SD values.  
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3.3 Discussion 
The data in the present chapter show that naïve CD8 T cells do not express the AhR or 
the ARNT transcription factors. However, the expression of both the AhR and ARNT is 
induced in response to TCR engagement of naïve T cells. In this context TCR 
engagement can induce transcription of AhR and ARNT or their mRNA translation. 
Microarray results of CD8 T cells stimulated with a cognate peptide for 4 hours 
compared to naïve unstimulated cells (data generated by Maria Navarro in the lab) 
showed an induction of 1.7 folds in AhR mRNA expression and no induction in ARNT 
mRNA levels. Of course it is possible that in order to see a more significant induction 
of AhR/ARNT mRNA, longer TCR stimulation is required. Nonetheless, a subtle 1.5 
fold induction in ARNT mRNA was observed in CD8 T cells stimulated for 20 hours 
using a cognate SIINFEKL peptide (not shown). It is established that TCR stimulation 
activates NF-κB in T cells in a digital manner within minutes (Kingeter et al., 2010). In 
addition, it was previously shown that NF-κB directly regulates ARNT mRNA and 
protein (van Uden et al., 2011). Therefore, it is possible that in T cells TCR stimulation 
induces initial transcription of ARNT mRNA whereas the subsequent protein translation 
requires signalling by cytokines such as IL-2 and IL-1β. 
The level of AhR expression in different effector T cells is quantitatively different. TCR 
activated T cells cultured under Tc17 polarising conditions express high levels of AhRs, 
whereas CD8+ T cells polarised to differentiate into CTLs express much lower levels of 
AhRs. Interestingly, AhR expression in activated T cells is transient. TCR activated 
CD8 T cells cultured under Tc17 polarising conditions could not sustain AhR 
expression following removal of TCR ligands. However, AhRs could be re-expressed in 
Tc17 cells following re-engagement of TCR complexes with cognate peptide. These 
results show that expression of AhRs in CD8 T cells is not ubiquitous but restricted to 
antigen receptor activated T cells. Moreover, levels of AhR expression are controlled by 
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cytokines. Hence antigen primed CD8 T cells primed in the presence of the Tc17 cells 
IL-6, TGF-β and IL-1β express high levels of AhRs compared to effector CTLs 
maintained in culture with IL-2. Moreover, Th17 and Tc17 cells express much higher 
levels of the AhR responsive gene CYP1A1 when activated with AhR ligands.  
In the context of these initial AhR experiments it is important to remember that western 
blot analysis and the mRNA experiments report subpopulations of lymphocytes. This 
means that it is impossible to determine whether or not the relatively low level of AhR 
expression in CTL versus Th17 or Tc17 populations reflects that a single CTL has a low 
level of AhR compared to a single Th17 or whether there is a difference in the 
frequency of cells that express AhRs. E,g is it possible that only a subpopulation of  
CTL expressed the AhR? Ideally, to assess this issue a single cell assay for AhR 
expression is required. One option would be to use AhR antibodies as an intracellular 
stain in a flow cytometry or fluorescent microscopy experiments. From personal 
communications with Prof. Brigitta Stockinger we came to recognize that the 
commercially available rabbit polyclonal AhR antibody, which works in western blots 
is not compatible for flow cytometry. Nevertheless, it would be valuable to have a 
single cell assay to report functional AhR activity in different immune cells. The 
following results chapter describes the development of a single cell assay that reports 
AhR functional activity at the single cell assay. This assay is then used to assess 
heterogeneity within lymphocyte populations in the context of AhR function.  
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Chapter 4 Establishing an AhR fate reporter mouse  
4.1 Introduction 
The results in the previous chapter show that populations of CTLs and Th17 cells 
express AhR/ARNT complexes. However, although it is unequivocal that AhR has a 
role in Th17 differentiation and can control IL-22 production, it has not yet been 
explored whether all Th17 cells express a functional AhR. Similarly, do CTL and Tc17 
populations uniformly express AhRs? Indeed this is also a key question for other 
lymphocyte subsets cells of the innate immune system.  
There is also evidence from the literature that T lymphocytes that are found in both the 
epithelial layer and the lamina propria of the small intestines express functional AhRs 
(Introduction section 1.6.3).  
In addition, since there are reports that AhRs can bind endogenous ligands such as 
arachidonic acid and tryptophan metabolites (Helferich and Denison, 1991; McMillan 
and Bradfield, 2007a; 2007b) another important questions was whether the AhR is 
activated by endogenous ligands in CD8 T cells. Indeed this is also a key question for 
other lymphocyte subsets including Th17 and T regulatory cells. 
One tool that would be useful to understand the role of AhRs in T cells and its 
responsiveness to ligands would be a method to assess AhR function in lymphocytes at 
the single cell level. We therefore decided to establish a mouse model to genetically 
mark single lymphocytes that activate AhR receptor signaling pathways. This model 
would allow us to monitor activation o the AhR in T cells in homeostasis and during 
immune responses.   
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4.2 Results 
4.2.1 Establishing a reporter mouse CYP1A1cre+/- X R26R EYFP model 
CYP1A1 is one of the best-studied and validated AhR target genes. This gene is highly 
inducible in cells that express AhR/ARNT complexes and are exposed to AhR ligands. 
Accordingly, single cell assay that could report induction of CYP1A1 expression would 
be a mechanism to report AhR function at the single cell level. In this context, mice 
with Cre recombinase knocked into the endogenous CYP1A1 locus have been made and 
these mice express Cre recombinase in cells that express the AhR and are exposed to 
AhR ligands. Therefore, in order to produce a mouse model that would report functional 
AhR activity at the single cell level we backcrossed CYP1A1Cre+/- mice to R26R EYFP 
mice. The R26REYFP mice have a knock-in of a gene encoding EYFP into the 
ubiquitously expressed Rosa26 locus preceded by a loxP flanked stop sequence 
(Srinivas et al., 2001). Expression of Cre recombinase in cells that express the 
R26REYFP allele results in deletion of the floxed stop codon and expression of YFP 
(Figure 4.1).  
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Figure 4.1 Schematic description of the genetic events that link AhR activation to the 
subsequent YFP reporter gene expression in the CYP1A1Cre+/- X R26REYFP mouse.  
 
Upon ligand binding AhR translocates to the nucleus and switches on CYP1A1 
promoter. In turn, CYP1A1 promoter drives the expression of Cre recombinase, which 
deletes the floxed stop sequence upstream to EYFP reporter gene, allowing it to be 
transcribed. 
 
 
The expression of YFP in cells isolated from the CYP1A1Cre+/-X R26REYFP reporter 
mice could be used to assess the functional activity of the AhR in lymphocyte 
subpopulations both before and after immune activation. The advantage of this 
inducible mouse model is that it provides us with a single cell assay for a functional 
AhR. There is the flaw that this model is not temporally dynamic; meaning that once 
AhRs are activated and cells delete the floxed stop sequence they will continue to 
express YFP protein even after the termination of AhR activity. In this respect, we 
considered making a mouse with a gene encoding EYFP knocked directly into the 
CYP1A1 locus. This kind of reporter system would allow us to follow the dynamics of 
AhR activation in a temporal manner. However, analysis of the CYP1A1Cre+/- X 
R26REYFP reporter mice would give us insight as to the usefulness of a more dynamic 
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CYP1A1 reporter and inform whether different T cell populations activate AhRs as they 
undergo development and differentiation. 
 
4.2.2 Validation of the reporter mouse 
When we started working with CYP1A1Cre+/- X R26REYFP reporter mice we initially 
considered the possibility that during mouse embryonic development some stem cell 
population might express AhRs and respond to endogenous AhR ligands to express Cre 
recombinase transiently. This would result in all naïve T cells becoming YFP positive. 
To test this possibility we analysed the expression of YFP in thymocytes and peripheral 
T cells isolated from the spleen and the lymph nodes of the CYP1A1Cre+/- X R26REYFP 
reporter mice. As a positive control for these experiments we used CD4 Cre X 
R26REYFP mice where the CD4 promoter drives Cre recombinase expression during 
thymus development such that all T cells are marked with YFP. As a negative control 
for any ‘leakiness’ in YFP expression from the R26REYFP locus we examined YPF 
expression in R26REYFP mice that do not express Cre recombinase. 
The data (Figure 4.2B) show that there was no YFP expression in any thymocyte 
population isolated from CYP1A1Cre+/- X R26REYFP mice. This in contrast to T cells 
from a CD4Cre+/- X R26REYFP thymus in which 38% of the DN thymocyte subpopulation 
expresses YFP, 90% of DPs and 97% of SPs express YFP (Figure 4.2A). This result 
could be explained by either the fact that AhR is not expressed in thymocytes or by the 
absence of endogenous ligands, which could activate the receptor during thymus 
development. To test those possibilities, thymocytes from a WT mouse were sorted to: 
double negative (DNs), double positive (DPs) and CD4+ single positive (SPs) fractions.  
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Figure 4.2 Thymocytes extracted from CYP1A1Cre+/- X R26REYFP  reporter mouse do 
not express a functional Aryl Hydrocarbon Receptor.  
 
(A) Thymocytes extracted from CD4Cre+/- X R26REYFP (A) and from CYP1A1Cre+/-X 
R26REYFP (B) mice were stained with CD4 and CD8 markers and analysed by flow 
cytometry. Histogram plots in A and B show YFP expression in each of the thymus 
subsets: DNs (CD4-CD8-), DPs (CD4+CD8+) and SPs (CD4+CD8- and CD4-CD8+). 
Numbers within the histograms represent the percentages of the YFP+ cells (n=3).  
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Western blot on each of those fractions showed that while all the fractions express 
ARNT, only DNs express the Aryl Hydrocarbon Receptor (Figure 4.3A).  
 
 
Figure 4.3 Double negative subset of thymocytes expresses a functional AhR 
 
(A) Thymocytes were extracted, stained with CD4, CD8 and Thy1.2 markers and sorted 
by FACS to DN, DP and SP subsets. Cell extracts prepared from these subsets were 
analysed by Western blot analysis for AhR and ARNT expression. Blotting with SmCI 
antibody was used as a control for equal loading (n=1). (B) Cell suspensions were 
prepared from livers extracted from CYP1A1Cre+/- X R26REYFP mice treated with 3-MC 
(40mg/kg body weight) or with corn oil alone. Results show qRT PCR analysis of Cre 
and YFP mRNA expression. mRNA levels represent mean values +/- SD and are 
normalized to HPRT. (n=2 mice) (C) Flow cytometry analysis of thymocytes extracted 
from CYP1A1Cre+/- X R26REYFP mice treated with 3-MC (40mg/kg body weight) or with 
corn oil alone and stained with CD4 and CD8 markers. Representative FACS plots 
show YFP expression in DN subset of 3-MC treated and untreated mice (n=2).  
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There is thus the potential for DNS to express a functional AhR. This result suggests 
that it is the lack of endogenous ligands for AhRs during thymus development, which 
doesn’t allow the reporter system to tag the population of double negative thymocytes. 
To test this possibility, we treated CYP1A1Cre+/- X R26REYFP mice in vivo with IP 
injections of 3-methylcolanthrene (3-MC), an exogenous AhR ligand. 3-MC is a 
toxicant which belongs to the group of polycyclic aromatic hydrocarbons and is known 
to activate the Aryl Hydrocarbon Receptor (Mullen Grey and Riddick, 2011). We used 
liver cells from 3-MC treated mice as our positive control for AhR activation by 3-MC. 
Previously, Roland Wolf and his group showed a robust induction in CYP1A1 in the 
liver after 3-MC treatment and used this promoter since as a tool to drive the expression 
of genes in a truly on/off manner (Campbell et al., 1996; Finn et al., 2007). Indeed, 
following 3-MC treatment of CYP1A1Cre+/- X R26REYFP mice, there was a massive 
induction in both Cre and YFP mRNA in the liver in comparison to their expression in 
livers of control mice treated with corn oil (Figure 4.3B). This result means that 3-MC 
in vivo treatment worked efficiently. Analyzing the thymus of 3-MC treated mice, we 
observed two main results: First, we found a significant reduction in the population of 
double positive thymocytes (Figure 4.3D). Second, 3-MC treated CYP1A1Cre+/- X 
R26REYFP mice also now had a very small but detectable population of YFP expressing 
double negative thymocytes (Figure 4.3D, right panel). This result suggests that a 
subpopulation of DNs express an AhR and that it is functional upon exposure to 
exogenous ligands. It was striking that DP thymocytes die following 3-MC injection 
even though we can see no evidence that they express the AhR (Figure 4.3A, second 
lane). The depletion in numbers and percentages of DPs is thus probably a result of an 
indirect effect of the 3-MC. It is worth to mention that DP thymocytes are extremely 
sensitive to any type of ‘stress’. 
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We also analysed splenic and lymph node derived lymphocytes from CYP1A1Cre+/- X 
R26REYFP mice for YFP expression. The data show that T cells isolated from lymph 
nodes and spleen of the CD4Cre+/- X R26REYFP mouse are all YFP positive (Figure 4.4A 
and B). However, no YFP-positive cells T cells were detected in the spleen or in the 
lymph nodes of the CYP1A1Cre+/- X R26REYFP reporter mice (Figure 4.4C and D). In 
addition, none of the TCRαβ negative (non-T cells) cells in lymph nodes or spleen was 
YFP positive. These data, together with the results that R26REYFP mice also did not have 
any YFP positive cells (Figure 4.4E and F) show that the expression of YFP from the 
R26REYFP  allele is not “leaky”.  
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Figure 4.4 T cells extracted from lymph nodes and spleens of CYP1A1Cre+/- X R26REYFP 
mice are negative for YFP expression.  
 
Flow cytometry analysis of cells extracted from spleen (A) and lymph nodes (B) of 
CD4Cre+/- X R26REYFP and stained with a TCRβ marker shows that all T cells express 
YFP. Flow cytometry analysis of cells extracted from spleen (C) and lymph nodes (D) 
of CYP1A1Cre+/- X R26REYFP mice shows that none of the T cells were YFP positive. T 
cells extracted from spleen (E) and lymph nodes (F) of R26REYFP were YFP negative 
and serve as a control (for all tissues n=3).  
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4.2.3 Functional activation of AhRs during Th17 T-cell development 
In the previous chapter we showed that during Th17 cell differentiation in vitro CD4 T 
cells express AhR and ARNT complexes and induce expression of CYP1A1. We 
therefore examined the expression of YFP in CYP1A1Cre+/- X R26REYFP CD4 T cells 
cultured under Th17 polarising conditions in vitro. In these experiments naïve CD4 
cells were extracted from lymph nodes of CYP1A1Cre+/- X R26REYFP mice, purified and 
then activated with CD3 and CD28 antibodies and cultured in vitro in the presence of 
the Th17 polarizing cytokines IL-6, IL-1β and TGF-β. As a control naïve CD4 T cells 
were cultured in the presence IL-7 over the same time period. Each day during 4 days of 
culture the CD4 T cells were analysed for YFP expression. The results (Figure 4.5) 
show that a subpopulation of CYP1A1Cre+/- X R26REYFP T cells express YFP within 2 
days of culture in the Th17 polarizing conditions. This frequency has increased to 14% 
by day 3 and 44% by day 4. There was no induction of the YFP reporter when CD4 T 
cells from CYP1A1Cre+/- X R26REYFP mice were only sustained in an undifferentiated 
state with IL-7 cytokine (Figure 4.5A - grey tinted line). There was no spontaneous YFP 
induction in Th17 differentiated from a control R26REYFP mouse (Figure 4.5C).  
To assess if the expression of the YFP AhR reporter observed in Th17 cells is driven by 
endogenous AhR ligands in the medium we examined the impact of the AhR antagonist, 
CH-223191 on the expression of the YFP reporter. The AhR antagonist specifically 
inhibits AhR dependent transcription by competing with ligands for the binding to the 
AhR (Kim et al., 2006). Accordingly, CD4 cells from CYP1A1Cre+/- X R26REYFP mice 
were cultured under Th17 conditions in the absence or presence of the AhR antagonist, 
CH-223191. The data show that CH-223191 prevents expression of the AhR reporter in 
Th17 cells (Figure 4.5B).  
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Figure 4.5 Under Th17 polarizing conditions a subset of CD4 cells expresses a 
functional AhR, which induces CYP1A1, thus driving expression of the reporter YFP. 
 
(A) Naïve CD4 T cells purified from lymph nodes of CYP1A1Cre+/- X R26REYFP mice 
were either cultured in vitro under Th17 conditions (black line) or kept with IL-7 
cytokine (grey line) for 4 days. Flow cytometry analysis shows YFP expression in CD4 
T cells during 4 days of differentiation. (B) Flow cytometry analysis of YFP expression 
in naïve CD4 T cells from CYP1A1Cre+/- X R26REYFP reporter mouse cultured under 
Th17 conditions in the presence of the CH-223191 antagonist (C) Naïve CD4 T cells 
from R26REYFP CD4 T cells cultured under Th17 polarizing conditions were used as a 
negative control (n=3).  
 
Moreover, CYP1A1Cre+/- X R26REYFP CD4 T cells activated with CD3 and CD28 
antibodies and cultured in the presence of IL-2 also fail to express YFP (Figure 4.6). 
These data suggest that specifically under Th17 polarizing conditions, the AhR is 
expressed and there are sufficient endogenous AhR ligands to activate AhR signaling in 
a subpopulation of CD4 T cells.   
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Figure 4.6 CYP1A1Cre+/- X R26REYFP CD4 T cells activated with CD3 and CD28 
antibodies and cultured in the presence of IL-2 fail to express a functional AhR.  
 
Time course Flow cytometry analysis of YFP expression in CD4 T cells cultured either 
under Th17 conditions or in the presence of IL-2 cytokine for 4 days (n=3). 
 
One striking feature of the expression of YFP in the CYP1A1Cre+/- X R26REYFP CD4+ T 
cell cultured under Th17 conditions was that YFP was not expressed in all cells and 
typically only ~40-50% of CYP1A1Cre+/- X R26REYFP Th17 cells expressed YFP. We 
therefore assessed if the CYP1A1Cre+/- X R26REYFP Th17 cells that failed to express YFP 
actually expressed the AhR. The western blot in Figure 4.7 shows equal AhR and 
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ARNT levels in YFP+ (pos) and YFP- (neg) CD4+ subsets of CYP1A1Cre+/- X 
R26REYFP Th17 cell (Figure 4.7A).  
 
 
Figure 4.7 The expression of a functional AhR in CYP1A1Cre+/- X R26REYFP  CD4+ T 
cells cultured under Th17 conditions is heterogeneous.  
 
(A) T cells from whole lymph nodes of CYP1A1Cre+/- X R26REYFP mice were 
differentiated under Th17 conditions and subsequently FACS sorted to CD4+YFP+ and 
CD4+YFP- subsets. Western blot analysis with AhR and ARNT antibodies shows equal 
AhR and ARNT expression levels in YFP positive and YFP negative Th17 extracts 
(n=2). (B) Flow cytometry analysis of YFP expression in T cells differentiated under 
Th17 polarising conditions treated with CH-223191 (10µM) or FICZ (300nM) or left 
untreated (n=3).  
 
 
We then considered whether or not the failure of CD4 cells activated under Th17 
polarising conditions reflects that there are limiting AhR ligands in the Th17 cultures. 
To examine this possibility CD4 cells from CYP1A1Cre+/- X R26REYFP mice were 
cultured under Th17 polarizing conditions in the presence of FICZ - a well-
characterised AhR ligand. The data show that following the addition of FICZ to the 
cultures of Th17 cells the frequency of YFP+ cells is strikingly increased (Figure 4.7B). 
These data reveal that the expression of the AhR reporter in Th17 cells is limited by the 
availability of endogenous AhR ligands in the in vitro culture conditions.  
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4.2.4 Properties of CD4 T cells that express a functional AhR. 
To examine the functional properties of CD4 T cells that express the AhR reporter 
versus those that do not, we examined the production of the cytokines IL-17, IL-22 and 
Interferon gamma (Ifn-γ) by YFP positive and YFP negative CYP1A1Cre+/- X R26REYFP 
CD4 T cells cultured under Th17 conditions. Figure 4.8A, B (representative plots) and 
figure 4.8C show a higher frequency of IL-17 producing CD4 T cells in YFP positive 
versus YFP negative CD4 T cell cultured under Th17 polarising conditions. However, 
some YFP negative cells were still able to produce IL-17. In terms of interferon gamma 
(Ifn-γ) production, it was clear that there was a much higher frequency of Ifn-γ 
production by YFP negative cells compared to the YFP positive cells (Figure 4.8D).  
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Figure 4.8 YFP positive CD4 effector cells express more IL-17 and less Ifn-γ cytokines 
in comparison to YFP negative Th17 cells.  
 
(A,B) A representative Flow cytometry dot plot showing an intracellular staining of IL-
17 and Ifn-γ cytokines in CYP1A1Cre+/- X R26REYFP CD4 T cells differentiated under 
Th17 conditions with (A) or without FICZ (B) and re-stimulated on day 4 with 
PdBU/Ionomycin in presence of a Golgi plug. (C) Graph representing frequencies of 
CD4+ YFP+ IL-17-producing cells and CD4+ YFP- IL-17-producing cells stimulated 
(black bars) or unstimulated (grey bars) with PdBu/Ionomycin in presence of Golgi 
Plug. (mean percentage values +/- SD represent 3 experiments). (D) Graph representing 
frequencies of Ifn-γ producing CD4+ YFP+ effector Th17 cells versus CD4+ YFP- 
Th17 cells following stimulation with PdBu/Ionomycin in presence of Golgi Plug (n=3).  
 
In subsequent experiments, CYP1A1Cre+/- X R26REYFP CD4 T cells were cultured under 
Th17 conditions for 4 days and then separated into YFP positive and YFP negative 
populations by FACS. We then analysed these different populations for the production 
of IL-17A and IL-22 cytokines by ELISA. 
Figure 4.9A,B shows that the YFP+ cells from the Th17 cultures produce more IL-22 
and IL-17A than YFP negative cells. These data reveal that there is not an absolute 
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requirement for AhR activation for IL-17 and IL-22 production by CD4 T cells, but 
CD4 T cells that express functional AhRs make more IL-17 and IL-22 than CD4 T cells 
cultured under comparable conditions without activating AhR function.  
In this respect it has been shown previously that exposure of CD4 T cells to FICZ under 
Th17-cell-inducing conditions strongly enhances IL-17 cytokine production (Veldhoen 
et al., 2009). Using the AhR reporter model, we show that only CD4 T cells, which 
have an active AhR induce IL-17 production upon FICZ addition, whereas YFP 
negative Th17 were not responsive to AhR ligands (Figure 4.8B, 4.9C). These results 
suggest that while AhR is not essential for IL-17 and IL-22 production, AhR activation 
by its ligands promotes the production of these inflammatory cytokines. 
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Figure 4.9 YFP+ CD4 T cells from CYP1A1Cre+/- X R26REYFP  Th17 cultures produce 
higher levels of IL-22 and IL-17A cytokines and induce more IL-17 production in 
response to FICZ addition compared to YFP negative CD4 T cells.  
 
(A) T cells from whole lymph nodes of CYP1A1Cre+/- X R26REYFP mice differentiated 
under Th17 conditions for 4 days were FACS sorted to CD4+YFP+ and CD4+YFP- 
subsets. YFP+ and YFP- effector CD4 T cells were re-stimulated with PdBu/Ionomycin 
and the supernatants were assessed for IL-17 (A) and IL-22 (B) production by Elisa (see 
materials and methods). (C) Graph representing mean values of frequencies of IL-17 
producing YFP+ CD4+ T cells versus YFP- CD4+ T cells cultured in presence or 
absence of FICZ from 3 experiments.  
 
 
 
 
 
 
 
!"
#"
$"
 149 
4.2.5 Exploring AhR function in CD8 cytotoxic T cells using the reporter 
CYP1A1Cre+/- X R26REYFP model  
Our previous observations show that CD8+ cytotoxic T cells express AhR receptors but 
at much lower levels compared to either Th17 cells or Tc17 cells (section 3.2). 
Nonetheless, these results do not address whether a functional AhR is expressed in 
every individual CTL. To answer this question we used the CYP1A1Cre+/- X R26REYFP 
reporter model, to examine the frequency with which CTLs express a functional AhR. 
The data show that CYP1A1Cre+/- X R26REYFP CD8+ T cells activated with CD3 and 
CD28 antibodies and then cultured in IL-2 to generate CTLs fail to express YFP (Figure 
4.10A). Moreover, the addition of FICZ to the cultures didn’t significantly increase the 
percentage of YFP positive CD8 T cells. For example, only 4% of all CTLs were tagged 
by the AhR reporter (Figure 4.10A). Can CD8 T cells ever express a functional AhR? In 
this respect figure 4.10B shows that when CYP1A1Cre+/- X R26REYFP lymph node T cells 
are activated with CD3 and CD28 antibodies and then cultured in the Th17 polarizing 
cytokines both CD4 and CD8 T cells in the cultures express YFP. Indeed approximately 
40% of these Tc17 cells expressed YFP. Moreover this frequency was increased when 
TCR activated CD8 T cells were cultured in the presence of Th17 differentiating 
conditions (IL6, TGF-β and IL-1β) and in the presence of FICZ, the endogenous AhR 
ligand. The addition of FICZ increased the percentage of YFP+ CD8 T cells to 80%.  
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Figure 4.10 IL-2 cultured CD8 T cells fail to express a functional AhR whereas CD8 T 
cells cultured in presence of Th17 conditions (IL-1β, IL-6 and TGF-β) induce 
expression of a functional AhR.  
 
(A) YFP expression in CYP1A1Cre+/- X R26REYFP CD8+ T cells activated with CD3 and 
CD28 antibodies and cultured with IL-2 to generate CTLs were treated with FICZ for 
24 hours or left untreated (n=4). (B) YFP expression in CYP1A1Cre+/- X R26REYFP CD8 
and CD4 T cells from whole lymph nodes activated with CD3 and CD28 antibodies and 
cultured under Th17 conditions in presence or absence of FICZ (300nM) (n>4).  
 
 
4.2.6 Expression of the AhR reporter in vivo  
Th17 cells generated in vitro activate the AhR and can be fate-marked by our AhR 
reporter. We therefore wished to assess whether Th17 cells produced in vivo activate 
AhR signaling. We therefore cutaneously infected the CYP1A1Cre+/- X R26REYFP 
reporter mice with Candida albicans hyphae. This infection induces an immune 
response mediated by IL-17 producing T cells. (Those experiments were done in 
collaboration and under the supervision of Dr. Joao Duarte and Dr. Keiji Hirota in Prof. 
Brigitta Stockinger laboratory in MRC NIMR, London). Hirota and colleagues have 
described the kinetics of infiltrating IL-17 producing cells during cutaneous infection 
with C. albicans. They have shown an early innate IL-17A response mediated by γδ T 
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cells, followed by progressive involvement of IL-17 producing CD4 T cells. This latter 
response peaks at day 5 post infection (Hirota et al., 2011). Since Th17 cells are 
important for the defense against this fungal infection and since they express high levels 
of AhR, we thought that this model would be suitable to test our reporter mouse in an in 
vivo system. On day 5-post infection there is a significant accumulation of TCRαβ and 
γδ T cells in the skin of the infected CYP1A1Cre+/- X R26REYFP mice. The increase was 
from 0.5% of T cells on day 1 to ~ 25% on day 5 and from 0.2% γδ T cells on day 1 to  
~ 5% on day 5 in the skin of the infected mice (not shown). However, none of these 
infiltrating cells expressed YFP (Figure 4.11B). R26REYFP mice served as negative 
controls (Figure 4.11A).  
There was a very small population of cells (0.3% of all live skin cells), which was 
tagged by YFP protein (Figure 4.11B, right panel). These cells could not be labeled by 
γδ TCR, CD11c (dendritic cell marker), F4/80 and LyC (macrophages marker) and 
Ly6G (neutrophil marker) antibodies (not shown). One possibility is that these YFP+ 
cells might innate lymphoid cells which are resident in the skin.  
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Figure 4.11 Cutaneous infection of CYP1A1Cre+/- X R26REYFP mice with Candida 
albicans did not induce expression of functional AhRs in T cells recruited to the skin.  
 
Cells were extracted from skin explants (1cm2) of control R26REYFP (A) and (B) 
CYP1A1Cre+/- X R26REYFP reporter mice on day 5 after cutaneous infection with C. 
albicans hyphae. Extracted cells were stained with TCRβ and TCRγδ markers and 
analysed for YFP expression in T cells by Flow cytometry.  
 
 
4.2.7 Gut intraepithelial T lymphocytes (IELs) and lamina propria T cells 
express the AhR reporter. 
Gut intraepithelial lymphocytes (IELs) reside in the epithelium of the intestines and thus 
are located at a critical interface between the core of the body and the outside 
environment. It has been shown recently that the maintenance of IEL lymphocyte 
subpopulation in the epithelial sites of the intestines intrinsically requires AhR 
expression (Li et al., 2011). Although development and proliferation were normal, IEL 
subsets including TCRαβ+CD8αα+ T cells and TCRγδ T cells, were lost upon AhR 
deletion. Moreover, the gut is an environment, which is rich in potential AhR ligands. 
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We therefore explored whether gut lymphocytes expressed the YFP AhR reporter. 
Accordingly, we assessed YFP expression in IELs and lymphocytes from the epithelial 
layer and lamina propria layer of the small intestines isolated from CYP1A1Cre+/- X 
R26REYFP   mice. As a positive control we used CD4Cre+/- X R26REYFP mice and as a 
negative control we examined YFP expression in R26REYFP mice that lack expression of 
the Cre recombinase. In the initial analysis we used CD45 antibodies to identify 
haematopoietic cells. No YFP positive cells were detected in the CD45+ cells from the 
intraepithelial or the lamina propria of the control R26REYFP mice (Figure 4.12A, 4.13A 
respectively). However, CD45+ and YFP positive cells were detected in cells isolated 
from the intraepithelial layer of CD4Cre+/- X R26R EYFP mice (Figure 4.12B).  
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Figure 4.12 Gut intraepithelial T lymphocytes (IELs) express the AhR reporter. 
Lymphocytes were isolated from the intestinal epithelium of (A) control R26REYFP, (B) 
control CD4Cre+/- X R26REYFP and (C) CYP1A1Cre+/- X R26REYFP reporter mice. (D) 
Extracted cells were stained for CD45, TCRβ, TCRγδ, CD4, CD8 and CD8β surface 
markers. Flow cytometry analysis identified distinct T-cell subsets among the CD45+ 
YFP+ intraepithelial population: (E) T cells and γδ cells, (F) CD4 and CD8 T cells and 
(G) TCRβ+ CD8αα+ T cells (n>5). 
 
Most importantly, YFP positive cells were in the cells isolated from both the 
intraepithelial layer and the lamina propria layers of the CYP1A1Cre+/- X R26REYFP mice 
(Figure 4.12D, 4.13B). 
These YFP positive cells included both CD45 positive cells i.e haematopoietic cells and 
CD45 negative cells. The CD45+YFP+ IELs, (Figure 4.12D) comprised both TCRαβ+ 
and TCRγδ cells. The majority (70%) of the YFP+ TCRαβ T cells were CD8+ CD4- T 
cells. In this context, TCRαβ T cells can express either a CD8αβ dimer or a CD8αα 
dimer. The data show that the majority (approximately 70%) of the CD8 + T cells 
expressed the CD8αα dimer. Cells extracted from the lamina propria of the 
CYP1A1Cre+/- X R26REYFP mice also included YFP positive cells, the majority of which 
were CD45 negative. The YFP+ CD45+ cells included both TCRαβ and TCRγδ cells 
and again the majority of the TCRαβ T cells were CD8+ T cells (Figure 4.13B). 
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Figure 4.13 Gut T lymphocytes from the lamina propria layer express the AhR reporter.  
 
Lymphocytes were isolated from the lamina propria layer of (A) control R26REYFP and 
(B) CYP1A1Cre+/- X R26REYFP reporter mice. Extracted cells were stained for CD45, 
TCRβ, TCRγδ, B220, CD4 and CD8 markers. Flow cytometry analysis identified 
distinct T lymphocyte subsets among the (B) CD45+ YFP+ lamina propria cells: (C) T 
cells and B cells, (D) CD4 and CD8 T cells and (E) TCRγδ cells (n>5).  
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4.3 Discussion 
This chapter explored the expression and functional capacity of AhRs in T cells. Our 
results showed that T cells will only express functional AhRs and be capable of 
responding to endogenous or exogenous AhR ligands in their environment following 
stimulation of their T cell receptor and encounter with a specific milieu of pro-
inflammatory cytokines. We describe an experimental model that allows single cell 
mapping of functional AhR activity in T cells responding to immune activation. This 
model is based on the fact that AhR signaling induces expression of CYP1A1. We 
therefore backcrossed mice with Cre recombinase knocked into the CYP1A1 locus to 
mice expressing a cDNA encoding EYPF preceded by a loxP-flanked stop sequence 
inserted into the Rosa 26 locus. The expression of YFP faithfully reports Cre expression 
and hence will faithfully report induction of CYP1A1. The analysis of lymphocytes 
from the CYP1A1Cre+/- X R26REYFP mice found no evidence for activation of AhR 
signaling during embryonic development of lymphocytes. The only lymphoid cells we 
could find that expressed the YFP reporter were TCRαβ+CD8αα+, CD4+, CD8+ and 
γδ T cells in epithelial and the lamina propria layers in the gut. There was no expression 
of the AhR reporter in T cells from secondary lymphoid organs such as the spleen or 
lymph nodes. However, if either CD4 or CD8 T cells from lymph nodes were activated 
by TCR/CD28 triggering followed by expansion in the Th17 polarizing cytokines they 
rapidly expressed the AhR reporter.  
Levels of endogenous AhR ligand present in culture limited the frequency of T cells 
that expressed the reporter within the lymphocyte population. Hence, in the presence of 
AhR receptor antagonists no Th17 cells could express the reporter whereas the addition 
of exogenous AhR ligands strikingly increased the frequency of Th17 or Tc17 cells that 
could express the reporter in vitro. In this context it was clear that although IL-17 
producing CD4 T cells differentiated in vitro could be ‘fate marked’ with the AhR 
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reporter, we could not see any evidence for functional activation of AhRs in Th17 cells 
induced in vivo following a cutaneous Candida albicans infection. This could reflect 
that there are insufficient AhR ligands in vivo in the skin under normal physiological 
conditions to initiate AhR signaling and reporter gene expression. Another option is that 
AhR is not expressed in IL-17 producing cells during cutaneous Candida infection. 
From microarray data it is very clear that AhR is highly expressed in Th17 T cells 
cultured in vitro (Veldhoen et al., 2008). It was also shown that AhR mRNA is 
expressed in CD4+CCR6+ Th17 cells isolated from lymph nodes of mice immunized 
with myelin oligodendrocyte peptide 35–55 (MOG35–55) in complete Freund’s 
adjuvant (CFA), which induces the EAE disease (Veldhoen et al., 2008). However, 
there is no similar mRNA or protein data for Th17 cells that are recruited to the skin of 
Candida infected mice. Although, experiments in which AhR KO mice were infected 
with cutaneous form of Candida clearly show that AhR has an anti-inflammatory role in 
this infection model it is still disputable whether this effect is AhR-dependent and 
intrinsic specifically to Th17 cells or is a result of its absence of function in other cells 
such as the Langerhans cells which, require AhR for their maturation and subsequent 
activation of T cells in the dermis (Jux et al., 2009).  
The AhR expression data in chapter 3 showed that naive CD8 T cells do not express the 
AhR or ARNT but CD8 effector T cells such as Tc17 cells and CTLs do. However, the 
level of AhR expression by CTLs was significantly lower both at the mRNA and the 
protein level than AhR levels in either Tc17 or Th17 populations. This made us 
question whether the lower AhR levels that we observe in a population of CTLs is a 
result of a low basal expression of this receptor in every individual CTL or there is only 
a small subset of CTLs that express the receptor. Using the reporter mouse, which 
genetically fate-marks cells which express a functional AhR we demonstrated that only 
a very small fraction of CTL could be fate marked with an AhR reporter even when 
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stimulated with exogenous AhR ligands. This did not mean that CD8 T cells never 
express functional AhRs. Hence, when CD8 T cells are cultured under Th17 polarizing 
conditions (i.e maintaining TCR activated CD8 T cells in the presence of IL-6, IL-1β 
and TGF-β) there was a very high frequency of CD8 T cells that were capable of 
responding to exogenous AhR ligands to induce expression of the AhR reporter. These 
data are relevant to previous observations that exposure of mice to TCDD suppressed 
the clonal expansion of influenza virus-specific CD8+ T cells (Lawrence et al., 2000; 
Warren et al., 2000; Mitchell and Lawrence, 2003). It is has not been clear how much of 
the CD8 T cell pathology in dioxin treated mice is caused by direct effects of dioxins on 
CD8 T cells. The present data show that dioxins cannot have direct effects on naïve T 
cells, as these do not express AhRs or ARNT. Our experiments show that only a very 
small subset of normal CTL express a functional AhR making it unlikely that dioxins 
are having direct effects on antiviral CTL effectors. However, the fact that a high 
frequency of Tc17 cells express a functional AhR and the fact that Tc17 cells have been 
observed in the lung of influenza infected mice (Crowe et al., 2009; Hamada et al., 
2009) argues that any direct effect of dioxins on CD8 T cells would be mediated via 
Tc17 cells.  
In future work it can be interesting to follow the role of the AhR during development of 
Tc17 and to examine whether it has a role in controlling the function of these cells.  
Here a key question is whether Tc17 cells are ever exposed to sufficient AhR ligands in 
vivo to activate AhR signaling. It is possible that there are never sufficient endogenous 
AhR ligands in the lung/skin to activate AhR signaling. Nonetheless, chronic exposure 
to pollutants could result in the accumulation of AhR ligands. Moreover it has been 
shown recently that human brain tumour cells produce the AhR ligand, Kynurenine 
(Kyn) which is generated during Tryptophan catabolism (Opitz et al., 2011). It must 
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therefore be considered that AhR signaling might have the potential to modify CD8 T 
cell function in tumour environments.  
Finally, analysis of T lymphocytes in the small intestines of the CYP1A1Cre+/- X R26R 
EYFP mice demonstrated functional AhRs in both TCRαβ and TCRγδ lymphocytes. We 
also detected functional AhRs in non-lymphoid cells in the gut. We haven’t identified 
those cells yet, but by judging their FCS/SSC it seems that they might be epithelial cells 
such as paneth cells or fibroblasts. Similarly, CD45 negative cells that had a functional 
AhR were also identified in the lungs of the reporter mice (data was not shown).  
It is important to note that the frequency of T cells expressing a functional AhR was 
very low. A possible explanation is that most of the gut lymphocytes do not express 
AhR or that ligands are limiting. It is less likely that ligands are limiting since a much 
higher frequency of non-lymphoid cells in comparison to T cells in the gut expressed a 
functional AhR. This data indicate that there are sufficient ligands to functionally 
activate AhRs. Much more probable option is that only few of the gut T cells actually 
express the AhR and ARNT complexes given that we know that AhR expression in T 
cells is dependent on TCR signaling and certain inflammatory cytokines such as IL-1β, 
IL-6 or TGF-β. In fact, it was recently shown that a continuous DC derived IL-1β was 
required for the maintenance of AhR and IL-22 expression by human immature natural 
killer (NK) cells resident in the gut (Hughes et al., 2010). Therefore, if cytokines such 
as IL-1β are required for AhR expression and are consumed by both innate and adaptive 
cells, cytokines might rapidly become a limiting factor in the gut micro-environment.  
It is interesting that although only few T cells seem to express a functional AhR, AhR- 
null mice have a significant loss of intraepithelial lymphocytes in small intestine (Li et 
al., 2011). Particularly, there was a striking loss of over 95% of TCRγδ cells in the 
small intestine in the absence of AhR compared with controls, in addition to a 
significant 5 fold decrease in the frequency of the TCRαβ+ CD8αα+ T cells. The AhR 
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is thought to be important for gut lymphocytes because it controls survival and IL-22 
production by the Rorγt+ innate lymphoid cells (ILCs) in the gut (Qiu et al., 2012). 
ILCs are crucial for the gut immunity since they support the formation of isolated 
lymphoid follicles in the cryptopatches, thus providing an environment for IgA 
producing cells (Tsuji et al., 2008). In addition ILCs are a major source of the IL-22 
cytokine (Sanos et al., 2008), required for the protection against intestinal infections that 
cause disease in mice and humans such as those with Citrobacter rodentium 
(Sonnenberg et al., 2011b). 
We have not directly addressed whether or not ILCs in the gut of CYP1A1Cre+/- X R26R 
EYFP mice express YFP and hence show evidence of canonical AhR signaling. One can 
test whether the reporter mouse marks ILCs in the lamina propria by gating on the YFP 
positive CD45 positive population in combination with markers such as ckit, IL-7Rα, 
lymphotoxin αβ and intracellular staining of Rorγt transcription factor. However, gating 
on CD45+ YFP positive cells in the lamina propria we do not detect any TCRαβ- and 
γδ- green cells. In this context, it also needs to be considered that the CYP1A1Cre+/- X 
R26R EYFP mouse is a reporter for a canonical AhR/ARNT signaling pathway. Although 
it was shown that ILCs can activate CYP1A1 and CYP1B1 in response to AhR ligands 
(Kiss et al., 2011)- supplementary data), it is still very possible that the role of AhRs in 
ILCs controlling the survival of gut lymphoid cells is not mediated by the canonical 
AhR/ARNT pathway. For instance, analysis by chromatin immunoprecipitation 
provided evidence that AhR interacts with Rorγt and then they are together recruited to 
the IL-22 locus (Qiu et al., 2012). Moreover, recruitment of AhR to the IL-22 locus but 
not to the locus of AhR target, CYP1A1, was strongly Rorγt-driven. From this data and 
other studies it is not clear whether ARNT is involved in this interaction.  
One way to address the role of AhR/ARNT complexes in controlling T cell maintenance 
in the gut will be by comparing the consequences of ARNT and AhR loss in T cells and 
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ILCs using CD4 Cre and Vav Cre mediated deletion of these proteins. Therefore, the 
impact of ARNT deletion on T cell biology will be the focus of subsequent chapters.  
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Chapter 5 ARNT in CD4 T cells 
5.1 Introduction 
As discussed previously, there is evidence that the AhR is important in T cells. It appears to 
be important for IL-22 production in both Th17 cells and TCRγδ T cells (Veldhoen et al., 
2008; Martin et al., 2009). In addition, AhR ligands promote IL-17 and IL-22 production by 
those cell subsets (Veldhoen et al., 2008; 2009). AhR activation by dietary compounds was 
recently shown to be important for the maintenance of the gut intraepithelial lymphocytes 
(Li et al., 2011) but also for the homeostasis of IL-22-producing Rorγt innate lymphoid 
cells in the lamina propria (Kiss et al., 2011). Therefore, AhR-null mice have a significant 
reduction in TCRγδ and CD8αα frequencies in the epithelial layer of the gut in addition to 
abnormal formation of cryptopatches and innate lymphoid follicular structures, which is a 
result of a deficiency in innate lymphoid cells.   
It is well-established that upon ligand binding, the ligand-AhR complex translocates 
to the nucleus where it dimerises with the AhR nuclear translocator (ARNT) and binds to 
specific response elements close to the promoters of genes involved in metabolism of 
xenobiotics, such as CYP1A1 gene (Nguyen and Bradfield, 2008). The AhR/ARNT 
complex is important for CYP1A1 induction. Moreover, mice with a T cell selective 
disruption of the ARNT gene are resistant to TCDD-induced thymic involution (Tomita et 
al., 2003). However, the role of ARNT in mediating AhR responses in the context of gut 
lymphocytes and/or IL-17 production has not been explored. In this context, it has been 
proposed that the AhR cooperates with Rorγt to induce IL-17 and IL-22 gene transcription 
(Zhou and Littman, 2009). In addition, direct AhR-Rorγt interaction was shown to enhance 
the recruitment of AhR to the IL-22 locus in gut lymphocytes (Qiu et al., 2012). 
Nonetheless, forced expression of AhR or Rorγt expression alone or in combination were 
found to be not sufficient for IL-22 production (Veldhoen et al., 2009). It is also not clear 
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whether ARNT participates or needed for the AhR-Rorγt dependent IL-22 transcription. It 
is thus possible that not all functions of the AhR are mediated by ARNT. We were therefore 
interested to explore whether ARNT has a role in peripheral T cell differentiation. 
Accordingly, we generated T-cell specific ARNT knockout mice by backcrossing mice 
expressing floxed ARNT alleles to mice with Cre recombinase driven by the CD4 
promoter.   
We knew that interpreting the phenotype of ARNT-null T cells would be complicated by 
the fact that ARNT also binds to Hif-1α transcription thus generating a heterodimeric 
complex which functions in response to oxygen deprivation. Hif-1α is typically expressed 
in Hypoxic cells and is rapidly degraded by the ubiquitin proteasome pathway under 
Normoxic conditions (20% O2) (Salceda et al., 1996; Semenza, 2001). It has also been 
shown recently that Hif-1α is important regulator of the glycolytic activity in CD4 T cells 
(Dang et al., 2011; Shi et al., 2011). In these reports it was demonstrated that Hif-1α, which 
is highly expressed in Th17 cells but not in T regs was responsible for a higher glycolytic 
activity in Th17 in contrast to T regulatory T cells. Moreover, the authors demonstrated that 
decreasing glycolytic activity in CD4 T cells following Hif-1α deletion or by using a 
glucose analogue 2-deoxyglucose (2-DG) resulted in diminished development of Th17 cells 
and enhanced T reg cell generation. However, it is not clear whether Hif-1α plays a role in 
these lineage choices between Th17 cells and T regs by operating via Hif-1α/ARNT 
complexes. It is thus proposed that Hif-1α controls IL-17 transcription via tertiary complex 
formation with Rorγt and p300 recruitment to the IL-17 promoter (Dang et al., 2011). 
Moreover, Hif-1α was proposed to control T reg development by targeting Foxp3 for 
proteasomal degradation (Dang et al., 2011). It is thus quite possible that ARNT is not 
important for either Hif-1α or AhR mediated responses in this context.  
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5.2 Results 
5.2.1 The impact of T cell specific deletion of ARNT on peripheral T cells 
ARNT or by its other name Hif-1β total body KO mice are embryonically lethal (Kozak 
et al., 1997). Therefore, it was decided to use Cre-loxP conditional knockout strategy in 
order to delete the gene specifically in T cells. ARNT-floxed mice (kindly provided by 
Dr. Andrey Panteleyev, University if Dundee) (Geng et al., 2006) were backcrossed 
with mice expressing Cre recombinase under the control of the CD4 promoter, 
generating ARNTfl/fl X CD4Cre+/- mice. Figure 5.1 shows that ARNTfl/fl X CD4Cre+/- (KO) 
mice do not express detectable ARNT protein in the thymus in contrast to WT mice.  
 
 
 
Figure 5.1 ARNT is deleted in the thymocytes of ARNTfl/fl X CD4Cre+/-  mice.  
 
Western blot analysis with ARNT and SmCI antibodies of total thymocytes in ARNTfl/fl 
X CD4Cre+/-  (KO) and ARNTfl/fl (WT) mice (n=4). 
 
To study the effect of ARNT deletion on T cells, whole thymi, spleens and lymph nodes 
were isolated from ARNTfl/fl X CD4Cre+/- mice and from control ARNTfl/fl mice. 
Subsequently, lymphocyte populations in those tissues were analysed by Flow 
Cytometry. Thymi of control and ARNT KO mice were identical in size and the total 
numbers of ARNTfl/fl X CD4Cre+/- and ARNTfl/fl (WT) thymocytes were not significantly 
different and within the normal range. Average numbers of total thymocytes were 
169X106 thymocytes in WT mice and 202X106 in ARNT KO mice (not shown). Figure 
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5.2A shows that ARNT KO and ARNT WT thymocytes have similar DPs (CD4+CD8+) 
and SPs (CD4+CD8- and CD4-CD8+) ratios. Staining of CD25/CD44 markers, which 
differentiate between the DN subpopulations also showed similar percentages of cells in 
DN1 to DN4 in ARNT KO and WT mice (Figure 5.2B). In addition, the overall surface 
expression of TCRβ and the percentage of TCRβhigh cells were similar in ARNTfl/fl X 
CD4Cre+/- and ARNTfl/fl  thymi (Figure 5.2C). This was also reflected in the production 
of mature SP (single positive) cells in the thymus as indicated by comparable 
percentages of TCRβhigh CD24low cells in the WT and KO thyme (Figure 5.2D). These 
results collectively show that the loss of ARNT did not effect T cell development in the 
thymus.  
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Figure 5.2 Normal development of T cells in the thymus of ARNTfl/fl X CD4Cre+/- mice. 
Thymocytes extracted from ARNTfl/fl and ARNTfl/fl X CD4Cre+/- mice were stained for: 
(stain 1) CD4, CD8, CD24 and TCRβ markers or (stain 2) Thy1.2, lineage markers 
(TCRγδ, CD4 and CD8), CD25 and CD24 surface markers and analysed by Flow 
cytometry. (A) Dot plots showing expression of CD4 and CD8 surface markers on total 
thymocytes of ARNT WT and ARNT KO mice. (B) Dot plots showing expression of 
CD44 and CD25 surface markers on Thy1.2 positive/lineage negative ARNT WT and 
ARNTfl/fl X CD4Cre+/- thymocytes. (C) Histogram showing the overall surface 
expression of TCRβ and the percentage of TCRβhigh cells in total live thymocytes of 
ARNT WT and ARNT KO mice. (D) Dot plots showing expression of CD24 and TCRβ 
surface markers on total live ARNT WT and ARNTfl/fl X CD4Cre+/- thymocytes. 
(representative data from n=3 biological replicates). 
 
Peripheral lymphocyte populations of spleen and lymph nodes of ARNTfl/fl X CD4Cre+/- 
and ARNTfl/fl WT mice were also isolated and compared by flow cytometry. 
Representative flow cytometry plots in figures 5.3, 5.4 show that percentages and ratios 
of T cells, B cells and TCRγδ T cells were normal in both lymph nodes (Figure 5.3) and 
the spleen (Figure 5.4) of WT and ARNT KO mice. Additionally, both lymph nodes and 
spleen showed normal ratios of CD4+ to CD8+ single positive T cells. The SP cells in 
these peripheral tissues were grossly normal, showing a normal expression of surface 
markers characteristic of naïve T cells. ARNT-null peripheral CD4 and CD8 T cells 
thus show high expression of CD62L and low expression of CD44 (Figure 5.3B, 5.4B). 
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Collectively, the results suggest that absence of ARNT did not impair T cell 
development in the thymus or the ability of T cells to survive in secondary lymphoid 
organs.  
 
 
 
Figure 5.3 Peripheral lymphocytes are normal in the lymph nodes of ARNTfl/fl X 
CD4Cre+/- mice.  
 
Lymphocytes extracted from lymph nodes of ARNTfl/fl (WT) and ARNTfl/fl X CD4Cre+/- 
(KO) mice were stained for TCRβ, B220, TCRγδ, CD4 and CD8 surface markers and 
analysed by Flow cytometry. (A) Dot plots showing expression of TCRβ and B220, 
CD4 and CD8 surface markers gated on TCRβ positive cells and expression of TCRβ 
and TCRγδ markers on all live lymphocytes. (B) Histogram overlay showing CD62L 
and CD44 expression on CD8 and CD4 T cells of ARNTfl/fl (WT- grey line) and 
ARNTfl/fl X CD4Cre+/- (KO-black line) mice. (representative data from n=3 biological 
replicates).  
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Figure 5.4 Peripheral lymphocytes are normal in the spleen of ARNTfl/fl X CD4Cre+/- 
mice.  
 
Lymphocytes extracted from spleens of ARNTfl/fl (WT) and ARNTfl/fl X CD4Cre+/- (KO) 
mice were stained for TCRβ, B220, TCRγδ, CD4 and CD8 surface markers and 
analysed by Flow cytometry. (A) Dot plots showing expression of TCRβ and B220, 
CD4 and CD8 surface markers gated on TCRβ positive cells and expression of TCRβ 
and TCRγδ markers on all live lymphocytes. (B) Histogram overlay showing CD62L 
and CD44 expression on CD8 and CD4 T cells of ARNTfl/fl (WT-grey line) and 
ARNTfl/fl X CD4Cre+/- (KO-black line) splenocytes. (representative data from n=3 
biological replicates).  
 
 
We then explored further the in vivo importance of ARNT for T cell function by looking 
at the ability of ARNTfl/fl X CD4Cre+/- mice to mount a T cell-dependent antibody 
response to a model antigen. We immunized control and ARNTfl/fl X CD4Cre+/- mice 
with NP-OVA, an antigen that elicits antibody production in a T-cell-dependent fashion. 
At different time points after immunization, the serum levels of antigen-specific Igs 
were determined by ELISA. As shown in Figure 5.5A and B baseline serum IgG and 
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IgM titres were normal in ARNTfl/fl X CD4Cre+/- mice. Moreover, ARNTfl/fl X CD4Cre+/- 
mice showed comparable antigen-specific IgG1 and IgM responses compared with 
those of wild-type (Figure 5.5 C,D and E, respectively). Thus T cell expression of 
ARNT is not essential for optimal T-cell-dependent antibody responses in vivo. 
It is of note that antigen-specific IgG1 and IgM responses in ARNT KO mice were 
more heterogeneous compared to ARNT WT mice. Further titration experiments using 
different Ag dosing may help addressing the origin of this heterogeneity.  
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Figure 5.5 ARNTfl/fl X CD4Cre+/- mice mount a normal T cell-dependent antibody 
response to a model antigen. 
 
ELISA of basal serum IgG (A) and IgM (B) levels in control and ARNTfl/fl X CD4Cre+/- 
mice bled on day 0. ARNTfl/fl X CD4Cre-/- (WT) and ARNTfl/fl X CD4Cre+/- (KO) mice 
were immunized with NP(13)OVALBUMIN (100µg/mouse) on day 0 and bled on day 
0, 7,14, 28 and 42. Serum anti-NP32 IgG (C) and anti-NP2 IgG (D) were determined on 
day 0, 7, 14, 28 and 42 after immunizations and serum anti-NP32 IgM (E) was 
determined on days 7 and 28 after immunizations by ELISA. On day 42 mice were 
boosted with a secondary challenge of NP(13)OVALBUMIN (50µg/mouse). Anti-NP32 
and anti NP-2 IgG levels were determined in terminal bleeds collected on day 49 by 
ELISA (C, D). Results are means +/− SD. (n = 5 mice per genotype for basal IgG, IgM 
levels and n=7 for IgM and IgG levels after immunizations with NP-OVA). 
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We then addressed whether ARNTfl/fl X CD4Cre+/- mice had normal gut lymphocytes. 
The rationale for these experiments is that recent studies showed that AhR expression 
plays a key role in maintaining intraepithelial TCRαβ+ CD8αα+ and TCRγδ T cells as 
well as innate lymphoid cells (ILCs) in the lamina propria layer (Li et al., 2011; Qiu et 
al., 2012). Figure 5.6 shows a representative flow cytometric analysis of intraepithelial 
lymphocytes (IELs) populations from ARNTfl/fl X CD4Cre+/- and ARNTfl/fl mice. The 
data show 5 fold significant reduction in the percentages of TCRαβ+ CD8αα+ T cells 
in ARNT KO versus ARNT WT mice. This result was similar to the reduction in 
CD8αα that was described in the intestines of AhR total KO mice by M. Veldhoen (Li 
et al., 2011).  
 
 
 
Figure 5.6 Loss of TCRβ+ CD8αα+ lymphocytes from the intestinal epithelium of 
ARNTfl/fl X CD4Cre+/- (KO) mice. 
  
Intraepithelial T lymphocytes extracted from small intestines of ARNTfl/fl (WT) and 
ARNTfl/fl X CD4Cre+/- (KO) mice were stained and analysed for the expression of TCRβ, 
TCRγδ, CD8 and CD8β surface markers by Flow cytometry. (A) Representative FACS 
dot plots showing distribution of TCRβ and TCRγδ IELs as well as frequency of 
TCRβ+CD8αα+ T cells in ARNT WT intestines. (B) Representative FACS dot plots 
showing distribution of TCRβ and TCRγδ IELs as well as frequency of 
TCRβ+CD8αα+ T cells in ARNT KO intestines. (C) Graph representing mean values 
+/- SD of TCRβ+CD8αα+ percentages in ARNT WT and ARNT KO intestinal 
epithelia (n=9 mice per KO genotype and n=8 mice per WT genotype). 
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5.2.2 ARNT deletion impairs Th17 differentiation in vitro 
AhR activation increases the production of IL-17 and IL-22 cytokines by immune 
activated CD4 T cells. Moreover, AhR-deficient Th17 cells exhibit a reduction in IL-17 
production and completely fail to express IL-22 (Veldhoen et al., 2008). We therefore 
asked whether AhR-dependent production of key cytokines by Th17 cells requires 
ARNT? CD4 T cells were therefore activated with CD3 and CD28 antibodies and 
cultured for 4 days in the presence of Th17 polarizing cytokines (IL-1β, TGF-β, IL-6). 
The numbers of ARNT deficient CD4 T cells found at the end of this culture period 
were comparable to the number of wild type T cells indicating that proliferation and 
survival of ARNT-null CD4 T cells was normal (Figure 5.7A). However, the frequency 
of IL-17 producing cells was reduced two fold in the ARNT-null cultures (Figure 5.7B). 
In addition, AhR activation by exogenous ligand, FICZ, increased the frequency of IL-
17 producing cells in the wild type CD4 T cells but not in ARNT KO CD4 T cells 
(Figure 5.7B - grey bars). 
Th17 cells also produce the cytokine IL-22. The level of IL-22 production by Th17 cells 
is further enhanced when the Th17 cells are stimulated with the AhR agonist FICZ. In 
contrast, the presence of the AhR antagonist CH-223191 ablates IL-22 production 
(Figure 5.7C). Strikingly, ARNTfl/fl X CD4Cre+/-  KO CD4 T cells did not produce IL-22 
cytokine and were not responsive to FICZ addition (Figure 5.7C). These data show that 
ARNT is required for IL-22 production by immune activated CD4 T cells. This 
phenotype is reminiscent of the phenotype observed in Th17 cells differentiated from 
AhR KO mice and the phenotype of decreased IL-17 and IL-22 production upon 
treatment with an AhR antagonist, CH-223191. These results suggest that ARNT is 
required for AhR-dependent IL-22 and IL-17 production by Th17 cells. 
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Figure 5.7 T cell specific ARNT deletion impairs Th17 differentiation in vitro.  
Cells extracted from whole lymph nodes of ARNTfl/fl (WT) and ARNTfl/fl X CD4Cre+/- 
mice were MACS-depleted from CD8 T cells, activated with CD3 and CD8 antibodies 
and cultured under Th17 conditions for 4 days. (A) Graph showing total CD4 T cell 
numbers on day 4 of the culture (n=independent 5 cultures). (B) Graph showing mean 
+/- SD values of CD4+ IL-17+ T cells from ARNT WT and ARNT KO Th17 cultures 
treated or untreated with FICZ from the start of the culture (n=3 experiments). (C) 
ARNT-null and ARNT WT CD4 T cells grown under Th17 conditions for 4 days in 
presence of FICZ agonist (300nM) or CH223191 antagonist (10µM) or with no 
treatment were re-stimulated with PdBU/Ionomycin on day 4. Supernatants were 
collected and assessed for IL-22 cytokine production by ELISA (n=3). 
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5.2.3 Cross talk between AhR and Hif-1α  signaling in T cells 
As discussed ARNT can partner with either the AhR or with the Hif-1α transcription 
factor complex (Tomita et al., 2000). While working on this project two papers which 
were published side by side described that Hif-1α is required for the differentiation of 
Th17 cells (Dang et al., 2011; Shi et al., 2011). Figure 5.8 shows that Hif-1α was 
strongly induced at the mRNA (Figure 5.8A) and protein level (Figure 5.8B) in CD4 T 
cells undergoing Th17 differentiation under normoxic conditions.  
 
 
Figure 5.8 CD4 T cells undergoing Th17 differentiation express Hif-1α under normoxic 
conditions.  
 
(A) qRT PCR kinetic analysis of Hif-1α mRNA expression in purified CD4 T cells 
activated with CD3 and CD28 antibodies and cultured under Th17 conditions (IL-1β, 
IL-6 and TGF-β cytokines) (n=3). (B) Western blot analysis with Hif-1α antibody of 
purified CD4 T cells cultured under Th17 conditions in 21% O2 for the indicated 
periods of time.  Probing with SmCI antibody was used to control equal loading on the 
gel (n=1). (C) Western blot analysis showing Hif-1α expression in titrated extracts of 
Th17 cells cultured under under hypoxic conditions (1% O2) and under normoxic 
oxygen tensions (21% O2) for 4 hours. (All protein extracts were similarly titrated in 2-
fold serial dilutions starting from 3X107 cells/mL) (n>3). 
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Moreover, Hif-1α expression in Th17 cells is further increased through its stabilization 
in Th17 cells that were exposed to a hypoxic environment (1% O2) for 4 hours (Figure 
5.8C). The Western blot in figure 5.9A confirms that Th17 cells generated from 
ARNTfl/fl X CD4Cre+/- mice do not express ARNT. However, it also shows that ARNT-
null Th17 cells retain expression of both the AhR and Hif-1α proteins. Indeed 
expression of both the AhR and Hif-1α was increased in the ARNT-null Th17 cells. 
However, despite the increased expression of Hif-1α, the ARNTfl/fl X CD4Cre+/- Th17 
cells did not express Glut1 (Figure 5.9B), which is a well-characterized Hif-1α/ARNT 
target gene. 
 
 
Figure 5.9 ARNT deletion in Th17 cells results in AhR and Hif-1α protein stabilization. 
Cells extracted from whole lymph nodes of ARNTfl/fl (WT) and ARNTfl/fl X CD4Cre+/- 
mice were MACS-depleted from CD8 T cells and cultured under Th17 conditions for 4 
days. On day 4 ARNT-null and ARNT WT differentiated Th17 CD4 T cells were 
exposed to hypoxic conditions or left under normoxic O2 tensions for 24 hours. (A) 
Western blot analysis showing expression of AhR, Hif-1α and ARNT in extracts of 
ARNT KO and ARNT WT differentiated Th17 cells exposed to normoxic or hypoxic 
conditions. Probing with SmCI antibody was used to control equal loading on the gel 
(n=2). (B) Western blot analysis of Glut1 expression in ARNT-null and ARNT WT 
Th17 cells. (n=2 experiments). 
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ARNT can dimerise with either Hif-1α or the AhR and as Th17 cells express both of 
these transcription factors we considered whether there might be competition between 
Hif-1α and AhR for ARNT. In fact, in the literature there are opposing views regarding 
AhR/Hif-1α competition for ARNT: some papers describe reduced AhR responses 
under hypoxic conditions (Gradin et al., 1996; van Uden et al., 2011) and others report a 
lack of competition for ARNT during hypoxia (Pollenz et al., 1999). To investigate 
whether there is competition between the AhR and Hif-1α for ARNT complexes in 
Th17 cells we exposed Th17 cells to FICZ in either normoxic or hypoxic conditions. 
We then measured expression of AhR and Hif-1α target genes, CYP1A1 and Glut1. 
The data show that hypoxia induced expression of mRNA encoding Hif-1α target gene 
Glut1, but decreased expression of the AhR target gene, CYP1A1 (Figure 5.10). 
Moreover, there was also a reduced level of IL-17 mRNA under hypoxic conditions, 
which together with reduced CYP1A1 mRNA levels suggests that AhR pathway in 
hypoxia is compromised.  
Moreover, the data in figure 5.10 (grey and black bars) show that expression of 
CYP1A1, Glut1 and IL-17 are all ablated following ARNT deletion. 
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Figure 5.10 AhR and Hif-1α compete for ARNT in hypoxia.  
qRT PCR analysis of CYP1A1, Glut1 and IL-17 mRNA expression in ARNT KO and 
ARNT WT differentiated Th17 cells exposed to normoxic or hypoxic conditions for 24 
hours. (mRNA levels were normalized to HPRT and the figure represents one 
representative experiment out of n=3). 
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5.3 Discussion 
The aim of this chapter was to explore the importance of the transcription factor ARNT 
in peripheral T cells. ARNT can complex with the AhR to control expression of 
cytochrome P450 (CYP1A1) genes. ARNT can also complex with Hif-1α to control 
expression of genes that control glucose uptake and glycolysis like the glucose 
transporter Glut1. In this context, oxygen tension is generally low (0.5%-4.5% O2) in 
the secondary lymphoid tissues compared with bloodstream (Neumann et al., 2005). 
Therefore, it was possible that T cells might need the ARNT/Hif-1α pathway to survive. 
However, analysis of ARNTfl/fl X CD4Cre+/- mice found no role for ARNT in thymocyte 
development or the survival of naïve T cells in secondary lymphoid organs. The result 
that ARNT is not needed for thymocytes development is reinforced by another study, 
which investigated the role of ARNT in AhR-dependent response of thymocytes to 
dioxins and used Lck-Cre;Arntflox/Δ mice (Tomita et al., 2003). The authors showed 
that thymocyte numbers and CD4/CD8 ratios in T cells did not change following Lck 
Cre mediated ARNT deletion.  
It was however striking that ARNT was required for IL-22 production in Th17 cells and 
seemed to be required for optimal IL-17 production in activated CD4 T cells. The AhR 
can regulate AhR production and is essential for IL-22 production by activated CD4 T 
cells. The importance of ARNT for IL-17 production could thus reflect that AhR/ARNT 
complexes are important for IL-17 and IL-22 production. However, the importance of 
ARNT for IL-17 and IL-22 production could reflect the role of ARNT in mediating the 
effects of the Hif-1α transcription factor complexes as well.  
In fact, Hif-1α has been shown to be important for the control of glycolysis in 
differentiating Th17 cells (Dang et al., 2011; Shi et al., 2011). Moreover, in the absence 
of Hif-1α T cells could proliferate but did not produce the IL-22 cytokine and secreted 
lower amounts of IL-17. It is difficult to design an experiment that can distinguish 
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between these two roles for ARNT. However, it was clear that ARNT was essential for 
AhR agonists such as FICZ to control IL-17 and IL-22 production. It was also clear that 
in the absence of ARNT, there was an increase in AhR expression levels. It is known 
that activation of AhR by its ligands leads to its translocation to the nucleus, 
dimerization with ARNT and subsequent proteasome dependent degradation (chapter 3 
results).  
This degradation is mediated by a covalent attachment of the ubiquitin peptide molecule 
by the E2 ad E3 ligase enzymes to a specific element termed “degron” in the target 
protein (Ma and Baldwin, 2000). It was previously demonstrated that this “degron” 
element is located in the transactivation (TA) domain of the AhR and that TA-deficient 
AhR is not degraded (Ma and Baldwin, 2000). It is also known that TA activation 
occurs in the presence of ARNT and AhR ligand (Ko et al., 1996). Therefore, we 
speculate that ARNT dimerization with AhR allows the recognition of dergon element 
in the TA domain by the ligases, which leads to a consequent ubiquitination of the AhR. 
This hypothesis might explain our observation that in the absence of ARNT in CD4 T 
cells, there is an increase in AhR expression since it is not degraded in the proteasome 
and suggest a role of ARNT in regulating the turnover of the AhR protein.   
It was striking that ARNTfl/fl X CD4Cre+/- mice had reduced numbers of CD8αα T cells 
in the epithelial layer of the small intestines. Our previous results using the CYP1A1 
Cre+/- X R26REYFP reporter mouse showed that AhR is functional in CD8αα IELs 
(section 4.2.7). Since the reporter operates through canonical ARNT/AhR complexes, 
this result suggests that AhR/ARNT signaling in response to endogenous ligands is 
important for the maintenance of this subset in the gut. However, since ARNT also 
dimerises with Hif-1α we cannot exclude the possibility that it is ARNT/Hif-1α 
complex that plays a role in the survival of these cells. This question can be addressed 
in future experiments using Hif-1α conditional KO mice. 
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Chapter 6 mTOR controls glucose metabolism and the 
expression of  Hif-1α  in CD8 T cells 
6.1 Introduction 
The ARNT transcription factor can dimerise with either the AhR or the Hif-1α 
transcription factor complex. The data in chapter 4 show that most CTLs do not 
express a functional AhR but how important is the Hif-1α/ARNT complex in effector 
CD8 T cells? For example, Hif-1α plays a role in controlling mTORc1-dependent 
glycolytic activity in Th17 cells thus determining the fate of this T cell subset (Dang 
et al., 2011; Shi et al., 2011). Is mTORc1/Hif-1α signaling similarly important for 
CD8 T cell metabolism? In this context, a striking feature of CD8 T cells is that they 
massively increase glucose uptake as they respond to an immune challenge and 
differentiate to cytolytic effectors (Fox et al., 2005a; Maciver et al., 2008). They also 
switch from metabolizing glucose primarily through oxidative phosphorylation to 
using the glycolytic pathway. Glycolysis requires that T cells switch on and sustain 
expression of rate limiting glycolytic enzymes such as hexokinase 2, 
phosphofructokinase 1, pyruvate kinases and lactate dehydrogenases and also requires 
that T cells can sustain high levels of glucose uptake by maintaining expression of the 
glucose transporter Glut-1. In this context it has been reported that relatively high 
levels of exogenous glucose are required to sustain the transcriptional program of 
cytotoxic T cells (Cham et al., 2008). 
During CD8 T cell differentiation the glycolytic switch is initiated by antigen 
receptors and co-stimulatory molecules but is then sustained by inflammatory 
cytokines such as IL-2. Triggering of the TCR or the IL-2 receptor is known to 
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activate mTORc1 but the role of mTORc1 in regulating glucose metabolism in CD8 T 
cells has not been fully explored nor is the role of Hif-1α fully understood. Indeed it 
has been recently reported that the initial glycolytic switch induced in response to 
antigen receptor triggering is mediated by c-myc and is independent of Hif-1α (Wang 
et al., 2011). It thus remains to be determined whether mTORc1 or Hif-1α play any 
role in controlling CD8 T cell metabolism.   
In this context, mTORc1 is proposed to play an essential role in monitoring the 
nutrient status of T cells and integrating inputs from antigen and cytokine receptors to 
control T cell differentiation (reviewed in (Waickman and Powell, 2012). For 
example, inhibition of mTORc1 activity in effector CD8 T cells can divert these cells 
to a memory fate (Araki et al., 2010). Moreover, mTOR signaling controls expression 
of cytolytic effector molecules in CTL (Rao et al., 2010) and dictates the tissue-
homing properties of these cells by regulating the expression of chemokine and 
adhesion receptors (Sinclair et al., 2008). The molecular mechanisms used by 
mTORc1 to control CD8 T cell differentiation are not fully understood. Accordingly, 
the focus of the present study was to explore links between mTORc1 and Hif-1α 
signaling in CD8 T cells.  
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6.2 Results 
6.2.1 mTORc1 regulates glucose uptake and glycolysis in TCR and IL-2 
stimulated CD8 T cells 
TCR triggering of naïve purified CD8 T cells with peptide/MHC complexes induces 
expression of the glucose transporter Glut1 (Figure 6.1A) and subsequently induces 
glucose uptake and lactate output (Figure 6.1B and C, respectively).  
 
 
Figure 6.1 TCR stimulated CD8 T cells induce glucose uptake and glycolysis.  
(A) Western blot analysis with Glut1 antibody of purified naïve P14-LCMV CD8 T 
cells TCR triggered with gp33-41 peptide and CD28 antibody or left un-stimulated 
with IL-7 cytokine for 18 hours. (B) Glucose uptake in naïve P14-LCMV CD8 T cells 
+/- TCR stimulation with gp33-41 and anti CD28 for 8 and 20 hours. (C) Lactate 
production in naïve P14-LCMV CD8 T cells +/-TCR stimulation with gp33-41for 20 
hours. For all panels, data are mean +/- SEM or representative of at least three 
experiments. All metabolic assays were performed in triplicates (**P<0.01, 
***P<0.001). 
 
In contrast to naïve CD8 T cells kept in presence of IL7 (Park et al., 2004), TCR 
triggering of CD8+ T cells for 4h, 8h and 20h activates mTORc1 activity (Figure 
6.2A), reflected by the phosphorylation of S6 ribosomal protein (pS6), a direct target 
of the mTOR-regulated p70S6 kinase, S6K1. mTORc1 activity could be inhibited by 
the addition of mTORc1 inhibitor, rapamycin (Figure 6.2A, lane 5). In addition, 
inhibition of mTORc1 activity with rapamycin blocked TCR-induced increase in 
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Glut1 expression (Figure 6.2B) and glucose metabolism, as judged by decreased 
glucose uptake (Figure 6.2C) and decreased lactate output (Figure 6.2D).  
 
 
Figure 6.2 mTORc1 regulates glucose uptake and glycolysis in TCR stimulated CD8 
T cells.  
 
(A) Western blot analysis with S6K, S6 and SmCI antibodies (from right) of naive 
P14-LCMV CD8 T cells +/- TCR stimulation for 4, 8 and 20 hours with or without 
Rapamycin (20nM) at 20 hours time point. mTORc1 activity measured by increased 
phosphorylation of target sequences on S6K1 (Thr389) and phosphorylation of the 
S6K1 substrate S6. SmCI was used as a loading control. (B) Western blot analysis of 
Glut1 expression (from right side) in naive P14-LCMV CD8 T cells +/- TCR 
stimulation for 20 hours with or without Rapamycin. (C) Glucose uptake assay and 
(D) lactate production in naïve CD8 T cells +/- TCR stimulation with or without 
Rapamycin for 20 hours. For all panels, data is mean +/- SEM or representative from 
at least 3 experiments (**, p<0.01; ***, p<0.001). 
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TCR triggered CD8 T cell cultured in IL-2 differentiate to effector CTL. One role for 
IL-2 is to sustain glucose uptake and glycolysis in immune activated T cells 
(Macintyre et al., 2011). Antigen receptor primed CD8 T cells cultured in IL-2 thus 
have high levels of Glut1 expression, high levels of glucose uptake and high levels of 
lactate output. The expression of Glut1 is lost when CTLs are deprived of IL-2 
(Figure 6.3A). Moreover, the removal of IL-2 causes CTLs to decrease glucose 
uptake and lactate output, i.e. glycolysis (Figure 6.3B and C).  
 
 
Figure 6.3 IL-2 regulated glucose uptake and glycolysis in CTLs.  
 
(A) Western blot analysis showing Glut1 expression in mature P14-LCMV CTLs 
cultured with or without IL-2 for 20 hours (n=3). (B,C) Analysis of glucose uptake 
(B) and lactate production (C) in P14-LCMV CTLs treated with or without IL-2 for 
20 hours. Data is mean +/- SEM or representative from at least 3 experiments (**, 
p<0.01; ***, p<0.001). 
 
 
We then examined the impact of another cytokine IL-15 on glucose metabolism in 
antigen receptor activated CD8 T cells. This cytokine is known to support the 
differentiation of antigen receptor primed CD8 T cells to a memory T cell phenotype 
(Becker et al., 2002; Wherry and Ahmed, 2004). The data (Figure 6.4A) show that IL-
15 can only sustain low levels of Glut1 expression and glucose uptake compared to 
IL-2 (Figure 6.4B). 
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Figure 6.4 IL-15 maintained CD8 T cells can only sustain low levels of glycolysis 
compared to IL-2 maintained CTLs.  
 
(A) Western blot analysis with Glut1 antibody of IL-2 cultured P14-LCMV CTLs 
versus IL-15 cultured CD8 T cells (n=2). (B) Analysis of glucose uptake in IL-2 
cultured P14-LCMV CTLs versus IL-15 cultured CD8 T cells (n=3). 
 
 
One difference between IL-2 and IL-15 is that IL-2 induced a much stronger level of 
mTORc1 activity than IL-15 (Cornish, 2006). We therefore examined the impact of 
rapamycin on the ability of IL-2 to sustain glucose uptake and glycolysis.  
Strikingly, when IL-2 maintained CTLs are treated with rapamycin they decrease 
glycolysis as judged by a reduction in lactate output (Figure 6.5A). The molecular 
basis for the failed glycolysis in rapamycin treated IL-2 maintained T cells was multi-
factorial. Rapamycin treated CTLs thus show severely decreased glucose uptake 
(Figure 6.5B) and loss of Glut1 expression (Figure 6.5C).  
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Figure 6.5 mTORc1 regulates glucose uptake and glycolysis in IL-2 maintained CTL.  
(A,B) Analysis of glucose uptake (A) and lactate production (B) in P14-LCMV CTLs 
treated with or without IL-2 for 20 hours. (C) Western blot analysis with Glut1 
antibody of P14-LCMV CTL treated with or without Rapamycin for 20 hours. Data is 
mean +/- SEM or representative from at least 3 experiments (**, p<0.01; ***, 
p<0.001). 
 
 
6.2.2 mTORc1 regulates Hif-1α  expression in TCR activated CD8+ T cells and 
in IL-2 maintained mature CTLs. 
The conclusion from experiments described in the last section is that TCR and IL-2 - 
driven mTORc1 activity regulate glucose metabolism in CD8+ T cells. This 
regulation of glucose metabolism, can be explained by the fact that mTORc1 controls 
Glut1 expression in TCR activated CD8 T cells. mTORc1 activity is also required to 
control Glut1 expression in IL-2 maintained CTLs. However the ability of mTORc1 
to control glycolysis is not only mediated via Glut1 expression.  In fact, it is likely 
that mTORc1 functions via additional mechanisms to control glycolysis. A SILAC 
(stable isotope labeling by amino acids in cell culture) whole cell proteomic 
experiment followed the change in protein expression following mTORc1 inhibition 
in CTLs by comparing rapamycin treated and untreated CTLs (unpublished data in 
!" #" $"
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our lab, experiment performed by Jens Hukelmann). The results of this analysis 
showed that rapamycin treatment decreased the expression of Glut1, but also 
downregulated the expression of several key rate limiting glycolytic enzymes that are 
involved in the enzymatic breakdown of glucose to pyruvate (not shown). Those 
enzymes included hexokinase-2, which phosphorylates glucose to glucose-6 
phosphate and phosphofructokinase enzyme that converts fructose-6 phosphate to 
fructose 1,6-biphosphate.  
Glut1 and these glycolytic enzymes are all verified Hypoxia inducible factor 1 (Hif-
1α) target genes (Semenza et al., 1994; Maxwell et al., 1997; Minchenko et al., 2003). 
Therefore, we wished to test whether Hif-1α is expressed in CD8+ T cells under 
normoxic conditions and whether it is regulated by mTORc1, which could explain 
how mTORc1 controls glucose metabolism in CTLs.  
Western blot analysis in figure 6.6A shows that as CD8 differentiate to CTLs they 
induce Hif-1α expression under normoxic conditions (21% O2), though at much lower 
levels compared to the expression under hypoxic conditions (1% of O2). ARNT is 
essential for the formation of the Hif-1α DNA-binding complex and when absent, 
Hif-1α complex cannot bind to hypoxia responsive elements and activate gene 
transcription (Wood et al., 1996). Analysis of ARNT expression shows that like Hif-
1α, ARNT is expressed in mature CTLs but not in naïve CD8+ T cells (Figure 6.6B). 
Western blot analysis shows that Hif-1α expression is induced following 18 hours of 
T cell receptor stimulation. Moreover, this TCR-dependent induction of Hif-1α could 
be inhibited by rapamycin meaning that mTORc1 regulates TCR dependent Hif-1α 
expression (Figure 6.6C).  
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Figure 6.6 Hif-1α and ARNT are expressed in mature CTLs under normoxic 
conditions and mTORc1 regulates TCR-induced Hif-1α expression. 
  
(A) Western blot analysis with Hif-1α antibody of titrated extracts prepared from IL-2 
maintained P14-LCMV CTLs cultured under hypoxic (1% O2) or normoxic (21% O2) 
for 4 hours. (All protein extracts were similarly titrated in 2-fold serial dilutions 
starting from 3X107 cells/mL). Gsk3 was used to confirm two-fold dilution of loading 
(n>3). (B) Western blot analysis with ARNT and Hif-1α antibodies of mature P14-
LCMV CTLs cultured with IL-2 for 6 days versus naïve purified CD8 T cells. SmCI 
was used to confirm equal loading on the gel (n=3). (C) Western blot analysis of Hif-
1α expression in naive and TCR stimulated P14-LCMV CD8 T cells treated or 
untreated with Rapamycin for 20 hours. Phospho-S6K1 (Th389) used as a measure of 
mTORc1 activity and SmCI was used to confirm equal loading (n=3).  
 
 
 
The next question we asked was what signals sustain Hif-1α expression in mature 
effector CTLs? 
In fully differentiated cytotoxic T cells IL-2 supports mTORc1 activity. When 
mTORc1 activity is lost upon IL-2 withdrawal from the cultures or inhibited by 
rapamycin treatment, Hif-1α expression in CTLs is also rapidly abolished (Figure 
6.7A, 6.7B, respectively). Moreover, figure 6.7C shows that IL-15, which only 
weakly activates mTORc1 can only sustain low levels of Hif-1α in TCR activated 
CD8 T cells in contrast to IL2-cultured CTLs (Figure 6.7C). Thus, Hif-1α expression 
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in IL-2-maintained CTLs is dependent on sustainable mTORc1 activity and its 
magnitude.  
 
 
 
Figure 6.7 mTORc1 controls Hif-1α expression in IL-2 maintained CTLs. 
  
(A) Western blot analysis of Hif-1α expression in P14-LCMV CTLs treated with and 
without IL-2, (B) with and without Rapamycin for 20 hours. Phospho-S6K1 (Thr389) 
and phospho-S6 (S235/236) were used as a measure of mTORc1 activity. SmCI, pan 
S6 and PKB were used to control equal loading (C) Western blot of Hif-1α and 
ARNT expression in IL-15 maintained CTLs and in IL-2 cultured CD8 T cells. SmCI 
was used to control equal loading. Data in all panels is representative from at least 3 
experiments.  
 
 
How does mTORc1 control the expression of Hif-1α/ARNT complex? Does it control 
Hif-1α and/or ARNT expression by regulating their transcription or the translation of 
mRNA transcripts?  
We examined whether mTORc1 regulates Hif-1α or ARNT expression by regulating 
their transcription. Comparison of Hif-1α and ARNT mRNA levels in CTLs treated 
or untreated with rapamycin showed that rapamycin treatment did not decrease 
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mRNA levels of Hif-1α or ARNT (Figure 6.8A). In addition, in contrast to Hif-1α 
which expression was downregulated following rapamycin treatment (Figure 6.7B), 
the level of ARNT protein was not affected by rapamycin treatment (Figure 6.8B). 
This result suggests that mTORc1 must control Hif-1α complex by regulating 
translation of Hif-1α mRNA and does not regulate ARNT at mRNA or protein level.  
 
 
 
Figure 6.8 mTORc1 does not regulate Hif-1α and ARNT mRNA transcription or 
ARNT protein levels.  
 
(A) Representative graph showing qRT PCR analysis of Hif-1α and ARNT mRNA 
expression in P14-LCMV CTLs cultured with IL-2 and treated with or without 
Rapamycin for 24 hours. (n >3 experiments and mRNA levels were normalized to 
HPRT expression). (B) Western blot analysis with ARNT antibody of P14-LCMV 
CTLs cultured with IL-2 and treated with or without Rapamycin for 24 hours. 
Phospho-S6K1 (Thr389) was used to measure mTORc1 activity and panS6K and 
SmCI were used to control equal loading (n=3).  
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6.3 Summary  
Data presented in this chapter shows that mTORc1 pathway in CD8 T cells integrates 
both TCR and IL-2 signaling to induce and sustain Glut1 expression and glucose 
uptake. mTORc1 also controls glycolysis by regulating expression of key rate limiting 
glycolytic enzymes in activated CD8 T cells. Recent studies showed that Hif-1α plays 
a role in the glycolytic switch of CD4 effector cells (Dang et al., 2011; Shi et al., 
2011), however it was not known whether the same mechanism applied for CD8 
effectors. Hif-1α and ARNT are induced upon TCR activation of naive CD8 T cells 
and are expressed in CD8 T cells cultured with IL-2 cytokine under normoxic 
conditions. 
Moreover, the sustained expression of Hif-1α transcriptional complex in TCR 
stimulated CD8 T cells and IL-2- maintained CTLs is dependent on continuous 
cytokine signaling and continuous mTORc1 activation. This correlates with the 
requirement for sustained mTORc1 and IL-2 signaling to control Glut1 expression 
and the glycolytic metabolism in CD8 T cells.  
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Chapter 7 The role of mTORc1/Hif-1α  axis in glucose 
metabolism of TCR activated CD8+ T cells and mature 
effector Cytotoxic T cells. 
7.1 Introduction  
The data described in the last chapter showed that the sustained expression of Hif-1α 
transcriptional complexes in IL-2 maintained CTLs is dependent on continuous 
cytokine signaling and continuous mTORc1 activation. This correlates very well with 
the requirement for sustained mTORc1 and IL-2 signaling to control glucose 
metabolism in CD8 T cells. To understand whether Hif-1α regulation by mTORc1 
plays a role in glucose metabolism in CD8+ T cells, we decided to study changes in 
metabolism of CD8 T cells following the loss of Hif-1α transcriptional complexes in T 
cells. For these experiments we looked at CD8 T cell immune responses in ARNTfl/fl X 
CD4Cre+/- mice. Peripheral T cells from these mice lack expression of functional Hif-1α 
/ARNT complexes. Moreover, results of chapter 4 demonstrated that CTLs do not 
express a functional AhR meaning that phenotypes in the ARNT-null CD8 T cells can 
be attributed to loss of Hif-1α/ARNT complexes. 
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7.2 Results 
7.2.1 ARNT/Hif-1α  deficient CD8 T cells activate and proliferate normally in 
response to T cell receptor stimulus. 
 To generate cytotoxic T cells from ARNTfl/fl X CD4Cre+/- mice we used a well- 
established in vitro model system in which we polyclonally activate spleen or lymph 
node-derived T cells by triggering their antigen receptors with CD3 antibodies in the 
presence of antigen presenting cells for 2 days. Thereafter cells are maintained in 
exponential growth by culturing in the presence of IL-2. This activation induces an 
increase in cell size and a strong proliferative expansion of CD8 T cells. The TCR and 
IL-2 activated CD8 T cells also differentiate to become polyclonal CTLs.  
ARNT/Hif-1α-null CD8 T cells activated normally in response to TCR as seen by a 
comparable blasting of ARNTfl/fl (WT) and ARNTfl/fl X CD4Cre+/- (KO) T cells (Figure 
7.1A). In addition, ARNT KO T cells responded normally to IL-2 triggering as judged 
by their ability to normally up-regulate expression of CD25, CD71 and CD44 surface 
markers (Figure 7.1B). Moreover, the culture of TCR activated cells in presence of IL-2 
resulted in equal clonal expansion and proliferation rate of ARNT KO and WT CD8 T 
cells (Figure 7.1C).  
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Figure 7.1 ARNT-KO CTLs activate and proliferate normally in response to T cell 
receptor stimulus. 
 
(A) Flow cytometric analysis of FSC and SSC profile and percentages of live ARNTfl/fl 
(WT) and ARNTfl/fl X CD4Cre+/- (KO) naïve splenic T cells unstimulated and stimulated 
with CD3 antibody for 48 hours. The data is representative of at least 5 experiments. (B) 
Histograms showing flow cytometric analysis of CD25, CD44 and CD71 expression of 
ARNT-KO and ARNT WT CTLs (gated on CD8+ T cells) (n=3). (C) Representative 
graph showing increase in cell numbers of TCR activated ARNTfl/fl (WT) and ARNTfl/fl 
X CD4Cre+/- (KO) splenocytes cultured in presence of IL-2 over 72 hours (n>3). 
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The ARNTfl/fl X CD4Cre+/- T cells that proliferate normally have deleted ARNT protein 
(Figure 7.2A). We have shown in chapters 3 and 4 that a very small subset of CTLs 
expresses a functional AhR. Nonetheless, these cells can respond to the AhR ligand 
FICZ and induce expression of the AhR/ARNT target gene CYP1A1 (chapter 3). Figure 
7.2B demonstrates that the lack of ARNT abolished the ability of CTLs to respond to 
the AhR ligand, FICZ.  
 
 
Figure 7.2 ARNT deletion and lack of function in CTLs differentiated from splenocytes 
of ARNTfl/fl X CD4Cre+/- mice.  
 
(A) Western blot analysis with ARNT antibody of ARNT-KO and ARNT WT CTLs 
maintained with IL-2 for 6 days. (B) qRT PCR analysis of CYP1A1 mRNA induction 
in ARNT-KO and ARNT WT CTLs treated with or without FICZ for 6 hours (n=3). 
(mRNA levels were normalized to HPRT expression).  
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7.2.2 ARNT controls glucose uptake and glycolysis in mature CTLs. 
At first sight, ARNT-null CTLs look normal. However, during activation of splenocytes 
with CD3 antibody as well as during six days of culture in presence of IL-2 cytokine, 
we observed that culture medium of ARNTfl/fl X CD4Cre+/- acidified less in comparison 
to the medium of ARNTfl/fl (WT) CTLs. This acidification could be detected by a pH-
dependent change in the color of the phenol red present in the medium (not shown). The 
highly glycolytic CTLs use glucose-6-phosphate to produce ATP and pyruvate. The 
majority of glucose-derived pyruvate is then converted to lactate which is secreted by 
monocarboxylic transporters. Lactate secreted to the medium results in pH decrease 
thus changing the color of the medium. Therefore, our observations could be explained 
by the fact that ARNTfl/fl X CD4Cre+/- CTLs have a reduced lactate output in comparison 
to ARNTfl/fl WT CTLs. Indeed, measuring the amount of lactate output demonstrates a 
significant decrease in lactate production by WT versus ARNT deficient CTLs (Figure 
7.3A). Moreover, there was a clear decrease in glucose uptake by ARNT-null CTLs in 
comparison to WT CTLs (Figure 7.3B). The failure to uptake glucose is a result of a 
pronounced decrease in the expression levels of glucose transporter, Glut1 in 
ARNT/Hif-1α-null T cells as measured by Western blot in Figure 7.3C. This phenotype 
of reduced glucose uptake and glycolysis following the loss of ARNT function 
phenocopies the glycolytic defect following inhibition of mTORc1 activity in CTLs 
(chapter 6).  
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Figure 7.3 ARNT controls glucose uptake and glycolysis in mature CTLs.  
 
(A) IL-2 maintained ARNTfl/fl (WT) and ARNTfl/fl X CD4Cre+/- (KO) CTLs were 
analysed for lactate output and (B) glucose uptake. Data is mean +/- SEM or 
representative from at least 3 experiments (**, p<0.01; ***, p<0.001). (C) Western blot 
showing Glut1 expression in ARNT-null and ARNT WT CTLs. SmCI was used as a 
control for an equal loading (n=3).  
 
 
These data argue that of Hif-1α/ARNT complexes control the glycolytic switch of 
cytotoxic T cells. Nonetheless, since we delete ARNT and not Hif-1α in T cells, we 
could not be confident that ARNT does not function in the glycolytic switch in CTLs 
via its other binding partner, AhR. Accordingly, CTLs were generated from AhR KO 
mice and analysed for their ability to undergo a glycolytic switch. Both glucose uptake 
and lactate output in AhR KO CTLs were normal and comparable to AhR WT CTLs 
(Figure 7.4A and 7.4B). This is in contrast to rapamycin treated CTLs, which behave 
similarly to ARNT-null CTLs and have decreased glucose uptake and reduced lactate 
production. Moreover, Glut1 expression in AhR KO CTLs was similar to that of AhR 
WT CTLs (Figure 7.4C). Hence, the best interpretation of the data is that it is 
ARNT/Hif-1α and not ARNT/AhR complexes that regulate the glycolytic switch in 
cytotoxic T cells. 
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Figure 7.4 AhR KO CTLs display normal glucose uptake and glycolysis.  
 
(A) IL-2 maintained AhR KO and AhR WT CTLs were analysed for glucose uptake and 
(B) lactate production. In both assays CTLs treated with rapamycin for 24 hours were 
used as a control. (n=4 experiments). (C) Western blot analysis of Glut1 and perforin 
expression in AhR KO and AhR WT CTLs. Probing with SmCI was used to confirm 
equal loading (n=3). 
 
7.2.3 Does mTOR regulation of Hif-1α  control the TCR-dependent glycolytic 
switch in CD8 T cells? 
It was shown previously that TCR stimulation triggers mTORc1 activation, initiating 
glucose uptake and glycolysis in CD8+ T cells (Figure 6.2A-D). It was also shown that 
TCR-dependent induction of Hif-1α could be inhibited by rapamycin (Figure 6.2A), 
meaning that mTORc1 regulates TCR dependent Hif-1α expression. Therefore, our 
hypothesis was that mTORc1 regulation of Hif-1α would be responsible for the 
glycolytic switch observed following T cell receptor activation. To test this hypothesis, 
lymph node derived lymphocytes extracted from ARNTfl/fl X CD4Cre+/- (KO) and 
ARNTfl/fl (WT) mice were activated with CD3 and CD28 antibodies or cultured in 
presence of IL-7 with no TCR stimulation for 20 hours. Following TCR stimulation, 
CD8+ T cells were MACS purified and analysed for their ability to uptake glucose and 
to produce lactate. Both ARNTfl/fl X CD4Cre+/- (KO) and ARNTfl/fl (WT) CD8+ T cells 
could equally well switch to glycolysis following TCR activation in contrast to CD8+ T 
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cells cultured with IL-7 only (Figure 7.5A and B). Therefore, the loss of ARNT 
function did not impair glycolysis in TCR activated CD8+ T cells. ARNT is thus not 
required for the mTORc1 dependent glycolytic switch that is triggered via TCR 
activation. However, ARNT is required for IL-2 maintained antigen receptor activated 
CD8 T cells to sustain glucose uptake and glycolysis. 
 
 
 
 
Figure 7.5 mTORc1 regulated ARNT/Hif-1α complex is dispensable for glycolysis in 
TCR activated CD8 T cells.  
 
(A) Cells extracted from whole lymph nodes of ARNTfl/fl (WT) and ARNTfl/fl X 
CD4Cre+/- (KO) mice were activated with CD3 and CD28 antibodies or cultured with IL-
7 for 20 hours. Following 20 hours CD8 T cells were MACS purified and analysed for 
(A) glucose uptake and (B) lactate output. (n>3 experiments). 
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Recent work has shown that c-myc but not Hif-1α is important for the TCR induced 
glycolytic switch (Wang et al., 2011). Indeed, a time course analysis of Hif-1α and c-
myc expression, showed that while c-myc was induced as early as 4 hours following 
TCR stimulation in purified CD8+ T cells, Hif-1α was only detectable at a time point of 
20 hours post TCR stimulus (Figure 7.6A). However, c-myc expression was normal in 
ARNTfl/fl X CD4Cre+/- (KO) CD8+ T cells (Figure 7.6B). 
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Figure 7.6 c-myc expression preceding the expression of Hif-1α following TCR 
stimulation is normal in ARNTfl/fl X CD4Cre+/- (KO) CD8 T cells.  
 
(A) Western blot analysis of Hif-1α and c-myc expression in (from right) purified naïve 
P14-LCMV CD8 T cells left un-stimulated with IL-7 or TCR stimulated with gp33-41 
and anti-CD28 for 4, 8 and 20 hours. Probing with Phospho-S6K1 (Thr389) and 
phospho-S6 (S235/236) antibodies was used to confirm TCR activation. Probing with 
pan S6 and SmCI were control for equal loading. (B) Western blot analysis of c-myc 
expression in naïve ARNTfl/fl (WT) and ARNTfl/fl X CD4Cre+/- (KO) CD8 T cells +/- 
gp33-41/anti-CD28 stimulation for 20 hours. Probing with pS6 (S235/236) antibody 
was used to confirm TCR stimulation and probing with SmCI antibody confirmed equal 
loading (n=3). 
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7.2.4 The ARNT/Hif-1α  regulated glycolytic switch is not required for CD8 T cell 
proliferation in vitro and in vivo. 
It is believed that an aerobic glycolytic metabolism is important for CD8+ T effector 
cell survival and proliferation (Vander Heiden et al., 2009). For example effector T cell 
proliferation was markedly reduced upon inhibition of glycolysis using 2-deoxy-D-
glucose (2-DG). However, Figure 7.7A shows an equal proliferation of in vitro cultured 
ARNTfl/fl X CD4Cre+/- (KO) CTLs and WT CTLs in response to IL-2. We also tested 
how well effector CD8+ T cells proliferate in vivo in response to immune challenge in a 
Listeria monocytogenes infection model.  
 
Listeria monocytogenes is a gram-positive intracellular bacterium, which infects mice 
and humans. This infection model is widely used to assess proliferation and effector 
functions of CD8+ T cells. Listeria-derived peptides are presented on MHC class I by 
infected macrophages and hepatocytes, thus activating CD8+ T cells (Kägi et al., 1994a; 
1994b). ARNTfl/fl X CD4Cre+/- (KO) and ARNTfl/fl (WT) mice were infected with an 
attenuated recombinant Listeria monocytogenes bacteria that secret OVA protein, ΔactA 
LM-OVA strain (Pope et al., 2001; Haring et al., 2005). Following i.v injection of 
Listeria, spleens of ARNTfl/fl X CD4Cre+/- and ARNTfl/fl infected mice were extracted and 
analysed on day 7-post infection. This is the peak time point of effector CD8+ T cell 
function (Haring et al., 2005; Porter and Harty, 2006). Listeria-responding CD8+ T 
cells were detected using FACS staining with MHC class I pentamers that comprise five 
MHC-(H-2kb)+SIINFEKL peptide complexes assembled through a coiled-coil domain 
with five fluorescent tags that are also linked to the coiled coil domain. 
A representative FACS plot and the scatter plot in figure 7.7B show an equal frequency 
of CD8 T cells recognized by the SIINFEKL+MHC class I complexes on day 7 after 
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Listeria infection. This result argues that ARNT-null CD8 T cells are able to activate 
and clonally expand in response to immune challenge with Listeria. 
 
 
 
Figure 7.7 ARNT/Hif-1α complex is not essential for CD8 T cell proliferation. 
  
(A) Proliferation analysis of in vitro generated ARNT-null and ARNT WT CTLs. Equal 
number of cells was seeded and cell number was determined after 24 hours. A scatter 
plot represents cell number as fold increase. Collated data from 5 independent 
experiments. (B) Analysis of proliferation of in vivo generated CD8 effector T cells. 
ARNTfl/fl (WT) and ARNTfl/fl X CD4Cre+/- mice were infected with Listeria 
monocytogenes (ΔactA rLMOVA strain). After 7 days, splenocytes were isolated and 
analyzed by flow cytometry to determine the percentage of CD8 effector T cells. 
Effector T cells were gated as B220-NK1.1-CD4- and CD8+Pentamer+ (pentamer, 
MHC class I+ SIINFEKL peptide complex). Representative dot plots for the different 
genotypes are show, and the percentage of CD8+Pentamer+ among the B220-NK1.1-
CD4- population for each mouse is represented in a scatter plot graph (n=6 mice). 
Uninfected mice (UI) were used as a negative control (n=3 UI mice). 
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In addition, figure 7.8 also shows that ARNTfl/fl X CD4Cre+/- (KO) CD8 T cells could 
mount a similar immune response against a primary infection with Listeria as judged by 
a similar percentages of IFN-γ producing CD8+ T cells following re-stimulation with 
the SIINFEKL peptide (Figure 7.8A). Moreover, there were similar percentages of 
CD44high (Fig.7.8B) and KLRG1 positive CD8 T cells in the spleens of ARNT-null and 
ARNT WT mice on day 7-post Listeria infection (Figure 7.8C).  
 
 
 
Figure 7.8 ARNT deficient CD8 effector T cells are similar to ARNT WT effectors. 
ARNTfl/fl (WT) and ARNTfl/fl X CD4Cre+/- mice were infected with Listeria 
monocytogenes (ΔactA rLMOVA strain). After 7 days, IFN-γ production and different T 
cell activation parameters were analyzed by flow cytometry, using uninfected mice as 
negative controls. (A) Data show IFN-γ cytokine production in CD8 effector T cells. 7 
days post-infection, splenocytes were re-stimulated with SIINFEKL peptide in presence 
of Brefeldin A for 5 hours, and IFN-γ production was determined by intracellular 
staining. Representative dot plots for the different genotypes are shown, and graph 
represents the percentage of IFN-γ producing cells among B220-NK1.1- CD4- 
population cells for each mouse (Collated data for n=10 mice in 2 independent 
experiments). (B,C) The data show the level of cell surface expression of CD44 (B) and 
KLRG1 (C) on CD8 effector T cells, gated as B220-NK1.1-CD4-. Representative 
histograms for the different genotypes are shown. Scatter plot graphs represent the 
percentage of CD44 and KLRG1 positive cells among the CD8+ population for each 
mouse. (n=2 independent experiments). 
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Figure 7.9A and B shows a similar recruitment of CD8 T cells and similar frequency of 
pentamer positive CD8 T cells in the liver of Listeria infected WT versus ARNTfl/fl X 
CD4Cre+/- mice. Hence ARNT-null T cells can clonally expand in vivo and differentiate 
into interferon gamma producing effector cells.  
 
 
 
Figure 7.9 A similar recruitment of CD8 T cells and similar frequency of pentamer 
positive CD8 T cells in the liver of listeria infected WT versus ARNTfl/fl X CD4Cre+/- 
mice.  
 
7 days post-infection with Listeria monocytogenes (ΔactA rLMOVA strain), 
lymphocytes were isolated from livers of ARNTfl/fl WT and ARNTfl/fl X CD4Cre+/-  (KO) 
mice. (A) Representative flow cytometry plots show the presence of CD8 effector cells 
in each genotype (gated as CD45+B220-NK1.1-CD4- and CD8+Pentamer+). (B) 
Graphs represent the percentage of CD8 T cells in the livers and the percentage of 
CD8+Pentamer+ cells among the B220-NK1.1-CD4- population for each mouse as a 
scatter plot (2 independent experiments). 
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In further experiments we tested the ability of ARNTfl/fl X CD4Cre+/- (KO) mice to 
generate a memory immune response following Listeria infection. Accordingly, 
ARNTfl/fl X CD4Cre+/- (KO) and ARNTfl/fl (WT) mice were immunized with Listeria 
bacterium for primary immunization and re-challenged 30 days later i.v for a secondary 
immunization. On day 7, post the secondary immunization, cells from spleens, livers 
and bone marrow were analysed by flow cytometry. The results showed that ARNTfl/fl X 
CD4Cre+/- mice did not exhibit a defect in their recall response to Listeria when 
compared to WT mice. They had comparable CD8+ T cell numbers in the spleen 
(Figure 7.10A), similar percentages of SIINFEKL pentamer positive CD8+ T cells 
(Figure 7.10B) and an equal ability of IFN-γ production by the secondary effectors 
(Figure 7.10C). It is worth to note that this experiment measures the secondary response 
to the challenge since in the primary challenge, approximately 6% of the CD8 T cells 
are SIINFEKL-specific in comparison to around 20-30% after the secondary response, 
which shows that there must have been a massive clonal expansion as occurs during 
memory response.  
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Figure 7.10 ARNT deficient CD8 T display a comparable memory response after a 
secondary challenge with Listeria monocytogenes to that of ARNT WT CD8 T cells. 
ARNTfl/fl X CD4Cre+/- (KO) and ARNTfl/fl (WT) mice were immunized with Listeria 
monocytogenes and challenged 30 days later with a second immunization. 7 days after 
the second immunization, splenocytes were isolated and analyzed by flow cytometry to 
identify CD8 effector T cells (gated as B220-NK1.1- CD4- and CD8+Pentamer+). 
Uninfected mice were used as negative controls. (A) Graph shows the number of CD8+ 
splenic T cells for the different genotypes. (B) Graph shows the percentage of 
Pentamer+ cells among the B220-NK1.1-CD4- for each mouse. (Data from 1 
experiment). (C) Data show IFN- γ cytokine production 7 days after secondary 
challenge. Splenocytes were re-stimulated with SIINFEKL peptide in presence of 
Brefeldin A for 5 hours, and IFN-γ production was determined by intracellular staining. 
Graph represents the percentage of IFN-γ producing cells among B220-NK1.1-CD4- 
population cells for each mouse (n=4 mice in 1 experiment). 
 
!"
"
#"
"
$"
"
 208 
7.2.5 Loss of ARNT/Hif-1α  function results in altered transcriptional program in 
CTLs. 
One question we wished to address was whether the role of ARNT in immune activated 
CD8 T cells was limited to control of Glut1 expression? These following results 
describe a whole genome transcriptional profiling of ARNT-null CD8 T cells performed 
using an Affimetrix microarray analysis. In brief: microarray technology records the 
expression levels of thousands of genes in parallel. The Affymetrix system uses 
millions of oligonucleotide probes, each designed to hybridise to a particular part of a 
transcript. This creates a microarray library of probe sets complimentary to all known 
transcripts. Analysed RNA samples are fragmented, labeled with a fluorescent tag and 
presented to the microarray libraries. Wherever there is a complementary probe 
sequence on the chip, the RNA can hybridise to it. When a laser scans the array, the 
tagged fragments glow, producing spots with brightness proportional to the amount of 
RNA that has hybridised. Then, the array image is recorded by a camera and processed 
to produce expression levels for the different genes. The end product is a list of probe 
sets with associated gene mRNA/names and signal strengths, along with a statistical 
score of how different the various experimental samples are from each other relatively 
to a particular probeset.  
In this microarray we compared two cell populations: ARNTfl/fl X CD4Cre+/- (KO) and 
ARNTfl/fl (WT) CTLs. For each cell population we used three biological replicates, i.e 
effector cytotoxic T cells were generated from three different mice. Following 
validation of T-cell specific ARNT deletion by western blot and validation of the 
glycolytic defect in the KO cells, mRNA was extracted from each of the ARNT KO and 
WT CTLs samples. Subsequently, Affimetrix microarray was performed in the Turku 
Centre for Biotechnology, Finland by Eveliina Vertanen. Initial output of the chip 
microarray results is intensity levels for each probe set in three replicates. In order to 
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translate intensity levels to expression levels a further calculation and normalization 
across the array are required. Dr. Carmen Feijoo - Carnero in the lab performed these 
calculations using MAS 5.0 and RMA algorithms. By processing the initial array results 
using those two algorithms, it was possible to measure a true signal versus a 
background noise and to perform quantile normalization of the data.  
 
Total number of 45000 probes were analysed, which correspond to approximately 
34000 genes. In at least one of the six microarrays, among the 45000 probes, 20669 
probe sets, corresponding to 11517 genes were selected by MAS 5.0. Only the genes 
that showed a significant change between ARNTfl/fl (WT) and ARNTfl/fl X CD4Cre+/- 
(KO) samples of at least 1.5 fold were selected for further analysis. From the 11517 
genes expressed by MAS 5.0, 899 genes were selected as significantly changed; 502 
genes were significantly upregulated and 397 genes were significantly downregulated in 
the ARNT/Hif-1α KO versus ARNT/Hif-1α WT CTLs.  
 
7.2.6 Microarray analysis of ARNT-null CTLs reveals that ARNT controls 
glycolysis, the expression of cytolytic effectors and chemokine receptors. 
Using DAVID bioinformatics Resources and KEGG pathways analysis programs, three 
groups of significantly changed genes belonging to three main biological pathways in T 
cells were identified (Table 7.1). The groups of significantly down-regulated genes 
included: cluster of genes taking part in glycolysis and pyruvate metabolism processes 
and a group of cytolytic genes participating in the cytotoxicity effector functions of 
CTLs. A third group included genes whose expression was increased in ARNT-null 
CD8 T cells and comprised of some of the cytolytic molecules and chemokine receptors 
and adhesion molecules that control T cell entry and exit from secondary lymphoid 
tissues (Sinclair et al., 2008). 
 210 
 
Table 7.1 KEGG pathway analysis identifying three groups of genes that were 
significantly changed in ARNT-null CTL 
 
 
 
Figure 7.11 represents a heatmap of glycolytic enzymes identified by the array chip and 
which were significantly downregulated following the loss of Hif-1α function. Among 
them, several key rate-limiting enzymes of the glycolysis process; 6-
phosphofruktokinase (PFK-1), aldolase A and hexokinase. Another important rate-
limiting glycolytic enzyme was identified, as significantly downregulated in the array 
was the pyruvate kinase M2 (PKM2) isoform.  
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Figure 7.11 ARNT/Hif-1α complex in CTLs is required for the expression of a battery 
of genes participating in glycolysis. 
 
A comparison of the transcriptional profile of ARNT-WT versus ARNT-null CTLs was 
performed by microarray analysis. A heat map showing the relative normalized 
expression of selected glycolytic genes identified by the KEGG analysis pathway and 
found as significantly decreased following ARNT deletion. Fold change of each of the 
genes is represented. (Red-high expression, blue-low expression). 
 
Apart from the glycolytic enzymes KEGG pathway analysis of the microarray data 
identified a group of genes belonging to the group of cytolytic molecules whose 
expression was downregulated in ARNT-null immune activated CD8T cells (Figure 
7.12) The most significantly downregulated genes in the ARNT null activated CD8 T 
cells included perforin and several granzyme isoforms (Figure 7.12). There were also 
cytolytic molecules such as Lymphotoxin A and FasL that were upregulated following 
ARNT deletion (heatmap in Figure 7.12).  
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Figure 7.12 ARNT/Hif-1α complex is required for the expression of cytolytic molecules 
in CTLs.  
 
A comparison of the transcriptional profile of ARNT-WT versus ARNT-null CTLs was 
performed by microarray analysis. A heat map showing the relative normalized 
expression of selected cytolytic effector molecules changing following ARNT deletion 
and identified by the KEGG pathway analysis. Fold change of each of the genes is 
represented. 
 
Using RT PCR and western blot analysis we validated some of the array data: 
ARNT/Hif-1α KO CTLs thus had dramatically reduced levels of both mRNA and 
protein expression of perforin (Figure 7.13A and B, respectively). Microarray data 
showed reduction in granzymes D, E, F and G genes and using Flow cytometry we also 
detected a reduction in the expression of granzyme B in ARNT-null CTLs (Figure 
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7.13C). Therefore, the ARNT transcription factor is crucial for the expression of 
perforin and granzymes.  
 
 
Figure 7.13 ARNT/Hif-1α complex is required for the expression of perforin and 
granzyme B in CTLs.  
 
(A) qRT PCR analysis of perforin mRNA expression in ARNTfl/fl (WT) and ARNTfl/fl X 
CD4Cre+/- (KO) CTLs. (Data is mean +/- SEM of 3 experiments, mRNA levels were 
normalised to HPRT expression). (B) Western blot analysis with perforin antibody of 
ARNTfl/fl X CD4Cre+/- (KO) and ARNT WT CTLs. Probing with SmCI was used to 
control equal loading (n>3) (C) Histograms showing Flow cytometric intracellular 
assessment of Granzyme B expression in ARNT WT and ARNTfl/fl X CD4Cre+/- (KO) 
CTLs. CD8 T cells cultured in presence of IL-15 were used as a negative control (n=3). 
 
 
To test further whether it is ARNT/Hif-1α complex that controls expression of perforin, 
we decided to study the effect of hypoxia on the expression of perforin in CTLs. The 
rationale behind this experiment is that under hypoxic conditions Hif-1α is stabilized 
and ARNT/Hif-1α complex is more active, thus driving more transcription of the 
perforin gene. In fact, it is published that under hypoxic conditions Glut1 mRNA levels 
are increased since Hif-1α binds to hypoxia responsive elements (HRE) in the Glut1 
promoter and transactivates its gene transcription (Zheng et al., 2008). Is it also the case 
for perforin? Although perforin mRNA levels do not change under hypoxic condition 
(not shown), exposing CTLs to hypoxic condition for 24 hours led to increase in the 
expression of both Glut1 and perforin protein levels (Figure 7.14A and B). This result 
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suggests that the ARNT/Hif-1α complex positively regulates expression of both Glut1 
and perforin.  
Hif-1α directly controls Glut1 expression but we could not detect Hif-1α binding sites 
in the proximal perforin promoter (ChIP data not shown). In this regard, we considered 
that the loss of perforin expression might be an indirect consequence of failed glucose 
uptake. Here it is relevant that previous studies have shown that glucose deprivation 
prevents perforin expression in immune activated CD8+ T cells (Cham et al., 2008). 
Data in figure 7.14C confirm this and show that cells maintained in 2mM and 0.5mM 
glucose express much lower levels of perforin compared to the control cells maintained 
in 10mM glucose.  
 
 
Figure 7.14 ARNT/Hif-1α mediates increase in perforin expression in CTLs under 
hypoxia and CTLs maintained under low glucose levels decrease perforin expression. 
 
(A,B) IL-2 maintained P14-LCMV CTLs were exposed to either hypoxic (1%) or 
normoxic (21%) oxygen for 24 hours before being subjected to Western blot analysis 
for (A) Glut1 and (B) Hif-1α and perforin expression. Data is representative of 3 
experiments. (C) P14-LCMV T cells were activated for 2 days with cognate gp33-41 
peptide and then cultured for a further 4 days with IL-2 in the indicated glucose 
concentrations. Cells were then subjected to Western blot analysis with perforin 
antibody. Probing with SmCI was used to control equal loading. (Data is representative 
of 2 experiments). 
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IFN-γ is another important cytokine produced by mature CTLs. However, IFN-γ 
expression was unaffected in ARNT/Hif-1α deficient CTLs as judged from the array 
results and RT PCR analysis (Figure 7.15A).  
Effector T cell differentiation is controlled by the balance of expression of the 
transcription factors, Eomesodermin and T-bet. We therefore considered whether 
decreases in the expression of these transcription factors explained the impact of ARNT 
deletion on CD8 T cells.  Our microarray data showed a significant 3.4 fold increase in 
T-bet mRNA expression in ARNTfl/fl X CD4Cre+/- (KO) CTLs versus ARNTfl/fl (WT) and 
no change in Eomesodermin. The T-bet result was validated by both RT QPCR (Figure 
7.15B) and by western blot (Figure 7.15C).  
 
 
Figure 7.15 Confirmation of changes in gene expression detected by microarray 
analysis in ARNTfl/fl (WT) and ARNTfl/fl X CD4Cre+/- (KO) CTLs using qRT PCR 
analysis of IFN-γ and T-bet and Western blot analysis of T-bet. 
  
(A) qRT PCR analysis of IFN-γ mRNA and (B) T-bet mRNA expression in IL-2 
maintained mature ARNTfl/fl (WT) and ARNTfl/fl X CD4Cre+/- (KO) CTLs. (mRNA 
levels were normalised to HPRT expression and data represents results of n=3 
experiments). (C) Western blot with T-bet and SmCI antibodies of ARNTfl/fl X 
CD4Cre+/- (KO) and ARNTfl/fl (WT) CTLs. (n=4 experiments). 
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7.2.7 The role of mTORc1 ARNT/Hif-1α  axis in regulating migration of CTLs. 
One unexpected outcome from the microarray experiment came from the bioinformatic 
pathway analysis of the genes whose expression was upregulated in ARNT-null T cells. 
This indicated that loss of Hif-1α transcriptional complexes up-regulated the expression 
of genes involved in cytokine/cytokine receptor interactions (Table 3). Closer 
interrogation of the data revealed that the Hif-1α regulated genes identified in the 
cytokine/cytokine receptor pathway analysis were genes encoding chemokines, 
chemokine receptors and adhesion molecules. For example, loss of ARNT/Hif-1α 
transcriptional complexes increased expression of mRNA encoding the chemokine 
receptors S1P1, CXCR4, CXCR3, CCR5 and CCR7 in immune activated CTL (Figure 
7.16).  
 
 
Figure 7.16 ARNT regulates expression of chemokine receptors in CTLs. 
 
Heat map showing the relative normalized expression of selected chemokines, 
chemokine receptors and adhesion molecules changing in expression following ARNT 
deletion in CTLs. 
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Some of these upregulated genes including CCR7, CXCR3 and S1P1 were confirmed by 
RT PCR analysis (Figure 7.17A). Moreover, the expression of the gene encoding the 
cell adhesion molecule CD62L (L-selectin) was increased in ARNT-null CTLs 
(Fig.7.17B). Immune activated CD8 T cells down-regulate CD62L gene transcription 
and hence CTL normally express low levels of this adhesion molecule (Sinclair et al., 
2008). In contrast, there were high levels of CD62L mRNA and protein in activated 
ARNT-null CD8 T cells (Figure 7.17B and C). CCR7 is a chemokine receptor that 
coordinates the migration of T cells into lymph nodes and is normally down-regulated 
in CTLs (Sinclair et al., 2008). PCR analysis confirmed the microarray data: immune 
activated ARNTfl/fl X CD4Cre+/- T cells retain high levels of CCR7 mRNA compared to 
WT CTL (Figure 7.17A). 
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Figure 7.17 Loss of transcriptional ARNT/Hif-1α transcriptional complexes in CTLs 
upregulates the expression of several adhesion molecules and chemokine receptors 
genes.  
 
(A) qRT PCR analysis of CCR7, S1P1, CXCR3 and (B) CD62L mRNA in ARNTfl/fl 
(WT) and ARNTfl/fl X CD4Cre+/- (KO) CTLs. (Data is mean +/- SEM of 3 experiments, 
mRNA levels were normalised to HPRT expression). (C) Overlay histogram showing 
surface expression of CD62L in ARNT (WT) and ARNTfl/fl (KO) CTLs measured by 
Flow cytometry (n>10). 
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CD62L and CCR7 are expressed at high levels in naive and memory T cells and are 
essential for lymphocyte transmigration from the blood into secondary lymphoid tissue.  
CD62L and CCR7 loss is thus part of the program that redirects effector T cell 
trafficking away from lymphoid tissue toward sites of inflammation. In this respect, we 
have shown previously that inhibition of mTORc1 with rapamycin can restore 
expression of CD62L and CCR7 on effector T cells and reprogram their trafficking such 
that they regain the ability to home to secondary lymphoid organs (Sinclair et al., 2008).   
The retention of CD62L and CCR7 expression on immune activated ARNT-null CD8 T 
cells thus raises the possibility that these cells may retain the migratory properties of 
naïve T cells and preferentially home to secondary lymphoid tissues. However, ARNT- 
null CD8 T cells not only retained expression of the secondary lymphoid organ homing 
receptors but also increased expression of inflammatory chemokine receptors such as 
CXCR3 and CCR5 (Figure 7.16 and 7.17A). These pleotropic effects make it more 
difficult to predict the impact of ARNT/Hif-1α loss on T cell trafficking in vivo. 
Accordingly, the in vivo lymph node homing ability of control or ARNT deficient 
effector CD8 T cells was compared. Strikingly, activated CD8 T cells that lack ARNT-
mediated transcription retained the capacity to home to secondary lymphoid organs and 
accumulated in the lymph nodes and spleens (Figure 7.18A and B).  
Therefore, despite the ability of ARNT/Hif-1α transcriptional complexes to negatively 
regulate expression of multiple chemokine receptors, there is a dominant requirement 
for ARNT/Hif-1α transcriptional complexes for the normal programming of effector 
CD8 T cell trafficking. 
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Is Hif-1α regulation of CD62L gene expression direct or is the impact of ARNT/Hif-1α 
on CD62L expression an indirect consequence of the reduced ability of ARNT-null 
cells to maintain glucose uptake? The experiment in figure 7.18C addresses this issue 
and shows that CD8 T cells stimulated by antigen and IL-2 in culture media with low 
glucose levels fail to down-regulate CD62L expression.  
 
 
 
Figure 7.18 Immune activated ARNTfl/fl X CD4Cre+/- (KO) CTLs retain the migratory 
properties of naïve T cells and preferentially home to secondary lymphoid tissues.  
 
ARNT-WT and ARNT-null CTLs were labeled with CFSE or Cell tracker orange 
(CMTMR) and mixed at a ratio of 1:1 before being injected into C57/BL6 host mice. 
Values indicate recovery of ARNT WT or ARNT-null cells as a percentage of the total 
recovered transferred cells from the (A) lymph nodes and (B) spleens 4 hours after 
transfer. (Each dot indicates a mouse; horizontal bars indicate mean. n=10 mice per 
genotype). (C) CD62L expression is affected by glucose levels in culture.P14-LCMV T 
cells were activated for 2 days with cognate peptide and then cultured for a further 4 
days with IL-2 in different glucose concentrations (10mM, 2mM and 0.5mM). Cells 
were then analysed for the surface expression of CD62L by flow cytometry (n=3) (**, 
p<0.01). 
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7.2.8 PI3K and PKB independent control of mTORc1 activity and Hif-1α  
expression in CD8 T cells. 
The data described in the previous section showed that inhibition of mTORc1 with 
rapamycin causes loss of Hif-1α expression and that Hif-1α complex activity is 
necessary for activated T cells to down-regulate expression of CD62L, CCR7 and S1P1 
adhesion molecules and chemokine receptors. The insight that ARNT/Hif-1α 
transcription factor complexes mediate mTORc1 control of the expression of key T cell 
trafficking molecules raises a question. How does the mTORc1/Hif-1α pathway that 
controls T cell trafficking connect to a well-documented PI3K/PKB/Foxo pathway that 
also controls expression of these key trafficking molecules? The retention of high levels 
of CCR7 and CD62L expression by immune activated ARNT-null CD8 T cells thus 
phenocopies the impact of inhibiting PI3K/PKB signaling in activated CD8 T cells 
(Sinclair et al., 2008; Waugh et al., 2009; Macintyre et al., 2011). It has been shown 
previously that CD62L and CCR7 expression in T cells is regulated by the Foxo1 
transcription factor (Fabre et al., 2008; Kerdiles et al., 2009). Foxo1 is inactivated by 
PKB, which phosphorylates Foxo1 resulting in its nuclear exclusion and retention in the 
cytosol. PKB inhibition results in de-phosphorylation of Foxo1 and restores its nuclear 
location, transcriptional activity thus leading to induction in the expression of CD62L 
and CCR7 in CTLs (Waugh et al., 2009; Macintyre et al., 2011).  
 
The key question is thus whether mTORc1 and/or expression of Hif-1α complexes 
regulate PKB activity and Foxo phosphorylation in T cells? 
In this respect, David Finlay showed that unlike PI3K/PKB inhibition in CTLs, 
mTORc1 inhibition by rapamycin does not affect the phosphorylation of Foxo1/3a 
(Figure 7.19A) or their translocation from the cytoplasm to the nucleus (Figure 7.19B): 
Foxos remained highly phosphorylated and excluded from the nucleus of rapamycin 
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treated CTLs. We also show that Foxo phosphorylation is normal in the ARNT-null 
CTL (Figure 7.19C). Here it should be noted that Foxos regulate CD62L expression 
indirectly by controlling expression of KLF2. The microarray analysis did not pick up 
KLF2 as an ARNT regulated gene. Moreover, the data show that KLF2 mRNA 
expression was comparable in ARNTfl/fl X CD4Cre+/- (KO) and WT CD8 T cells (Figure 
7.19D). It is also critical that, in contrast to mTORc1 inhibition by rapamycin, 
inhibition of PI3K and PKB pathways did not downregulate Hif-1α expression (Figure 
7.19E). Collectively, those results suggest that mTORc1/Hif-1α axis and PI3K/PKB 
pathway are two distinct and independent mechanisms that regulate CD62L and CCR7 
expression, thus regulating T cell migration.  
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Figure 7.19 PI3K and PKB independent control of mTORc1 activity and Hif-1α 
expression in CD8 T cells.  
 
(A) Western blot analysis with pPKB (S473), pFoxo1/3a (T24/T36) and pan PKB 
antibodies of P14-LCMV CTLs treated with and without PKBi1/2 and rapamycin for 24 
hours. Probing with PKB confirms equal loading (B) P14-LCMV CTL were treated 
with and without rapamcyin and PKBi1/2 for 24 hours and subjected to 
nuclear/cytoplasmic fractionation. Western blot analysis with Foxo1 and Foxo3a 
antibodies shows Foxo1 and Foxo3a subcellular expression. Purity of cytoplasmic and 
nuclear fractions was confirmed by IκBα and SmC1 expression. (C) Western blot 
analysis of ARNTfl/fl (WT) and ARNTfl/fl X CD4Cre+/- (KO) with pPKB (T308), 
pFoxo1/3a (T24/T36), pS6K (T371), p4EBP1 (S65) and pS6 (T235/6) antibodies, 
measuring PKB/Foxo and mTORc1 signaling. ARNT-null CTLs were treated with 
rapamycin as a negative control for mTORc1 activity. For all panels, data is 
representative of at least 3 experiments. (D) qRT PCR analysis of KLF2 mRNA 
expression in ARNT-WT and ARNT-null CTLs. (E) P14-LCMV CTLs were cultured in 
the presence or absence of Akti1/2, IC87114, or rapamycin for 24 hours and subjected 
to Western blot analysis using Hif-1α, PKB, pPKB (Ser 473), pS6, pS6K (Thr 389) and 
SmCI antibodies measuring the impact of mTORc1 and PKB/PI3K activity on Hif-1α 
expression.   
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7.3 Discussion 
Naïve CD8+ T cell differentiate into effector and memory cytotoxic T cells (CTLs) 
following recognition of a specific antigen presented by MHC class I molecules on the 
surface of cells infected with viruses or bacterial pathogens (Germain, 1994).  
Upon engagement with antigen, activated CD8+ T cells expand rapidly and either 
directly kill the infected target cells (Milstein et al., 2011) or produce cytokines and 
chemokines, including IFN-γ and TNF that recruit other immune cells. The execution of 
these effector functions is associated with a dramatic increase in bioenergetic and 
biosynthetic demands in parallel to differentiation of CD8 T cells into effector cytotoxic 
T cells. In order to meet these biosynthetic demands, antigen activated CD8+ T cells 
induce the expression of glucose transporters and a subsequent glucose uptake, which 
they also need to be able to sustain. In this chapter the ability of mTORc1 to induce 
glycolysis following TCR stimulation was demonstrated. We have also shown that IL-2 
regulated mTORc1 activity is required to sustain glycolysis in mature CTLs. 
However, the main objectives were to explore 1. the mechanism of mTORc1- 
dependent regulation of glycolysis during differentiation and 2. to investigate whether 
mTORc1 pathway is the link that co-ordinates sustainable glycolysis and differentiation 
of CD8 to mature effector CTLs.  
The novel finding in context of mechanism was that IL-2-dependent mTORc1 activity 
sustains glucose uptake and glycolysis through the induction of Hif-1α transcription 
factor complex. In fact, mTORc1-regulated Hif-1α complex controlled the expression 
of glucose transporter, Glut1 and the expression of several key glycolytic enzymes such 
as phosphofructokinase 1, lactate dehydrogenase and Pyruvate kinase M2 in effector 
CD8 T cells. Therefore ablation of Hif-1α activity in IL-2 maintained CTLs either by 
inhibiting mTORc1 or by genetic deletion of its binding partner ARNT, which is 
essential for Hif-1α function, resulted in a consequent decrease in glucose uptake and 
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glycolysis.  
Recently, an interesting cross talk between Hif-1α and PKM2 pyruvate kinase which is 
one of the genes that were downregulated upon the loss of Hif-1α activity has been 
described (Luo et al., 2011). It was found that PKM2, enzyme that catalyzes the final 
step in glycolysis was induced by Hif-1α. On the other hand, it also served as a co-
activator of Hif-1α. It was further demonstrated that by its interaction with Hif-1α, 
PKM2 promoted Hif-1α binding to the hypoxia responsive elements (HRE) thus 
enhancing transactivation of Hif-1α target genes, mainly the proglycolytic genes 
including LDHA and SLC2A1 (Glut1 transporter).  
The results of this study proposed that PKM2 promotes a shift toward anaerobic 
metabolism by inducing genes that are involved in glycolysis. This cross talk between 
PKM2 and Hif-1α is particularly interesting since this glycolytic enzyme was recently 
identified to operate also as a protein kinase in tumors (Gao et al., 2012). It was shown 
that in its dimeric form, PKM2 can translocate to the nucleus and phosphorylate STAT3 
on tyrosine 705, whereas activation of STAT3 represents probably one of the most 
important molecular signatures involved in promoting cancer progression (Frank, 2007; 
Groner et al., 2008). Moreover, in response to growth factors STAT3 was shown to 
induce Hif-1α whereas targeting STAT3 with a small-molecule inhibitor blocked Hif-
1α and VEGF expression in vitro and inhibited tumor growth and angiogenesis in vivo 
(Xu et al., 2005).  
Collectively, these findings demonstrate the complexity of the Hif-1α/STAT3/PKM2 
network and explain how Hif-1α mediated PKM2 functions promote tumor and cell 
proliferation (Sun et al., 2011). In light of the fact that CTLs share the “Warburg effect” 
phenomenon with cancer cells, it would be of a great interest to investigate the role of 
Hif-1α/PKM2 cross talk in the aerobic glycolysis and proliferation in CTLs. 
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Moreover, our data demonstrated lower Glut1 expression and glycolysis in CD8 T cells 
maintained with IL-15 in comparison to IL-2 maintained CTLs, which correlated with 
lower Hif-1α expression in IL-15 cultured CD8 T cells. This observation suggested that 
a magnitude and sustainability of mTORc1 activity that is differentially driven by 
various γ chain cytokines (Cornish, 2006) thus dictates the level of Hif-1α expression 
and subsequently the level of glucose uptake and glycolysis in CD8 T cells.  
The question that remained unanswered is whether Hif-1α could also explain how 
mTORc1 operates to induce glucose uptake following TCR stimulation. This is relevant 
since it has been shown recently that another transcription factor, c-myc is required for 
the initial TCR-induced glycolytic switch in naïve T cells (Wang et al., 2011). However, 
in our hands although mTORc1 inhibition in antigen activated CD8 T cells resulted in 
decreased glycolysis, it did not affect c-myc expression. Furthermore, myc expression 
did not change in ARNT/Hif-1α deficient TCR-activated CD8 T, which displayed lower 
glycolysis. The present data thus reveal that c-myc expression alone is not sufficient to 
maintain glucose uptake and glycolysis in CD8 T cells. Moreover the co-ordination of 
c-myc and Hif-1α expression must be required for T cells to sustain glucose uptake and 
glycolysis during CD8 T cell differentiation.  
A surprising lesson we learnt from ARNT/Hif-1α deficient CTLs was that CD8+ T cells 
could proliferate normally even with half the amount of glucose uptake in comparison 
to the WT controls. On one hand, this result challenges the common dogma arguing that 
glycolysis is absolutely central to T cell proliferation and on the other hand it raises 
additional intriguing questions: If not for proliferation, are there any other CTL 
functions for which ARNT/Hif-1α linking mTORc1 and metabolism would be crucial? 
And also, what signals link ARNT/Hif-1α complexes to the regulation of glucose 
metabolism in CTLs?  
In particular, it is well documented that mTORc1 activity is required for expression of 
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CTL effector molecules. Our data showed that ARNT deficient CTLs lacked perforin 
and granzyme expression, which correlates with the downregulation of perforin 
expression in rapamycin treated CTLs.  
Although in response to Listeria monocytogenes infection model ARNTfl/fl X CD4Cre+/- 
(KO) CD8 T cells proliferated normally and produced IFN-γ similarly to the ARNTfl/fl 
(WT) mice, the clearance of the bug was not measured due to technical issues related to 
the usage of attenuated Listeria strain (ΔactA rmLOVA) in the experiments. Therefore, 
we cannot exclude the possibility that the lack of perforin impaired the ability ARNT-
null mice to clear Listeria infection.  
Moreover, analysis of single perforin KO shows that perforin-dependent cytolysis 
participates in, but is not absolutely essential for CD8+ T cell immunity to Listeria 
(Messingham et al., 2003). Hence, in order to test the impact of perforin deficiency on 
the immune function of ARNT-null CTLs, we need to choose a different in vivo model 
in which perforin was proven to be crucial. A good alternative would be an LCMV 
infection model since perforin KO mice infected with lymphocytic choriomeningitis 
virus (LCMV) could not mount a viral defense and died (Walsh et al., 1994; Kägi et al., 
1994b). Unfortunately, we could not test our mice with LCMV because of restrictions 
in our animal facility.  
In addition, several works proposed a role for perforin in regulating memory formation 
after infection. For instance, studies by Binder et al. and Matloubian et al. showed that 
perforin is involved in the expansion and then a contraction of CD8+ T cells after 
LCMV infection (Binder et al., 1998; Matloubian et al., 1999). These studies showed 
that in the absence of perforin activation-induced cell death during clonal expansion 
was downregulated, thus leading to increased memory formation. Those conclusions 
were supported by an additional study which using Listeria monocytogenes - a pathogen 
that is cleared, in part, by a perforin-dependent pathway - indicated that perforin dictates 
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T-cell memory by controlling the clonal expansion of CD8+ T cells in response to 
antigen (Badovinac et al., 2000). Data published in these works motivated us to test 
ARNT-null CTLs in memory responses after Listeria infection. Yet again, the fault in 
the experiment that we designed was that we looked at the memory responses at day 7 
after secondary challenge, which is not the peak of the memory response that occurs 
much faster. Therefore, we cannot conclude how well ARNT-null CD8 T cells mount 
memory responses and further experiments are required.   
 
Apart from regulating the expression of glycolytic enzymes and cytolytic effector 
molecules, a striking finding was that ARNT/Hif-1α complex also regulates the 
expression of several key lymph node homing receptors and adhesion molecules 
including CD62L, S1P1 and CCR7; these latter are a feature of naïve and memory T 
cells, whereas downregulation of these receptors is part of the differentiation program of 
mature effector CTLs. Strikingly, in the absence of ARNT, those receptors were 
retained on the surface of effector T cells and affected their ability to switch their 
trafficking program to that of an effector cell.  
Previous work in our lab, demonstrated that active mTORc1 switched off expression of 
CD62L, CCR7 and S1P1 chemokine receptors and adhesion molecules in effector CD8+ 
T cells, whereas its inhibition by rapamycin retained expression of those molecules and 
altered trafficking properties of CTLs in vivo (Sinclair et al., 2008). The fact that Hif-1α 
expression is controlled by mTORc1 and that mTORc1 inhibition and loss of ARNT 
have a similar affect on CTL trafficking program, support the idea that Hif-1α links 
mTORc1 to the control of metabolism and T cell differentiation. It is worthy to note that 
mTORc1/Hif-1α axis probably does not act as a direct transcriptional repressor of the 
lymph node homing receptors, but it rather functions as a sensor of decreased glycolysis 
in ARNT-null CTLs. This observation demonstrates that effector T cells can use 
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mTORc1 in order to integrate extrinsic metabolic cues in their environment and their 
migration patterns, thus determining the course of the immune response. 
How does this mTORc1/Hif-1α pathway coordinate with other signaling pathways that 
control CD8 T-cell differentiation? Biochemical work demonstrated that PDK1 kinase 
and not PI3K/PKB exclusively mediated regulation of the mTORc1/Hif-1α axis. This 
was a novel result since PKB/PI3K/Foxo mediated pathway is a well-studied and 
verified pathway that controls CD8+ T cell migration. Present study showed that 
mTORc1/Hif-1α operated independently of PKB and did not involve Foxos, thus 
defining a separate additional pathway controlling T cell migration.  
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Chapter 8 Final Discussion 
The work presented in this thesis explores the expression and function of the Aryl 
Hydrocarbon Receptor (AhR) and AhR nuclear translocator (ARNT) transcription 
factors in T cells. An important observation was that only activated but not naïve T cells 
express AhR and ARNT. We also produced a mouse model that would report functional 
AhR activity at the single cell level. For this model we backcrossed CYP1A1Cre+/- mice 
to R26REYFP mice that have a knock-in of a gene encoding EYFP into the ubiquitously 
expressed Rosa26 locus preceded by a loxP flanked stop sequence. If cells express 
active AhR/ARNT complexes they will express Cre recombinase and delete this loxP 
flanked stop codon and hence begin to express YFP. The expression of YFP in cells 
isolated from the CYP1A1Cre+/-XR26REYFP reporter mice is thus a marker that a cell has 
activated AhR signaling. Experiments in vitro that looked at how this reporter model 
functioned during CD4 T cell differentiation to Th17 cells indicated that this a 
reasonably effective reporter for functional AhRs. If a cell expresses an AhR and there 
are sufficient AhR ligands then cells will express YFP. It was particularly clear in the 
Th17 differentiation experiments in chapter 4 that the availability of endogenous AhR 
ligands present in the culture medium is rate limiting for expression of the AhR 
reporter.   
Analysis of thymocytes and T cells in peripheral lymphoid organs using the reporter 
model showed no evidence for active AhR signaling during embryonic development of 
lymphocytes. This result, together with the AhR expression data, clearly demonstrated 
that unless T cells are Ag stimulated in the presence of proinflamatory cytokines, they 
would not express the AhR and thus will not be able to respond to its ligands. We did 
observe that small percentage of TCRαβ+CD8αα+, CD4+, CD8+ and γδ T cells in 
epithelial and the lamina propria layers in the gut expressed the YFP reporter. In this 
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context, it will be interesting to explore why only a small fraction of the gut CD45+ 
immune cells is marked by this fate reporter. Is it because only a small subset of gut-
lymphocytes expresses the AhR and/or ARNT? Are endogenous AhR ligands limiting 
in the gut? To address this question we intend to probe AhR expression in sorted YFP+ 
TCRβ+ and YFP- TCRβ+ gut IELs ex vivo. In addition, we aim to inject reporter mice 
with an exogenous AhR ligand, 3-MC, in order to examine whether an exogenous 
ligand would increase the proportion of gut cells that express functional AhRs.   
Another issue that requires a further investigation is whether the CYP1A1Cre+/- X 
R26REYFP reporter mice can mark innate lymphoid Rorγt-expressing cells (ILCs) in the 
lamina propria. Recent studies point out that AhR expression is essential for the survival 
of Rorγt+ ILCs and propose that the interactions between AhR and Rorγt is crucial 
(Kiss et al., 2011; Lee et al., 2012). Using the reporter model, we will able to examine 
whether each Rorγt+ cell in the gut also expresses a functional AhR/ARNT complex 
and is responding to AhR ligands. This can be done by intracellular staining and flow-
cytometric analysis of Rorγt expression in CD45+YFP+ cells versus CD45+YFP- cells 
using this reporter.  
 
In the second part of the project, we investigated how much of the AhR function in T 
cells is ARNT-dependent, by generating mice that lack ARNT in αβ T cells. ARNT 
deficiency resulted in impaired Th17 differentiation in vitro and a significant reduction 
in a CD8αα IEL populationin the gut. The phenotype of reduced production of IL-17 
and IL-22 cytokines in ARNT KO CD4 T cells differentiated under Th17 conditions 
could be an outcome of (a) decreased activity of AhR/ARNT complex, (b) reduced Hif-
1α/ARNT function, which is involved in Th17 differentiation and glycolysis, or (c) 
impairment of the function of both complexes (Dang et al., 2011; Shi et al., 2011). 
Interestingly, although both Hif-1α and AhR pathways were affected, as judged by 
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decrease in the expression of their target genes, Glut1 and CYP1A1, respectively, 
ARNT-null CD4 T cells could still produce some IL-17, whereas IL-22 production was 
completely abolished. Therefore, the question is whether there is an additive or 
redundant contribution of each of these pathways for Th17 differentiation.  
To answer this question one will need to distinguish between Hif-1α/ARNT and 
AhR/ARNT pathways in Th17 cells. For this purpose, the ideal experiment will be a 
Chip-seq (chromatin immunoprecipitation and massive parallel sequencing) analysis of 
ARNT, AhR and Hif-1α in Th17 cells. This type of analysis will help to define and 
compare between the genome-wide specific AhR, Hif-1α and ARNT target genes in 
CD4 effectors.  
Another experimental strategy that can assist in obtaining a more detailed picture with 
respect to the AhR-regulated genes in Th17 cells is an Affymetrix microarray analysis. 
Using the CYP1A1Cre+/- X R26REYFP reporter mouse, we can perform the array on sorted 
Th17 cells with a functional AhR (YFP-positive cells that produce IL-17 versus the 
YFP-negative Th17) following treatment of cells with agonist/antagonist of the 
receptor. This will allow us to examine the target genes that are specifically controlled 
by AhR. 
In addition, despite recent key studies describing the importance of AhR in immune 
cells of the gut (Kiss et al., 2011; Li et al., 2011; Lee et al., 2012; Qiu et al., 2012), we 
cannot rule out the possibility that the decrease in CD8αα IEL population in the gut 
following ARNT deletion is due to lack of Hif-1α/ARNT function. To address this, we 
plan to analyse gut-resident immune populations in conditional Hif-1α KO mice (Hif-
1αfl/fl X CD4Cre) that lack Hif-1α in their T cells and Hif-1αfl/fl X VavCre KO mice that 
lack Hif-1α in all cells of the haemotopoietic origin. 
One other issue we wish to address concerns the fact that the observed decrease in 
CD8αα IEL population in the gut following ARNT deletion (Results, Chapter 5) and 
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reduction in TCRγδ population following AhR deletion (Li et al., 2011) are much more 
dramatic in comparison with the percentages of those subpopulations marked by the 
AhR reporter model. This result raises a question regarding the role of the non-
canonical AhR and Hif-1α pathways that are ARNT-independent. Accordingly, recent 
reports showed a function of both AhR/Rorγt and Hif-1α/Rorγt complexes in 
transactivating the transcription of IL-22 (Qiu et al., 2012) and IL-17A (Dang et al., 
2011) loci, respectively. The mechanism of AhR and Hif-1α ARNT-independent 
functions is also relevant in context of Th17 cells. It will be interesting to identify 
additional binding partners of these transcription factors by performing 
immunoprecipitation of AhR/ARNT complexes from the nuclear fractions of Th17 
cells, using ARNT antibodies, followed by mass spec analysis of complexes that are left 
unbound to ARNT.  
The phenotype of ARNT deficiency in CD8 T cells is attributed to the activity of Hif-
1α/ARNT rather than the AhR/ARNT complex, since AhR reporter mice demonstrated 
that the AhR/ARNT pathway in CTLs is insignificant. Studies in ARNT-null CTLs 
showed that the Hif-1α/ARNT complex plays a crucial role in the glycolytic switch of 
CD8 T cells, by regulating the expression of Glut1 and key rate-limiting glycolytic 
enzymes, such as phosphofructokinase 1, lactate dehydrogenase and pyruvate kinase 
M2. The other important observation was that ARNT is also required for the expression 
of the effector molecules perforin and granzymes and for the suppression of the lymph 
node-homing molecules CD62L, S1P1 and CCR7. The lack of perforin and high 
expression of CD62L, S1P1 and CCR7 molecules in ARNT-deficient CD8 T cells is 
reminiscent of features of naïve CD8 T cells and at first sight can lead to the assumption 
that ARNT-null CTLs would be incompetent effectors. However, a closer examination 
of the genes that are changed following ARNT deletion demonstrates that those cells 
have also many features of effector CD8 T cells, such as normal IFN-γ production and 
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expression of other cytolytic effector molecules, such as Fas ligand and lymphotoxin A 
and B, which were up-regulated according to microarray analysis. Additionally, ARNT-
null had increased expression of CXCR3 and CCL5 molecules. CXCR3 mediates 
trafficking of effector CD8 T cells into the inflamed tissues and high expression of 
CCL5 is a feature of resting memory CD8 effectors (Marçais et al., 2006). Additionally, 
ARNT-null cells are normal in cell size and can rapidly proliferate.  
Cumulatively, the features of ARNT-null CTLs suggest that the Hif-1α/ARNT complex 
has pleotropic effects in CD8 T cells. Examination of ARNT-null CTL responses in a 
Listeria monocytogenes infection model could not infer us whether those cells are 
potent effectors, since in this model CD8 T cells are not involved in the clearance of the 
pathogen. In fact, in order to examine the impact of perforin deficiency on the ability of 
CTLs to clear pathogens, we ought to use an infection model, which is highly perforin-
dependent, such as the LCMV (Lymphocytic choriomeningitis) viral infection.  
To address the question of whether ARNT deficiency prevents CD8 T cells from 
becoming competent effectors, we used another mouse model that allows assessing 
cytotoxic and migratory capacities of CTLs in vivo (data were not shown in this thesis). 
In this model, OT-I TCR transgenic CD8 T cells are adoptively transferred into RIP-
mOVA mice expressing a membrane-anchored form of OVA under the control of the 
rat insulin promoter (RIP) in their pancreatic islet beta cells, followed by LPS 
immunizations (Kurts et al., 1996). Differentiation of CD8 T cells into CTLs and their 
successful migration into the pancreas lead to distraction of the pancreatic islets and 
mice becoming diabetic. Delay in the onset of diabetes would suggest an impaired 
cytotoxic capacity of CD8 T cells. RIP-mOVA mice that were adoptively transferred 
with ARNTfl/fl X CD4Cre+/- (KO) CD8 T cells and RIP-mOVA that were transferred with 
ARNTfl/fl (WT) CD8 T cells became diabetic at the same time, suggesting that ARNT 
deficiency did not impair the ability of CTLs to kill. This suggests that ARNT-null 
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CTLs used other redundant cytolytic mechanisms, such as the Fas/FasL pathway, or 
could recruit other types of immune cells that mediated the killing.  
Therefore, the overall phenotype of ARNT-null CTLs is intriguing and leads to many 
additional questions. Since the absence of ARNT affected trafficking properties of 
CTLs in vivo due to retention of high CD62L and CCR7 expression, the molecular 
mechanism of ARNT regulation of CD62L remains to be elucidated. Does Hif-
1α/ARNT complex directly control CD62L transcription, or rather, the inability of 
CTLs to down-regulate CD62L expression is a result of reduced glycolysis in ARNT-
null CTLs? This question can be addressed by performing Chip-Seq analysis of ARNT 
and Hif-1α in CD8 cytotoxic T cells.  
Collectively, our data reveals a surprising role of ARNT/Hif-1α complexes in 
differentiation, metabolism and migration of CD8 T cells, which is independent of its 
role in regulating cellular responses to hypoxia.  
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